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Abstract 
Aims/objectives: The objectives of this research were to investigate and compare aspects 
of Quality of Life (QoL) in adult patients who require HPN, in adult patients who have 
pseudo-obstruction, and in carers of, and children on, HPN.  
Methods: Demographic data, clinical parameters and current symptoms were collected 
and analysed. Generic QoL questionnaires were applied to the above groups.  
Results: HPN patients have significantly lower QoL than the rest of the UK population, 
report increased levels of bodily pain, anxiety and depression, a reduction in physical 
functioning, social functioning, general health, vitality and satisfactory levels of mental 
health and emotional functioning. Aspects of QoL improve over the first 6 months on 
HPN. Pseudo-obstruction has a negative impact on all aspects of QoL when compared to 
a normal population. A previous intestinal resection and opiate use had a negative impact 
on aspects of QoL. Carers of a child on HPN seek more social support and use more 
positive reappraisal coping strategies, more planful problem solving and less distancing 
than the controls and a higher level of psychiatric disorder is also seen. Children on HPN 
have a poorer functional status than those not on HPN, and there is a correlation between 
level of child dysfunction and parental general health. Families caring for a child on HPN 
function within normal and healthy parameters. 
Conclusions: Our studies indicate that the loss of intestinal function does have a negative 
impact on aspects of QoL but patients make adjustments to meet everyday requirements, 
even if it produces limitations with which these persons have to live by.
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1.0 Introduction 
It is well known that eating related pleasures go beyond nutrition (1); food is more than 
just nourishment and it is often the central focus of some of the most important moments 
and events in our life. Indeed the Greek philosopher Epicurus articulated this belief when 
he wrote “The root of all pleasures is the satisfaction of the stomach” (Epicurus c. 341-
270BC), although it is undeniable that losing the ability to eat in ancient times would 
have eventually resulted in death, this quote identifies the significance of the 
multidimensional role that food plays in our lives. However, the advancement of medical 
science has allowed the therapeutic provision of nutrients to people who no longer have 
the full capacity to eat, posing the questions; 
 How do people cope with the medicalisation of nutrition/food? 
 Does loss of the enjoyment of eating impact on the quality of one’s life?  
The purpose of this body of work is to present research that attempts to examine and 
answer aspects of the above speculations and notions.  
To this end, three different groups of people with intestinal failure were studied  
 Adult Home Parenteral Nutrition (HPN) patients 
 Paediatric HPN patients and their carers  
 Chronic Idiopathic Intestinal Pseudo obstruction (CIIP) patients 
Food is defined as anything ingested which has nutrient value and diet is that food and 
drink which is consumed or provided on a regular basis (2). These groups were chosen 
for study as their medical situation (intestinal failure) compromised both their diet and 
ability to eat food. 
1.1 Intestinal Failure 
The term intestinal failure was originally defined by Fleming and Remington in 1981 and 
implied a functional rather than an anatomical definition, resulting in a reduction of the 
functioning intestinal/gut mass below the amount necessary for adequate digestion and 
absorption of food (3). Paediatric authors have also described it as any condition in which 
the gastrointestinal (GI) tract fails to satisfy the nutritional and fluid requirements of the 
body (4) to allow for growth (5). 
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However this definition does not take into account disease aetiology. In 2006 an 
international group of experts tried to address this issue by proposing that intestinal 
failure results from obstruction, dysmotility, surgical resection, congenital defect, or 
disease associated loss of absorption and is characterised by the inability to maintain 
protein-energy, fluid, electrolyte or micronutrient balance (6).   
 
In 2002 a novel classification of intestinal failure was devised which describes 3 different 
types of IF (7):  
 
Type I – this type of Intestinal Failure is short-term (days/weeks) and self limiting, where 
the gut can not be accessed for feeding via the enteral route. The majority of patients will 
be normal to moderately malnourished and the majority of the feeding will be by the 
parenteral route, but partial enteral feeing may be possible.  
 
Type II – Type II is IF in severely ill patients with major resection of the bowel. Septic, 
metabolic and nutritional complications may be present, requiring multidisciplinary 
intervention with metabolic and nutritional support to permit recovery. 
  
Type III – Type III is  chronic IF requiring long term nutritional support (7)  
 
More recently in 2008, the Strategic Framework for Intestinal Failure and Home 
Parenteral Nutrition Services for England expanded on these definitions and included 
information about where these type of patients should be treated 
(http://www.specialisedcommissioning.nhs.uk/index.php/key-documents/intestinal-
failure-and-home-parenteral-nutrition/)(8).The report goes on to state that intestinal 
failure comprises a group of disorders with many different causes, all of which are 
characterised by an inability to maintain adequate nutrition via the intestines. It is 
characterised not only by the inability to maintain protein-energy, but also often in 
difficulties in maintaining water, electrolyte or micronutrient balance, particularly when 
there has been a major loss of length of the small bowel. If it persists for more than a few 
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days it demands treatment with the intravenous delivery of nutrients and water – 
parenteral nutrition (8).  
  
1.1.1 Causes of Intestinal Failure 
Four major underlying causes can be identified: 
 Short Bowel Syndrome (SBS), defined as intestinal failure resulting from 
massive resection of the small intestine (9) or when there is less than 200cm of 
bowel remaining. It can be congenital (e.g. intestinal atresia) or acquired 
(resulting in surgical resection of the bowel) (10).   
 Total parenchymal bowel disease (e.g. Crohn’s disease) 
 Motility disorders (e.g. pseudo-obstruction and visceral myopathy) 
 Small bowel fistulation causing premature loss of enteric content (11).  
All these disorders result in devastating losses of GI function. 
 
1.1.2 Complications of Intestinal Failure 
Untreated intestinal failure eventually leads to starvation or severe undernutrition caused 
by caloric and nitrogen deficiency. It may also result in fluid, electrolyte, mineral, 
vitamin and trace element deficiencies. This can be due to lack of adequate dietary intake, 
poor or absent nutrient absorption, increased intestinal losses, and a potential increase in 
energy requirements if an active disease is present. Intestinal failure can be temporary or 
permanent. In the past if intestinal failure was deemed to be irreversible, such patients 
were chronically malnourished, often unable to work or enjoy normal social activities and 
sometimes confined to hospital for indefinite periods, or they died (12). One social 
worker even referred to these individuals using the unfortunate epithet “nutritional 
cripples” (13). 
 
Consumption of food provides the body with essential nutrients. Requirements for 
nutrients vary with age, gender and at times of physiological adaptation, for example 
during pregnancy, lactation, growth and during illness. Moreover, nutritional 
insufficiency during different stages of development can have varying consequences. 
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Perhaps the most important difference between adults and children is that adult 
nutritional requirements must meet the basal energy needs for maintaining the body’s 
physiological functions, whereas paediatric nutritional requirements are imposed by the 
basal energy needs in addition to the demands of essential brain and linear growth. This 
can be obviously demonstrated by the reality that an adult can, if supplied with water 
alone, survive starvation for many weeks whereas a premature infant will only withstand 
starvation for 4 days (14), moreover, there are fundamental differences in the nutritional 
demands of the growing infant when compared to those of the older child or adult (15).  
 
Malnutrition at any age will increase the risk of morbidity and mortality - if it occurs in 
early childhood it can also result in failure to thrive (16) short stature and impaired 
neurological development that will decrease performance at school (17) and is associated 
with severe and prolonged episodes of infection (18).  Persistent nutrient deficiency in 
childhood can result in growth and sexual maturation suppression, highlighting the 
central importance of nutrition to a child’s current health and the ability to reach their full 
potential for growth and neurocognitive development. Any sustained interruption to 
nutrition, if not treated early can result in irreversible damage to a child’s development 
(19).  
 
1.1.3 Effects of Intestinal Failure on Growth and Development 
Growth occurs in 3 phases: infancy, childhood and puberty (adolescence) (20). Growth 
failure is the cessation, retardation or impairment of linear growth, characterised by a 
deceleration of growth velocity, or a fall in the percentile channels for height and weight 
in any of these three phases. More specifically it can be defined as height or weight 
below the third centile for age (21) and is usually associated with delayed skeletal or 
bone age.  
 
GI disease frequently leads to growth failure from impaired nutritional status in children 
(22). Variation in both weight loss and nitrogen balance is accounted for by two factors, 
the previous nutritional status of the infant and the degree of ongoing  stress (23), 
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therefore recognition of the underlying intestinal disorder, with appropriate therapy and 
dietary counselling for nutritional restitution, are important approaches in reversing 
growth retardation so that the child can achieve full growth potential (22). The role of 
nutrition in growth must not be underestimated, in one study of Mexican children growth 
failure was not related to frequency of diseases (including infection, fever and hepatitis), 
but seemed to be the result of chronic under-nutrition (18). 
 
1.1.4 Effects of Intestinal Failure on Neurological and Cognitive Development 
Cognitive functions may be conceptualised as those constituting the neural processes 
necessary to support the flexible use of information in the execution of adaptive, goal-
directed behaviour (24). During the first 3 years of life, child development is dynamic 
and involves the maturation of interrelated cognitive and physical functions. A child’s 
brain rapidly develops through generations of neurons, synaptogenesis, axonal and 
dendritic growth, each of which build upon each other. Nutrition provides the building 
blocks for brain development thus it has a strong influence on cognitive and fine and 
gross motor skill development (25). 
 
Although most early research on nutrition and mental development in humans concerned 
severe protein energy malnutrition (26), animal studies have made important 
contributions to understanding the role of nutrition in the development and operations of 
the brain, by allowing manipulations and controls that would not be possible in similar 
studies conducted in humans (24).  
 
There is evidence linking many nutritional deficiencies to deficits in cognition. In 1995 
Grantham McGregor published a review on the effect of severe malnutrition on mental 
development (27). The author identified 14 studies in which malnourished children were 
compared with reasonably well matched controls. Severely malnourished children 
demonstrated marked behavioural abnormalities in the acute stage, displaying more 
apathy, less activity, and less environmental exploration both in quantity and complexity, 
than with children who were ill with other diseases.  Formerly malnourished children 
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were found to have poorer cognitive function, school achievement and behaviour 
differences, neurological soft signs and poorer fine motor performance when compared 
with controls (28). The author goes on to report in a further publication that severe 
growth retardation between 12 and 24 months of age was associated with a ten point 
deficit in IQ on the Wechsler Intelligence scale for children (29).  
 
The mechanisms linking malnutrition to poor development are not known with certainty 
but must arise through changes to the brain’s anatomy or function (26). During brain 
development, changes in the availability of nutrient supply may result in disturbances of 
specific brain and behavioural functions, through their selective effect on some of these 
systems (24) including: 
 Functional interactions between the prefrontal cortex, hippocampus and amygdala 
 The ability to flexibly apply or generalise acquired knowledge in novel situations 
 The ability to flexibly switch between different behavioural tendencies 
 The ability to flexibly adapt to new situations and to change behaviour with 
changing task demands 
 
Another mechanism known as the “functional isolation hypothesis”, suggests that lack of 
dietary energy leads to reduced activity levels, which in turn leads to reduced exploration 
and subsequently results in developmental delays (30).  
Children’s developmental levels are extremely low in the acute stage of malnutrition, but 
generally improve during recovery in all areas of development. Nutritional 
supplementation has been associated with an increase in children’s activity levels and an 
improvement in development (30). But, if the nutrient deficiencies continue over a long 
period and the child’s behaviour remains abnormal, it is possible that acquisition of skills 
will be slow eventually leading to irreversible cognitive deficits and behavioural change, 
indeed, electro-physiological abnormalities have been found in children several months 
after recovery from severe malnutrition (27).  
 
Although there is consistent evidence of growth retarded children having cognitive 
deficits it would be incorrect to attribute the entire deficit to poor nutrition or infection as 
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environmental and social variables are confounding, In fact in one series of paediatric 
HPN patients, 2 of the children were mentally gifted and attended special schools because 
of their advanced capability (31).  
 
Most cases of short bowel syndrome in childhood occur in the newborn period when the 
brain is still increasing rapidly in size and in the complexity of its interneuronal 
connections. More than 90% of infants and children survive after extensive bowel 
resection (32). Consequently, neurodevelopment may be adversely affected by prolonged 
under-nutrition at this sensitive stage. There are often adverse neuro-developmental 
effects from prolonged admission to hospital. Not surprisingly, many children exhibit 
developmental delay during the course of short bowel syndrome, but subsequently 
improve (33). 
 
1.1.5 Management of Intestinal Failure  
The main goals of medical therapy in the adult are the immediate provision of nutritional 
needs to meet requirements and promote weight gain (if necessary), to keep the patient 
out of the hospital (to minimise institutionalisation) (34) and for the patient to return to 
society i.e. resume work and a normal lifestyle – or as normal of one as possible. These 
goals are the same in paediatrics, but also include provision for growth (35).  
 
Adequate nutrition support must provide both macro and micro nutrients (to prevent 
malnutrition and specific nutrient deficiencies), sufficient fluid (to prevent dehydration), 
and to correct and prevent any acid-based disturbances (10). It is important to remember 
that some patients develop a protracted dependence on PN (36) and these patients may 
require nutritional support for a substantial portion – if not the remainder of their lives 
(37). 
 
In addition to providing extra food and food/nutrient supplements there are 2 main types 
of artificial nutritional support available to those suffering with intestinal failure: 
 Enteral feeding (EN) – The provision of liquid food administered via a tube into 
the stomach or intestine.   
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 Parenteral feeding (PN) – The intravenous administration of nutrients, (an 
aqueous food formulation) (38).  
 
The choice of nutritional support is dependant on the cause and degree of intestinal 
failure. Both methods bypass the normal processes of eating, chewing and swallowing 
and can be administered at home. Enteral feeding is cheaper and safer than PN and is 
preferred if the GI tract is functioning sufficiently (39). Patients may require a varied 
combination of both EN and PN according to the degree of dysfunction of their intestinal 
tract (40).  
 
The challenge of nutritional support is to devise a nutritional regimen that will not only 
support weight gain and maintenance, but also provide an optimal developmental internal 
milieu for the brain and other organs. PN can be seen as a substitutive technique in gut 
failure. It must be remembered that nutrition support does not cure non nutritional 
diseases (41). 
 
Intestinal transplantation (ITx) is a surgical option for both adult and paediatric patients 
with irreversible intestinal failure (42;43). Complications of IF treatment are the main 
indications for transplantation. On the basis of the relative safety and efficacy of ITx, 
HPN is still considered the primary treatment for chronic intestinal failure (44).  
 
1.1.6 Oral Intake 
The parenteral method of feeding is un-physiological as the feeds are typically infused 
continuously (as opposed to intermittent ingestion of solid food at meal times), 
sometimes nocturnally, and the nutrients bypass all of the GI tract which is normally 
involved in the regulation of appetite and food intake (45;46)  The effects of parenteral 
nutrition (and the macronutrients within it) on hunger and satiety remain poorly 
understood (47).  
 
Disturbances in appetite sensations may occur in people receiving PN, and this is thought 
to be partly due to 2 main factors.  
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Firstly when nutrients are administered intravenously, the cephalic phase response that is 
normally elicited by the presence of food in the upper GI tract is absent. The cephalic 
response is defined as a myriad of pre-absorptive changes in thermogenesis, metabolite 
and hormone concentrations that follows the oral ingestion of food (48). It has been 
reported that PN is less effective in relieving appetite sensations than food intake (49-52) 
and proposed that this may be due (in-part) to the bypassing of the cephalic phase.   
 
Secondly, when nutrients are infused intravenously they may fail to generate endogenous 
gut signals which typically follow oral food ingestion (53). The GI tract elicits numerous 
signals regulating food intake and satiety (54) The release of these satiety signals are 
induced by the presence of nutrients in both the stomach and the small intestine (55-57). 
Examples of these gut derived peptides include ghrelin, peptide YY (PYY), 
cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1). PYY, CCK and GLP-1 
have an anorexic effect, whereas ghrelin is orexogenic.  Recently Murray et al (47) 
demonstrated that intravenous infusions of carbohydrate (10% dextrose), lipid (10% 
Intralipid)  or mixed protein carbohydrate (PN) in stable HPN patients had no affect on 
subjective symptoms of hunger, satiety or nausea. Ghrelin levels decreased significantly 
during the dextrose and PN infusions and the lipid infusion led to a significant decrease 
in PYY, however the changes in peptide levels were not associated with changes in 
appetite and the authors suggest that ghrelin antagonists and PYY agonists may not be 
viable targets for the treatment of distressing symptoms of hunger in HPN patients. 
 
Stratton et al published several abstracts (1998-1999) relating to the impact of PN on 
appetite, summarised in Stratton and Elia 1999 (53) and Stratton 2001 (58). They studied 
weight stable HPN patients who had no oral intake and found that 75% experienced 
hunger, 44% were distressed by the severity of their hunger and 88% had a desire to eat.  
A few patients regularly chewed, tasted and subsequently spat out food (modified sham 
feed) in an attempt to relieve distressing appetite symptoms (58). In 2008 Oz et al found 
that 35 (out of 50) patients were eating normally in addition to HPN, reporting quite good 
appetite, but not eating what they were partial to. While many patients retained their 
appetite, 44% could not tolerate “heavy” foods and satiety was reached quickly due to the 
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feeling of gastric fullness. Nearly half experienced abdominal pain during a meal and 
67% report that they did not enjoy food. Oz et al also showed nutritional intake was 
related to level of work and social activity and related inversely to emotional status. 
While willing to eat, patients experienced significant side effects which impaired their 
ability to complete a meal (59). 
 
Oral intake can also depend on the underlying diagnosis. Some patients on PN choose to 
limit food intake for various reasons including increased pain and diarrhoea (for example 
in Crohn’s disease), rapid transit with a predictable increase in stoma care in patients with 
short bowel, and a general depressed appetite if receiving nutrients parenterally (60). 
Patients who can eat without GI discomfort are encouraged to do so if they wish to 
minimise feelings of social alienation (13). When patients do consume food orally, an 
intake of less than 10% of basal energy expenditure has been observed (61), or they have 
been found to consume from 600kcals (52) to1000kcals (13) per day.  
 
Oral intake is beneficial if the side effects are not too great. Oral intake has been 
associated with fewer metabolic complications (62) and more rapid intestinal adaptation 
(63).  
 
In paediatrics early initiation of oral feeding allows the infant to learn how to suck and 
swallow and is the best way to avoid food refusal which often occurs secondary to the 
absence of sucking during long hospitalisations. In addition oral feeding is more 
physiological, stimulating gall bladder motility and GI secretion (43). 
 
1.1.7 Intestinal Adaptation  
The intestine has an inherent ability to adapt morphologically and functionally following 
intestinal resection at the physiological, molecular and cellular level (64). The adaptive 
response in humans has not been well characterised, but increases in the absorption of 
nutrients have been documented (65-67) in humans following resection. The adaptation 
of the residual bowel is an important factor in determining whether a patient with a short 
bowel will progress to permanent intestinal failure and dependence on PN (6).  
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After massive enterectomy, the intestine hypertrophies and becomes more efficient in 
nutrient absorption. There is a slight lengthening as well as an increase in both diameter 
and villus height which effectively increases the absorptive surface leading to enhanced 
segmental absorption of many nutrients (68-70). Hyperplasia of the mucosa also occurs 
along with increased mucosal blood flow (6). 
 
Adult Intestinal Adaptation 
There is a wide variation in normal adult small bowel lengths ranging from 3-8.5m, with 
the mean length for women being shorter than that for men (71). Thus the total intestinal 
length prior to resection will have an impact on the recovery of the patient. If a large 
percentage of the small bowel is removed, then the degree of small bowel adaptation will 
need to be greater if enteral autonomy is to be achieved. In adults, resection of 75% or 
more of small intestine (leaving the patient with 70-100cm of intestine) usually leads to 
loss of enteral autonomy (72-74). After resection, the presence or absence of a colon in 
continuity with the remaining small intestine will affect the amount and type of 
nutritional support required. Generally speaking if the colon is preserved, HPN is likely if 
<50cm of residual jejunum remain; however with no colon, a longer jejunal length of 
<75cm will indicate the need for HPN (75).  
Clinical evidence suggests that in adult humans, although the majority of spontaneous 
bowel adaptation takes place during the first 3 months after resection, it can take up to 
three years or more for adaptation to become fully established (11). From this it can be 
loosely inferred that if HPN is needed for more than 3 years – it is likely to be permanent. 
In adults, there is a general consensus that there is reduced likelihood of intestinal 
adaptation 1-2 years after initial bowel resection (76-78), and the probabilities of weaning 
from HPN decline substantially after 3 years (79). 
 
Infant Intestinal Adaptation 
The subject of pre and post natal bowel growth / adaptation is beyond the scope of this 
thesis. In children, short bowel syndrome is usually defined anatomically as less than 
30% of normal intestinal length or less than 75cm (80).  Infant adaptation to full enteral 
nutrition has been reported with as little as 10cm of residual intestine (81) and indeed, a 
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high proportion of children receiving HPN make the transition back to enteral feeding in 
due course (82) if sufficient bowel adaptation occurs. The intestine of the new born and 
young infant has an enormous potential for re-growth, and given enough time, some 
patients can achieve sufficient absorptive capacity to sustain growth by enteral feedings 
alone (83). However often a combination of enteral and parenteral feeding is the most 
efficacious route to this end (84). Previous research has suggested that infants were likely 
to require permanent HPN if residual small intestinal length was less than 40cm and the 
ileocecal valve was absent (32), if there was less than 20 cm residual small bowel 
remaining (35), if the length of aganglionic bowel is <50cm (43) and if more than 70% of 
the intestine was resected (33). The most recent evidence suggests that if the remaining 
jejunoileum is <12cm the ability to wean paediatric patients off PN is small (85). In 
paediatrics, intestinal adaptation may take as little as 6-8 months or up to 5 years (86). 
1.2 Chronic Idiopathic Intestinal Pseudo Obstruction (CIIP) 
The term Chronic intestinal pseudo-obstruction (CIP) was first used in 1958 (87). The 
condition had in fact been described as early as 1896 when ‘spastic ileus’ was used, cited 
by Steigmann and Singer  (88) and was the subject of an international working team 
report in 1990 (89). It encompasses a range of rare heterogeneous enteric nerve and 
muscle disorders (90) which are characterised by a severe impairment of gut propulsive 
motility with signs and symptoms of intestinal obstruction without evidence of organic 
causes occluding the intestinal lumen (91;92).   
 
1.2.1 Causes & Symptoms 
CIP may be primary (chronic idiopathic intestinal pseudo-obstruction: CIIP) or secondary 
to connective tissue disorders such as scleroderma, paraneoplasia or to diabetes mellitus. 
It results from disease involving the enteric neuro-musculature (with characteristics of 
myopathy, neuropathy, or both) of either one or more segments of the intestine or the 
entire gastrointestinal tract. The onset of CIIP can occur at any age with varying degrees 
of symptoms including severe abdominal pain/distension, nausea, vomiting, constipation 
or diarrhoea, intestinal distension, dysphagia and associated urological problems. 
Symptoms and signs may be variable in their mix and degree but tend to be intractable, 
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though the patient may experience good and bad periods over months or years. Pain may 
frequently require opiate analgesia and the multi-disciplinary approaches of a chronic 
pain team. Constipation may prove severe enough to justify colectomy, which however 
often results in ileostomy dysfunction. 
 
1.2.2 Diagnosis 
CIIP is distinguished from irritable bowel syndrome, functional bowel disorders or slow 
transit constipation by combinations of the  
 Radiological findings of dilatation of the proximal small bowel  
 Manometric results  
 Characteristic histological changes 
 Inability to maintain normal nutrition  
CIIP may require changes in nutritional input to maintain weight and micronutrient intake 
varying from oral nutritional supplements to home intravenous nutrition (HPN). There 
are as yet no formally accepted diagnostic terms for “illnesses which fall between 
pseudo-obstruction and irritable bowel syndrome (93) though for these, the term enteric  
dysmotility has been proposed (94). Wingate et al (94) regarded abnormal small bowel 
contractile activity, in combination with episodic or chronic signs mimicking mechanical 
obstruction of the small bowel, as the defining feature of intestinal pseudo-obstruction, 
whereas enteric dysmotility was described as abnormal small bowel manometry “without 
sub-occlusive events”. 
 
1.2.3 Management  
Management of pseudo-obstruction is largely conservative and focuses on maintenance 
of optimal nutrition (95). “Pseudo-obstruction” and “systemic sclerosis” combined 
represented 12.6% of new registrations for home parenteral nutrition (HPN) in the British 
Artificial Nutrition Survey 2005, the time period closest to patients recruitment to this 
thesis, 13.7% of the point prevalence of HPN patients. At the Royal London Hospital, the 
specialist Intestinal Failure (IF) clinic attracts patients who may require a multi-
professional approach to artificial nutritional support, and assesses patients for HPN. By 
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virtue of hospital expertise in intestinal motility and the histopathology of intestinal 
neuro-musculature, a large number of such patients are referred to the IF clinic. Some 
require HPN, some do not, but all represent considerable problems of management. 
1.3 Parenteral Nutrition (PN) 
Today, Parenteral Nutrition (PN) enables us to provide patients with adequate calories, 
water, nitrogen, electrolytes and vitamins completely independent of a functioning 
gastrointestinal tract. However the idea of intravenous infusion is not a new concept. For 
more than 3 centuries, physicians and scientists had dreamed of providing all required 
nourishment by vein (2). 
 
1.3.1 A Historical Perspective 
The first documented reports of intravenous infusions date back over 350 years. In 1616 
William Harvey discovered the circulation of blood (96). The first experiments on 
intravenous injection took place sometime in 1656, in Robert Boyle’s quarters in the 
United Kingdom by Sir Christopher Wren (the architect of St. Paul’s Cathedral), who 
introduced substances including wine, ale and opium into the veins of dogs (97). His 
intravenous administration apparatus was a goose quill attached to a pig’s bladder.  
 
Until the late 19th century this research was followed by a series of experiments into the 
intravenous infusion of many substances into both animals and humans. 
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Table 1.1: First Attempts of Intravenous Infusion into Animals and Humans   
Year Researcher Experiment 
1616 William Harvey Discovery of the circulation of blood (96) 
1666 Sir Christopher Wren IV infusion of wine, ale and opium into dogs (98) 
1667 Jean Baptiste Denis Lamb to human (Louis XIV) blood to blood transfusion (96) 
1679 Courten IV infusion of oil (99) 
1818 James Blundell First man to man blood transfusion (100) 
1832 Thomas Latta Use of IV saline in patients dehydrated due to cholera (101) 
1843 Claude Bernard Infusion of egg white into animals (102) 
1873 Hodder Infusion of milk into humans (103) 
1891 Matas Use of IV saline in treatment of clinical shock (102)  
1896 Biedl and Kraus IV infusion of dextrose into humans (104) 
 
The method of IV administration was not safe or fully accepted until Joseph Lister and 
Louis Pasteur identified the principles of asepsis (1870) and the implications of microbial 
infections (1877) respectively (105), and until in 1923 when Siebert brought an 
understanding and solution to the causes of frequent pyrogenic reactions (106). Even at 
this stage the improvement of nutritional status was not the main focus of developing the 
IV technique. 
 
1.3.2 PN - First Attempts 
It was not until the early 20th century that the idea of IV infusion being used as an 
artificial gut started to develop. In 1911 Kaush administered (5% and 10%) IV glucose 
into man and Yamakawa (1920) started to investigate the IV infusion of fat (caster oil) 
(107), which caused serious intolerances.  Henriques and Anderson demonstrated that 
normal weight and positive nitrogen balance in a goat could be achieved and maintained 
with intravenous feeding (1930) (105). Elman, Weiner and their co-workers began to 
experiment and develop the peripheral infusion of protein hydrolysates and dextrose 
(108). As late as 1947 Robert Elman repeated his belief that PN was only for short term 
use, however advances in medicine and surgery (e.g. antibacterial bacteriostatic drugs 
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and radical intestinal surgery) increased the number of patients who would benefit from 
more long term support cited by (41). 
 
The first report of successful parenteral nutrition was in a child and was published in 
1944 by Helfrick and Abelson (109). This paper was partly republished in another journal  
in 1978  (110). It describes the case of a 5 month old infant with Hirschsprung’s disease 
who was given intravenous feeding with carbohydrates (50% glucose) and amino acids 
(10% casein hydrolysate), followed by an homogenised olive oil-lecithin emulsion for 5 
days. The child survived and the Hirschsprung’s was eventually treated with prostigmine. 
However these papers are rarely cited. 
 
1.3.3 Evolution of Intravenous Catheters for Nutrition 
PN solutions were becoming more advanced and physiologically stable, but it was not 
until Aubaniac, a French surgeon, perfected the subclavian venipuncture technique (111) 
that the administration of PN as we know it today started to appear. Stanley Dudrick (and 
his colleagues) working in Rhoads’s laboratory (1968) initially attempted complete 
intravenous hyperalimentation in dogs (112-114), and it was first successfully 
demonstrated in 1966 when Dudrick and his co workers devised a method by which a 
catheter could be implanted and maintained in the superior vena cava for long periods of 
time (115), allowing physicians to feed higher concentrations of PN (hypertonic), as the 
glucose and amino acids were being administered into the superior vena cava and 
immediately diluted with large volumes of blood, preventing injury to the intimal wall of 
the vessel (116). Thus it became unnecessary to give the very large volumes of PN given 
previously. They went on to describe the first demonstration in any animal species 
(almost 100 Beagle puppies) of growth and development with total intravenous feeding 
(117).  
 
1.3.4 Development of PN Infusions 
Between the first successful case of PN in an infant in 1944 (109), and the development 
of what was thought to be a safe fat emulsion (Intralipid) in 1963 by Edgren and Wretlind 
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(118), interest in PN was increasing, and there are several publications reporting the use 
of PN as a viable method of maintaining both human and animal nutritional status 
(112;119-121).  
 
In these first reports the PN consisted of only nitrogen (protein hydrolysate) to attain 
nitrogen balance, large amounts of dextrose (protein sparing), in a volume of 
approximately 3 litres (maximum volume tolerated). The protein and the glucose had to 
be sufficiently diluted for peripheral vein administration to ensure the solution had a low 
enough osmotic load to prevent thrombophlebitis. However this combination did not 
provide enough calories to sustain patients over long periods. Rhoads pioneered the 
approach of feeding large volumes of PN (5-7 litres) simultaneously with high strength 
diuretics (122). Further research by Dudrick suggested that positive nitrogen balance 
could not be achieved unless 150 Kcals per gram of nitrogen was provided (123). 
Hydrolysates of casein and of beef-blood fibrin were the primary sources of amino acids 
in PN into the early 1970s (41). The first commercially available amino acid solution was 
Freamine, which had the amino acids as chloride salts (124).     
 
In 1968 Wilmore and Dudrick went on to report what they term “the first clinical 
application of TPN”(2), where a newborn infant with multiple congenital GI anomalies 
(massive atresia of the small bowel) was referred to Dudrick to try his “puppy feeding” 
method. She was fed entirely by vein for 45 days and, thereafter primarily by intravenous 
hyperalimentation for 22 months (125).  After 6 months of intravenous feeding they 
estimated that 97% of all the nutrients she’d had during her entire life were by vein. She 
represented the first human demonstration that one could give enough prolonged nutrition 
by vein to grow, and that tissue synthesis could be achieved when nutrients are provided 
exclusively by vein. In 1969 Dudrick et al reported methods and results of total 
intravenous feeding used as the sole means of nutritional support for prolonged periods of 
time in adults (over 300) and children with severe GI disability (126). They report normal 
growth and development of 12 newborn infants fed intravenously for 7-400 days.  
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In 1969, Filler et al (127) reported survival of 14 infants under 2 months of age who were 
fed an intravenous fat free solution via a central venous catheter for 14 – 60 days. All 
infants survived and were discharged well. They note that this method of feeding reduced 
the length of hospital stay and improved the clinical status of the infant during the 
preoperative and convalescent periods. The patients who were fed intravenously had 
weight gain comparable to that of healthy well nourished infants. In those with sepsis and 
increased metabolic requirements, nutrients available for growth were reduced – which 
was reflected in a flatter growth curve. Two of the infant’s non-specific chronic diarrhoea 
was resolved completely as a result of complete bowel rest for an extended period.    
 
There are a series of reports that focus on PN being used as a temporary therapy, and 
provide a lot of details regarding clinical parameters such as growth charts, 
albumin/nutritional status and disease remission. In children growth can be used as a 
proxy for overall nutritional status (82).   This was followed by (mainly anecdotal)  
reports of the use of parenteral nutrition for the reversal of growth arrest in adolescents 
with active Crohn’s disease (128;129). At this time the controversial question of how best 
to manage these patients was being addressed, with resection of diseased bowel, or by 
reversing nutritional inadequacy either via the enteral or parenteral route? (130) 
 
This is followed by numerous reports of successful parenteral feeding in children 
(23;127;128;131;132). From this point on PN is considered a clinical reality and many 
reports of prolonged PN can be found in the literature. 
 
1.3.5 Lipids  
The history of fat emulsions is chequered with episodes of haemorrhage, toxicity and 
coagulation problems (133). The first generation of parenteral fat emulsions used various 
emulsifiers, including egg lecithin in the late 1920s. After severe side effects had been 
reported, the emulsion was withdrawn by the end of the 1930s (134).  
The second generation of parenteral fat emulsions contained purified soya lecithin in 
combination with a synthetic emulsifier and the oil phase used consisted of cottonseed 
oil. Again, pharmacological issues necessitated development of a new formula, since 
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long-term administration of cottonseed-emulsions led to toxic side effects owing to 
gossypol contamination (135).The introduction of Intralipid® in the early 1960s (136) 
marked the third generation, and many emulsions with similar compositions (soybean oil, 
egg lecithin) have since been introduced. Initially it was reported to be used with caution 
in neonates (137), but as soybean lecithin was reported to be more toxic than egg lecithin, 
this is now not used in commercial products, and glycerol is the only isotonicity agent.  
 
In the late 1980s a new approach was made in the oil phase, using a combination of 
medium-chain triglycerides (MCT) derived from coconut oil and possessing C8-10 
chains, together with conventional long-chain triglycerides (LCT). Eckart et al. (138) and 
Guisard and Debry (139) claimed MCT to have the advantage over LCT by providing 
better availability, owing to faster metabolisation and faster clearing and also from a  
metabolic and immunologic point of view. This resulted in development of synthetic 
Sructured Lipids (SL) in the early 1990’s, an example of which being Structolipid 
(Fresenius-Kabi). These SLs are made by hydrolysis of Soyabean Oil and MCTs with 
subsequent random reesterification of MCFAs and LCFAs. The advantages of 
structolipid include improved liver tolerance, controlled plasma concentration of 
triglycerides and improved protein economy (140). 
 
More recently advances of the use of fish oil in parenteral lipid emulsions have been 
explored. Parenteral Fish Oil is a novel emulsion available in a ready-for-use form, 
compounding soybean oil, medium-chain triglycerides, olive and fish oil (SMOF) (141). 
This so-called SMOFlipid (Fresenius-Kabi) is a 20% lipid emulsion with the lipid being a 
mix of 30% MCT, 30% Soyabean Oil, 25% Olive Oil, and 15% Fish Oil (142). A 2004 
study reported that a short infusion of SMOF in healthy male volunteers, when compared 
with pure SoyabeanOil (Lipovenoes; Fresenius-Kabi), was well tolerated and increased 
plasma elimination, as evidenced by a less marked increase in serum triacylglycerol 
concentration at the end of infusion and lower serum triacylglycerol concentrations (143), 
although there is very little evidence for the use of SMOF in HPN.  
  
 31     
The advantages of using lipid emulsions are that they are isotonic, so are suitable for 
peripheral infusion, they allow greater provision of nutrients in a smaller volume and are 
considered protein sparing (144). Dextrose solutions are more likely to lead to thrombosis 
than a lipid mix (145;146). Choline is required to transport fat in the liver to peripheral 
fat stores. Choline is synthesised from ethanolamine by transmethylation of a methyl 
group from the amino acid methionine. This amino acid is in high concentration in the 
crystalline amino acids usually added to TPN solutions (116). Although lipids are 
essential in PN solutions, they are toxic, in the accumulation of the non oxidised fraction 
in the reticuloendothelial system of the liver and in peroxidation by essential fatty acids 
(4;147). 
 
1.3.6 The Evolution of Modern PN 
The basic principles leading to the success of parenteral nutrition were 1) the provision of 
all nutrients available in intravenous form, 2) concentrated in a fluid volume equal to 
normal daily water requirements, 3) infused into a high flow central vein, 4) at a constant 
rate over 24 hour period to permit maximum utilisation and renal excretion (148). In both 
adults and paediatrics, the infusion of a hypertonic nutrient mixture at a constant rate into 
an area of rapid blood flow circumvented problems previously encountered in patients 
when hypertonic mixtures were infused into peripheral veins (149).    
 
By the early 1970s PN had established itself as an important therapy. On both sides of the 
Atlantic, PN was being administered using separate bottles and bags to which further 
additions were frequently made by medical or nursing staff (150). It was not possible to 
purchase PN fluids in a complete form, as there were many problems with stability and 
shelf life. This meant that PN was administered as a sequential single bottle regimen, or 
as a multi bottle regimen using Y or W connectors.  Then in 1974, Solassol and Joyeux  
from Montpellier introduced the concept of “melange nutritive” utilising a reusable 
silicone bag into which all the nutrients were mixed and infused over 24 hours (151). 
Pharmacy compounding of all in one PN solutions was then started in France by Solassol 
& Joyeux (152), in Canada by Jeejeebhoy and in the UK by Powell-Tuck and his 
colleagues who developed a sterile disposable 3L PVC bag to enable infusion of feeds 
 32     
compounded by pharmacists under lamina flow conditions. In 1977 this ambulatory 
system allowed the first UK patients to go home from St. Marks hospital (153). 
 
1.3.7 Early Clinical Administration of PN 
Initially parenteral nutrition was administered in the inpatient setting for set periods of 
time of between 25 – 50 days (154) and provided the fluid, electrolytes and minimal 
calories to support life (2). The nutrient solution was delivered by gravity drip in adults 
and by peristaltic pump with variable speed control (enabling delivery at a constant rate) 
in paediatrics. The nutrient solution consisted of glucose, fibrin hydrolysate, minerals, 
vitamins and trace elements, and did not contain any lipid as safe intravenous fat 
emulsions were unavailable at that time. It was administered over 24 hours to achieve 
maximum metabolic efficiency and assimilation of the nutrients (126). It was becoming 
clear that tissue synthesis, weight gain, growth and development could be achieved by 
intravenous administration of basic nutrients.  
 
This led to a tailoring of specific PN regimens to the patient and the disorder (126). 
Community hospitals were also being encouraged to embark on PN programs (155). 
Ambulatory HPN was a logical and obvious outpatient extension of the clinical 
application of intravenous hyperalimentation in hospitalised patients (156) as parenteral 
nutrition proved both expensive and psychologically disabling to the patient. 
 
By the early 1970s indications for PN had extended from patients with severe alimentary 
disorders to a host of debilitating illnesses whose metabolic demands often exceed the 
capacity of the normal alimentary route (157). 
1.4 Home Parenteral Nutrition (HPN) – First efforts 
When TPN was first introduced, it was thought that it could only be performed in the 
hospital under the strictest aseptic procedures. As experience with the technique was 
gained and the procedures simplified, parenteral nutrition become widely used, both in 
small community hospitals and tertiary medical centres (158). The introduction of TPN at 
home was a logical extension, it was used almost exclusively in relatively stable patients 
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with extreme short bowel (36;159-162). Technical developments in feeding together with 
the growth of support structures in the community led to a steady increase in the number 
of paediatric (82) and adult patients receiving HPN.  
 
Shils (41) states the first reported case of HPN was in December 1969 (163), however 
Dudrick claims he was the first to report an adult patient fed at home entirely by vein. 
She was a 36 year old woman with widespread metastatic ovarian carcinoma, who was 
discharged from the Hospital of the University of Pennsylvania in 1968 (2). The 
capability for providing long term PN out of the hospital was pioneered by Dr. Belding 
Scribner at the University of Washington (124)  
 
The first mention of paediatric HPN in the literature was in the form of a short abstract by 
Scribner and Riella in 1975 who report successfully feeding 3 children by TPN at home 
(164). The general criteria for instituting paediatric HPN was the inability to maintain 
fluid and nutritional balance on a therapeutic diet or elemental formula and a need for 30 
days or more conventional inpatient TPN (165).  
 
1.4.1 Development of HPN 
The first report of HPN was by Scribner in 1970 (158), in which he describes the concept 
of an artificial gut providing prolonged nutritional support. This paper was later criticised 
as being premature by Scribner and Cole in 1978 (166). The system, which they earlier 
described, worked well in uraemic patients, but the arterio-venous shunts were clotting 
when used in malnourished patients due to poor quality veins and abnormal clotting 
parameters. They then tried a new technique by inserting a stiff Tenckhoff catheter via 
the subclavian route into the right atrium. However this resulted in mechanical trauma to 
the superior vena cava causing thrombosis, obstruction and failure of the catheter. In 
1973 Broviac (167)  reported experience with a soft silicone (Silastic) rubber right atrial 
catheter which was flexible, inert and anti-thrombogenic. Local and generalised infection 
was reported as the main complication with a mean catheter life of 144 days. Dacron felt 
(a type of polyester (168)) placed subcutaneously was shown to promote tissue 
 34     
fibroblastic in-growth, prevent accidental dislodgement and to and fro motion, as well as 
obliterating the continuity of the sinus tract between the exit site and vein, thereby 
forming an anatomic barrier  to organisms ascending along the outer aspect of the 
catheter (167). Silastic catheters have a long life due to their absence of corrosion and 
their inert behaviour in tissues (169). The ensuing successful long-term venous access 
resulted in the Tenckhoff catheters being replaced by the Broviac catheters.   
 
Initially the gravity system of infusion overnight was used, but this was found to be 
unreliable and required constant vigilance. A powered portable device contained in a 
specially designed vest (2) was developed by Dudrick which eliminated this problem 
although some of the patients criticised the device as being cumbersome (170). Shils then 
developed a standard portable pump system equipped with infusion rate monitors which 
allowed cyclical night time infusion (usually over 10-14 hours) (171). The safe 
administration of feed during the night gave patients freedom during the day.  
 
Initially lipid infusions were still given separately as they could not pass through the 
filters. Half of the energy requirements were provided by the lipid infusion.  
 
Cases of intestinal failure which were previously fatale became manageable and HPN 
technology diffused to Europe from the USA in the late 1970s (170). In 1973 Jeejeebhoy 
reported total parenteral nutrition at home for 23 months, without complication (161) 
which was followed by further favourable reports of adult and paediatric HPN (160;171-
174). The first patients discharged home on HPN in the UK were at St Mark’s Hospital , 
London and Hope Hospital, Salford in 1978 (175).  
 
1.4.2 Benefits of HPN Compared to Hospital TPN 
Generally there were several benefits observed by providing PN in the home.  
 
In adults lower sepsis rates (and thus morbidity) were reported due to reduced exposure 
to nosocomial flora by being out of the hospital environment, being on a cycled infusion, 
and being nutritionally rehabilitated with restored immunocompetence (176). Patients’ 
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activities tend to increase as number of hospitalisations decrease (36), improving the 
likelihood of social rehabilitation. 
 
In paediatrics, resultant hospitalisation due to the necessity of long term nutritional 
support is both expensive and psychologically disabling (177).The negative side effects 
of prolonged hospitalisation are well established, including impairment of social and 
intellectual development in children. So along with the achievement of normal skeletal 
growth, weight gain and improved states of general well being, HPN offered an 
acceptable solution to the resolution of social and psychological developmental issues 
upon return home (36;177-179). 
 
In 1980 Cannon et al were the first group to look at HPN during the first 2 years of life 
(180). Up to this point, there had been no prospective studies which looked at infants who 
were raised from the neonatal or early newborn period solely on HPN. They used the 
Gesell score to determine neurological development, and found that those infants who 
remained hospitalised or were at home less than 2 months at the time of the test scored 
lowest in gross motor, adaptive and language skills compared with children who had been 
discharged for >2 months. At dinner time the children sat with the family for social 
purposes but showed a persistent disinterest in food. They concluded that if infants were 
neurologically normal, appropriate developmental milestones could be expected during 
the first 2 years of HPN. The single most important factor contributing to the 
normalisation of neurological development was probably the home environment. It was 
too early to tell if the HPN child would exhibit normal intellectual function in school. 
They concluded that HPN in infants promoted normal physical growth and development 
during the first 2 years of life. 
 
HPN emerged as a life saving nutritional therapy which permitted patients ranging in age 
from 1 – 72 years old to resume normal lives at home (2), and the ability of the patients to 
learn the aseptic technique within a few weeks with daily training sessions was also noted 
(171). 
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1.5 Current Techniques of HPN 
1.5.1 Administration of HPN 
HPN can be total or partial, permanent or temporary (181). Today parenteral nutrition is 
administered either peripherally or centrally. Peripheral catheters are appropriate for short 
term PN and are usually used to feed low osmotic load PN solutions. Therefore it is 
unusual to see them used in HPN patients who require long term (often life long) 
nutritional support.  
 
Central Venous Catheters (CVCs) are used for longer-term administration of PN and are 
inserted by a radiologist.  The catheter tip should lie above the junction of the superior 
vena cava and right atrium, correct placement and absence of insertion related 
complications (vessel puncture and pneumothorax) should be confirmed by X-ray. 
Peripherally Inserted Central Catheters (PICC lines) are occasionally also used. There is a 
range of central catheters available which include catheters with single or multi-lumen. In 
Europe portacatheters are widely used (Dr. J. Shaffer, personal communication 23rd July 
2010). The clinical picture and the clinician’s personal preference dictate choice of 
catheter.  
 
In the UK intravenous nutrition is administered through a volumetric pump with 
occlusion and air-in-line alarms to minimise infusion complications. Specifically in 
paediatrics, other pump requirements have been reported to be: simplicity of priming the 
set and clearing entrapped air, the pre-selection of infusion rates, a minimum number of 
false alarms and motor noise, light weight and a carry handle (182). However there is a 
variability in the administration of PN, for example pumps are not routinely used in 
Poland (J. Shaffer, personal communication 23 July 2010), and the parents of children on 
HPN have been reported to compound the HPN mixtures in their homes (183).   
 
In an acute setting PN will usually be administered over a 12- 24-hour period, however 
this would not be appropriate for patients at home. Generally patients infuse over a 
limited period (cyclic PN) – frequently approximately 12 hours over night, three to seven 
nights per week. The goal of cyclic PN is to infuse the nutrients that the patient requires 
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in a shorter time period - the proposed advantages being the physiological benefit of 
mimicking the fasting and fed states and the psychosocial benefit of giving the patient 
“time off” from the infusion for normal activities of daily living (184). Cyclic PN appears 
to be as effective as continuous PN in maintaining nutritional status (185;186), potential 
advantages of cyclic infusion include improved insulin levels, reversal of hepatic 
steatosis and liver enzyme changes associated with continuous infusion (186). 
Interrupting PN infusion allows the body to convert to the oxidation of fat as opposed to 
the oxidation of carbohydrate that dominates during continuous PN, promoting 
mobilisation of lipid, transport of fat out of the liver and positive nitrogen balance with 
decreased lipid storage (187). It is important to get the correct regime to allow the patient 
a sufficient amount of time disconnected from the pump to lead an independent existence, 
whilst providing the patient with adequate nutrients. So there can be some degree of 
flexibility to allow for social and recreational needs (13).  
 
1.5.2 Content of HPN 
PN solutions bags are mostly compounded in a commercial pharmacy 90% or hospital 
pharmacy 10% (2001 BANS Data), and then delivered to patients in their own home. 
Special arrangements must be made to store the PN bags, as it is customary for patients to 
have on average two weeks supply at any one time. PN bags are frequently refrigerated as 
this better maintains the stability of its macro and micronutrients and helps to prevent 
bacterial growth – as PN solution is an excellent culture medium for most aerobic 
bacterial pathogens and all Candida pathogens (188). Off the shelf bags (PN bags which 
require the addition of vitamins and trace elements) often are, but do not have to be 
stored in a refrigerator.  
 
The content of the feeding bags is tailored to individual patient needs, and range from 
simple intravenous fluids to entire nutrient requirements including protein, carbohydrates, 
fats, minerals and trace elements. The energy in PN bags is described as non-protein 
calories. 
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1.5.3 Nitrogen / Protein 
Nitrogen is usually supplied as a balanced mixture of crystalline amino acids, or 
dipeptides for the more labile amino acids e.g. glutamine. Different amino acid profile 
solutions are available for particular disease states. Most patients can be maintained with 
0.16 - 0.2 g N/kg body weight/day but should not exceed 0.3 g N/kg body weight per day. 
The optimum amino acid profile for PN reflects known requirements of essential amino 
acids. The ratio of essential amino acids: total nitrogen should be 1:3. Some amino acids 
may be conditionally essential or may be necessary to improve the utilisation of others.  
 
1.5.4 Lipid 
Lipid serves two purposes in parenteral nutrition – as a source of calories, and as a source 
of essential fatty acids (EFA) to prevent EFA deficiency. Excess lipid has been 
demonstrated to result in hepatic complications, but the optimal dose and type of 
parenteral lipid that should be provided to minimise hepatic dysfunction remains unclear 
(189). The lipid content of HPN is very variable and reflects the energy needs of the 
individual and the extent to which essential fatty acids can be absorbed enterally (190). 
US guidelines suggest that fat should provide 20 – 30% of energy needs in PN (10) 
commonly in the form of long-chain triglycerides and essential fatty acids which are 
needed to maintain cell membrane integrity and immune function. In clinical practice 
many centres use relatively low parenteral lipid regimes in order to ensure the provision 
of EFAs and minimise the risk of hepatic complications associated with HPN. The use of 
SMOF, Structolipid and ClinOleic in preference to Intralipid (100%LCT) is slightly 
increasing in clinical practice, as there is some evidence that 100% LCT emulsions can 
cause physiologic and metabolic problems.  Addition of lipid increases the cost of PN, 
but the clinical benefits of reducing high glucose loads and hypertonic feed may offset 
this cost. Lipid emulsion is the most unstable constituent of an all in one bag. Stability is 
primarily affected by pH, amino acid composition and electrolyte content.  
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1.5.5 Carbohydrate 
Carbohydrate is added in the form of glucose, which is a cheap energy source. There is a 
stated maximum rate of glucose oxidation (about 4-7mg/kg/min), and although exceeding 
this can increase the risk of complications such as increased CO2 production, fatty liver 
secondary to hypertriglyceridaemia and hyperinsulinaemia, many HPN patients will 
tolerate higher glucose infusion rates during cyclical PN. A study by Williams et al (191) 
demonstrated no elevation in plasma HbA1c levels in a group of patients receiving 
glucose based solutions (median infusion rate 11.8mg/kg/min) for HPN. It is thought that 
there is some degree of adaptation to glucose infusion rates during prolonged glucose 
infusion, resulting in an increased capacity to oxidise glucose (192).  
 
1.5.6 Electrolytes 
Electrolyte content of the PN bag is altered according to serum measurements, fistula and 
stoma losses and must be checked at outpatient visits. 
 
1.5.7 Vitamins 
The American Medical Association provide guidelines that suggest water soluble 
vitamins exceed normal daily requirements in order to offset tissue losses and facilitate 
the synthesis of new tissue. Fat soluble vitamin requirements are often dependant on the 
number of fat versus fat free bags given per week. 
 
1.5.8 Trace Elements and Minerals 
In enteral nutrition the GI tract selectively absorbs the amount of trace elements required. 
PN bypasses this mechanism and the risk of over dosage is increased. The needs of most 
patients can be met by standard trace element solutions devised for PN, however, 
micronutrient requirements for parenteral nutrition (PN) are not well understood and 
guidelines for supplementation are outdated (193).  
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1.5.9 Complications 
The main complications of PN can be divided into metabolic, physiologic, mechanical or 
infectious.  
Table 1.2: Complications of Parenteral Nutrition 
Type of Complication Example of complication 
Metabolic Fluid overload, hyperglycaemia and electrolyte abnormalities 
Physiologic Rise in serum bilirubin, fatty liver, choleliathiasis, and 
cholestasis 
Mechanical Catheter related thrombus occlusion or fracture. Insertion 
related pneumothorax, chylothorax, air embolism, cardiac 
arrhythmias or nerve injury 
Infectious May be secondary to catheter or other concurrent infection 
 
Many non specialist centres are not used to dealing with HPN related complications and 
it is therefore most important that the patient or carer be adequately trained to recognise 
and react appropriately to serious symptoms which often requires contacting or returning 
to the HPN centre – which may be many miles from the patients home. The nutritional 
requirements of the patient remain the clinical responsibility of the hospital that has 
arranged the HPN service. 
 
Many patients report that at least some of the equipment was primarily designed for 
hospital rather than home use. Therefore a patients’ organisation PINNT has devised its 
own stand to hold the feed pump. It has found increasing use in the UK (194).  
 
1.5.10 Multidisciplinary Team (MDT) Approach to Care 
Both adult and paediatric centres have recognised the importance of a MDT approach to 
care (124;149;195). Reduced rates of catheter sepsis were noted to be directly related to 
the formation of nutritional support teams. Specialist centres providing HPN will have a 
team of clinicians, surgeons, anaesthetists, intensivists, radiologists, clinical nutritionists, 
specialist nurses, pharmacists, dietitians, biochemists and social workers. The conditions 
 41     
which lead to intestinal failure are often associated with disabilities such as high output 
stomas, profuse diarrhoea, abdominal distension, vomiting and pain. Patients therefore 
potentially have a lot to cope with in addition to the invasive provision of PN, thus the 
support of a good team is essential for success. An ongoing team effort can yield benefits 
of continuity, cohesiveness, mutual frame of reference and development of a skill 
peculiar to HPN care and management (13).    
 
Training is often provided to patients (or carers) whilst they are inpatients, which requires 
a substantial dedicated training programme for the maintenance and care of CVCs. 
Specialist nurses and MDTs need to undertake and assess training. The patient, carers and 
GP must be provided with education material. Most minor problems are handled by 
telephone calls (60), and if adjustments to the HPN infusion are needed, the local carer 
can contact the HPN centre by phone.  
 
Industry has already changed its service system from one which predominantly dealt with 
delivery to a more complete service (194). Commercial home care companies started to 
assume much of the care, supply and oversight responsibilities of HPN (41). In 2003 it 
was estimated that PN was supplied by commercial homecare companies in 89% of cases 
in the UK (175). Some companies provide telephone support and now telemedicine. 
Centres who do not use commercial homecare companies to provide community support 
offer a less than optimal service (175). 
1.6 HPN Training 
It can not be denied that discharge from hospital is vital to the rehabilitation of patients 
with intestinal failure, markedly improving their self image and the desire to participate 
in their own personal care (179). However, extensive training is required for both patients 
and the parents of a child on HPN (196), and in many ways patients (and or their carers) 
have to learn a professional clinical skill (197).  Users must become technology friendly 
for the technology to fulfil its role and it must be recognised that technology is always 
both enabling and constraining (198).   
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In paediatric centres, training is generally reported to take between 2 -5 weeks in the 
inpatient setting, sometimes parents or carers are required to be resident in the hospital 
(199) or nearby hotel if the patients home is many miles from the training centre (159) 
and in one centre a nurse from the unit went home with them for 1 or 2 nights (200). 
Written guidelines for handling CVCs are also given to patients (201). This can be an 
extremely stressful period and families who are anxious should be encouraged to cope 
with their needs before hospital discharge so that they can feel and be perceived as 
competent carers (202).  
 
In adult centres the length of training varies from between 2-6 weeks. At the Royal 
London Hospital, patients are often sent home for their training. The patient/carer is 
initially taught basic aseptic technique and how to disconnect from the equipment so they 
know what to do if anything goes wrong in the night. A company nurse then will go to 
the patient’s home to aid the set up and disconnection of the HPN for 3 months. The 
nurse is responsible for gradually teaching the patient/carer the whole process. This 
enables much earlier discharge of the patient.   
 
Both adult and paediatric training programs include observation to familiarise the patients 
or carers with the technique, repeated interviews, active training in aseptic techniques and 
equipment handling for connection, disconnection and simulation of the home situation in 
an isolation room.  
 
Adult and paediatric literature agree that training should be given to other members of the 
family so there is a back up, alternative caregivers can also allow the main carer to take 
time off from the demands of daily HPN administration (12;203;204). However this is 
not always possible and in one paediatric study only 25% of the families could rely on 
someone else to connect or disconnect the HPN (205). In 1998 the Carers National 
Association estimated that in the UK, around 850,000 carers provide a range of care for 
more than 50 hours per week and 60% of carers receive no regular support services (206). 
BANS has drawn attention to the need to provide care for the carers (194). In carers of a 
child on HPN, distress may be alleviated by paid help, but those who can provide direct 
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care (e.g. registered nurses who can offer respite from a patient’s medical care demands) 
are more effective at decreasing stress levels (207) and sometimes considered essential 
(182). 
Points taught to patients or carers before discharge include: 
 Hand washing technique 
 Principles of asepsis 
 Catheter care 
 Infusion 
 Care of parenteral nutrients 
 Care of infusion pump 
 Monitoring at home 
 Problem solving 
 Emergency contacts 
 
Homecare involves more than simply transferring a particular technology from the 
hospital to the home – it requires transferring knowledge and skills to lay people and 
making sure that the home and social environment enable a safe, effective, appropriate 
and personally satisfying use of technology, otherwise ineffective potentially hazardous 
and socially compromising treatments may be disseminated (208).  Typically health 
professionals emphasise infection prevention more than managing depression or other 
problems (209). MDT staff should be sensitive to the psychological as well as 
technological needs of HPN patients (210).  
 
1.6.1 Adult HPN Patients and Family Support 
Typically adult patients are encouraged to care for their own HPN administration if 
possible. However, family support can be important, and carers should be included in the 
teaching programme if willing and able. If self care is not viable, given careful training, 
an intelligent lay person can look after a patient as long as adequate community nursing 
support is available, but physical and mental strain while carrying out care has been 
reported (211). It is not uncommon for both the patient and spouse in the family to 
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experience fear, anger and depression resulting in marked changes in family life (37). 
The transition from hospital to home may be smoother if the patient has another patient 
contact who has previously undergone the same process (10). Patients have stated that 
they would like to have a means of communicating with other individuals who also 
receive HPN (210).   
 
1.6.2 Caring for an Adult on HPN 
Caregiving effectiveness is defined as the provision of technical, physical and emotional 
care that results in outcomes of optimal patient Quality of Life (QoL) and physical 
condition, minimal technological side effects for the patient, and the maintenance of the 
caregivers health and QoL (212). Caregivers of HPN patients must have some knowledge 
of technical nursing care, of the organisation and delivery of the HPN supply, and are 
required to make judgements about the day to day impact of the treatment. This can be 
extremely stressful and major depressive disorders (situation depression) have been 
observed (212). A distressed, anxious caregiver has a deleterious effect on patient 
condition. A link between negative care giver – care receiver interactions and patient 
complications has been observed, while positive interactions have been associated with 
increased compliance and QoL (213).    
 
1.6.3 Caring for a Child on HPN 
Paediatric HPN patients and their families benefit psychologically by being at home and 
resuming relatively normal lives (177), and although the benefit of bringing their child 
home can not be underestimated, they are accepting a huge responsibility by becoming 
both parents and medical providers (207). Along with the task of mastering the technique 
of HPN, parents and their families potentially cope with multiple setbacks, extensive 
hospitalisations and re-operations (83). 
 
Parents function as gatekeepers of their children’s health (214), often becoming 
responsible for many of the highly skilled nursing care tasks (207). When commencing 
HPN, parents need to make a physical and emotional commitment if the therapy is to be 
 45     
successful (179) and perhaps the most difficult factor to assess pertains to the time, effort 
and dedication required by these parents (83). The majority of parents tend to be highly 
motivated but daunted by the prospects of having to take on their child’s total nursing 
care (203). Parents have been shown to provide a high quality of HPN care (16). Thorn 
highlights that home management of a gastrostomy and its physical and social 
complications require an intensive effort, high level problem solving and constant 
adaptation (215), and parents of children on HPN must face similar problems by 
becoming experts in the technical care of their child (202). 
 
Caring for a young child on HPN differs from an adult caring for themselves or being 
cared for. Babies and young children will want to pay with, pull at and chew on the 
catheter and tubing if it is within reach (216). Parents are advised to coil and tape 
catheters close to the body at all times and should try to limit active play during HPN 
infusion by making it a special time for quiet play. Once the child is home the family is 
faced with integrating these procedures into the family lifestyle (204) .  
 
Carers are aware that the survival of their child is dependant on their skill in delivering 
the HPN (217), and many find this a great burden (199). In one study the authors state 
that sepsis related deaths of a 1/3 of the children could have been prevented had the 
parents followed instructions and brought the child into hospital when fever developed 
(31). This burden is further illustrated in 4 reports in which psychological investigation 
showed that all parents had behaviour disorders (depression) strongly related to the 
knowledge that their child was dependant on HPN for an indefinite period (218), 77% of 
parents exceeded the threshold for psychiatric morbidity (219), over 60% of families 
experienced deterioration in their family life i.e. social life activities and overall QoL 
after their child started HPN (202) and over 50% of parents abstained from alcohol (205). 
A child’s illness can have a negative effect on the parents’ marriage and result in the 
experience of marital distress (220).  
 
The first group to identify problems caused to the carers of a child on HPN was Byrne et 
al. In their series of 6 children treated on the HPN programme, a mother elected to 
 46     
discontinue the HPN as she felt unmotivated and received little support from her husband 
and family. She felt depressed by the prospect that the HPN would be required 
indefinitely and chose to feed the child orally. The child did poorly from a nutritional 
standpoint, but the authors do not state if the child survived (165).  Despite the growing 
numbers of families involved in HPN, little attention has been given to the effect of 
caring for their child on the parents (202). A study which looked at the parents caring for 
children with pseudo-obstruction (38% of the children were on HPN) found that these 
parents had poorer emotional status, were less resilient emotionally and that the child’s 
mental health and self care/mobility were strong predictors of the parent’s emotional 
status (90). 
 
Parents with a medically fragile child may be at a greater risk of psychological distress, 
however quantitative research specifically on this group of patients is minimal, Leonard 
et al found high numbers of parents (over half of the mothers and fathers) caring for a 
medically fragile child reported symptoms high enough to merit psychiatric intervention. 
Overall both parents distress levels were affected by increased family responsibilities 
(207). 
 
There are many sources of stress reported (221) including 
 General uncertainty about the child’s future 
 The unpredictability of hazardous events that may occur 
 The need to balance domestic and employment responsibility 
 Physical exhaustion associated with sleepless nights/sleep disturbance 
 
Much of the success of homecare depends on the parent’s psychological status (207) this 
has lead authors to advocate parental support (82;215) of an informational, instrumental 
and emotional nature (202). Family members should be encouraged to talk about their 
feelings with someone who can assist them in dealing with these emotions. Such 
assistance may come from a social worker, support group, close friend, family counsellor 
or clergy person. This support is vital as parents with higher rates of psychologic stress 
may be less able to nurture their children (222). Unfortunately many find that when they 
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seek support from support agencies there is no understanding of the medical problems of 
the child or the social or emotional needs of the parents (199). 
 
Parents frequently feel trapped by the needs of the child (199), suffer with social isolation 
and feel as if they lose some control over their child’s care to the healthcare team (202). 
Networking with other parents often provides one of the best resources to reduce feelings 
of isolation (204). Engstrom et al showed that social integration of the parents is high, 
whereas attachment which deals with deeper, emotional relations is affected. The authors 
postulate that families are in contact with more people than usual because of the complex 
medical situation but the level of the contact is superficial, allowing less time  for deeper 
relationships with relatives and friends (205). 
 
A recurring theme in the literature is the question of candidacy of single parent families. 
Some centres feel that the main carer must be in a stable relationship (199) , while others 
felt single parent families were not a contraindication for HPN (223) provided that social 
help and home nursing assistance were organised (224). There is general evidence to 
suggest that parents who do not share parenting with another adult experience the 
psychologic strain of making decisions of potential lifelong consequences alone and they 
lack time to carry out household and child rearing tasks (222). Also married subjects 
tended to have moderately lower levels of depression and anxiety than those who were 
not married (220). 
 
There are a variety of reasons some parents may not able to administer HPN including 
the technical and emotional demands (199), inadequate home situations (83) and 
disruption of families secondary to marital disharmony (225).  
 
There are very few reports in the literature of grandparents providing total care (223). 
Younger parents (younger than 30 years) had significantly greater psychosocial 
adjustment difficulties (220). 
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1.6.4 Maternal Burden 
Although HPN represents a challenge for the whole family (204), the mother is usually 
the parent responsible for administering HPN (31;226;227). A study by Thyen & Perrin 
reported that one third of mothers quit employment to take care of a technology 
dependant child (defined as children with ‘a medical device to compensate for the loss of 
a vital bodily function and substantial and ongoing nursing care to avert death or further 
disability’ (228)), and that mothers still carry the major burden of child health care (82% 
attributing their non employed status to limitations arising from the disability of their 
child). Those who remained employed reported significant work related problems 
including having to  work fewer hours, to take time off, to change jobs to accommodate 
care at home or to remain at jobs because they feared the loss of health insurance (229). 
In society, mothers of chronically ill children have a more intense involvement with the 
sick child whilst ensuring the well being of all family members, and fathers have more 
concerns about competing obligations between work and family (230). In a recent study 
of families with a child on HPN, mothers QoL scores were lower than the normal 
population, and lower than the father’s scores for items related to work, inner life and 
freedom. This group also found that maternal anxiety was associated with fear of being 
judged and culpability (231). In 1999 Thyen et al found that employment acted as a 
protective factor when caring for a chronically sick child, with relatively higher levels of 
psychological well being reported than those who were unemployed (229).  
 
1.6.5 Caring for a Chronically Sick Child at Home 
HPN is an intricate procedure and the ability of the carers to provide this complex care is 
an issue. Reported ideal candidacy for HPN training includes motivation, intelligence, 
previous para-medical training (232), minimal/adequate housing conditions (bathroom 
facilities, telephone), ability to understand the basic rules of asepsis (200), psychological 
stability (202) and having a reliable home environment (227).  
 
The health and well being of children are inextricably linked to their parents’ physical, 
emotional and social health, social circumstances and child rearing practices (222). 
Parenteral adjustment in terms of psychological distress, marital distress and family 
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functioning caused by caring for a chronically sick child are well described (220). 
Parents’ mental health affects their individual functioning; social relationships with their 
spouses, partners, co-workers, and other adults, and their child rearing behaviours (222). 
Parents with a medically complex child at home report satisfaction in relation to 
witnessing the emotional and social growth of their child (233;234), but caring for such a 
child can result in adverse health impacts on the primary caregivers (228).  
 
Recent research has shown that parents caring for children with other chronic illnesses 
have an increased risk of stress: 
 
Cancer - Parents experience feelings of loneliness and uncertainty, post traumatic stress 
symptoms, fear of relapses, worries about infertility and uncertainties about the future. 
Although family functioning is satisfactory and consistent over time (220), higher levels 
of stress are associated with lower levels of family cohesion (235). Social support and 
family relationships have shown to significantly influence parental adjustment in a 
number of studies (236-238). Escape avoidance, mainly through wishful thinking, is used 
to a great extent by parents of children with cancer and to an even greater extent by 
parents of children infected with HIV (239). 
 
Autism - Parents with a child with autism tend to use coping behaviours of distancing 
and escape, a behaviour aimed at withdrawal from a stressful situation. Seeking social 
support from within the family’s social network is a large part of the external family 
coping strategies (240).  
 
Type 1 Diabetes – Parents of a child with type 1 diabetes tend to use planful problem 
solving, positive reappraisal and seek social support. Parents must deal with the risk of 
severe insulin reactions, current and future medical complications, repeated 
hospitalisations and the fact that the child’s lifespan may be reduced (241).  
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Cystic Fibrosis - Parents HRQoL is not affected by the severity of the cystic fibrosis. 
The importance for parents to be able to express their emotions and call on social support 
has been reported (242). 
1.7 Epidemiology of HPN in the UK 
Data on the number of patients treated by HPN in the UK has been collected since the 
early 1970s. In 1977 it was decided that, because individual centres in the UK were 
unlikely to accumulate a large experience of this type of treatment, that a national register 
of cases should be established. Data were recorded on the University of Manchester 
/MRC computer at Hope Hospital (243).  The British Artificial Nutrition Survey (BANS) 
has been officially recording this information since 1995 and all providers should be 
supplying data to this register on a regular basis. Each annual report has been 
highlighting increasing numbers of HPN patients.  
 
The majority of adult patients are treated in one of two NCG (National Commissioning 
Group) funded Intestinal Failure (IF) centres: Hope Hospital and Saint Marks Hospital IF 
services were designated from 1 April 1998. However BANS data has identified up to 50 
adult centres with experience of providing HPN at one time or another, only 20 – 25 of 
these centres having regular experience. Many of these other centres are already working 
closely with the two national IF centres whose services can be saturated for long periods 
of time.  
 
Paediatric small bowel transplantation is currently commissioned with Birmingham 
Children’s Hospital and King’s College Hospital in the UK, but the current contract does 
not include the management of those children with complex intestinal failure in whom 
small bowel transplantation may not be necessary. Therefore intestinal failure services for 
children are managed regionally, with approximately 10 centres demonstrating a degree 
of expertise. 
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1.7.1 Adult Prevalence of HPN  
In 2001 BANS estimated that in the UK at any one time approximately 500 patients were 
being treated by HPN, but this could have been as high as 700 allowing for 
underreporting. This 40% inaccuracy in the recorded data may seem large, but was 
probably due to a large number of services treating small numbers of patients (sometimes 
for long periods) and failing to report. However by 2007 this figure had increased to 870 
(period prevalence). The continued collaboration between HPN provision providers and 
BANS to try to obtain accurate numbers means that the current BANS HPN data 
accounts for approximately 91% of all known HPN patients.  
 
BANS publish an annual report which includes detailed information on HPN in the UK. 
The latest 2008 report can be found at the following URL: 
http://www.bapen.org.uk/pdfs/bans_reports/bans_report_08.pdf.  
The BANS data that is most relevant to the subjects in this thesis is the 2001 report.  
 
In 2001 there were 120 new adult HPN registrations; however the total number of 
patients treated by HPN tends not to rise so quickly because of either death or cessation 
of therapy. There are 3 broad categories of patient 
 Those for whom it is likely that PN will be required for a limited period of time – 
e.g. a patient with a temporary stoma formed high in the small intestine 
 Those for whom the underlying disease causing the intestine to fail has an 
uncertain prognosis, but with the provision of PN can live an acceptable quality of 
life 
 Those in whom the prognosis of the underlying disease is usually good and PN 
may need to continue for many years. PN may be reduced if intestinal adaption 
occurs and absorptive capacity improves. (DoH specialised service definitions 
http://www.dh.gov.uk/en/Managingyourorganisation/Commissioning/Commissio
ningspecialisedservices/Specialisedservicesdefinition/DH_4001679) 
 
There was an upward age shift overall from 1996 and 2001, the commonest age range for 
new patients on HPN was 41- 60 years accounting for 50% of new registrations. 
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The majority of patients lived relatively independently on HPN, however there was a 
change in practice across the UK shown by the rate of independent living new 
registrations falling from 75% in 1996 to 55% 2001(BAPEN position paper 2003).   
 
The prevalence of HPN is much higher in the USA than in Europe as much as 3-10 times 
greater (244). This is perhaps explained by the lack of a unified health care system in the 
USA where hospitals benefit from rapid patient discharge and both insurance companies 
and hospitals want all nutrition dependant patients home as soon as possible (245).  
 
1.7.2 Paediatric Prevalence of HPN 
Epidemiological data based on nationwide series of children do not exist (4). The 2007 
BANS report 10 new paediatric HPN registrations which was the lowest number recorded 
since 2001. This is perhaps due to the fall in the number of reporting centres, (in 2005 
there were 10 reporting centres which fell to 3 in 2006). Point prevalence - 95 and period 
prevalence -107, was not considerably different from 2006. The age distribution of new 
and established registrations have changed with the 6-9 years being the most prevalent. It 
is interesting to note that the 13-15 year olds have increased over the period 2000-2006 
which represents the children on permanent HPN getting older (246). 
 
There seems to be little recent data on prevalence of paediatric HPN in the USA. In 1988 
it was estimated that children accounted for 14% of new registrations. Extrapolating from 
the 1988 data Colomb and Ricour suggest that in 2003 at least 16,000 children could be 
involved in HPN programs (247). However it is estimated that HPN in the USA is at least 
10 times higher than in Europe (248).  
 
1.8 Indications for HPN 
Adult and paediatric PN is not so much a treatment for a disease as it is a treatment for a 
complication, notably intestinal failure common to a wide spectrum of diseases (249). It 
is important when looking at HPN therapy to consider the primary diagnosis, as the 
disease more than the therapy dictates the clinical outcome (176).  
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1.8.1 Indications for Adult HPN  
In the UK the commonest indications for adult HPN are Crohn’s disease, mesenteric 
vascular disease, volvulus and surgical complications, which can all lead to short bowel 
syndrome. Other disorders include intestinal fistulae, sequelae of radiation damage 
(radiation enteritis) and motility disorders including pseudo-obstruction syndromes and 
systemic sclerosis. Malignancy accounts for less than 5% of HPN in the UK which is in 
contrast with the some countries in Europe and the USA where cancer is the most 
common indication for HPN. 
 
In 1995 Howard et al (176) published a nationwide survey of Home Parenteral and 
Enteral nutrition in the USA from 1989-1992. They estimate 40,000 patients were 
receiving HPN, cancer being the most common diagnosis. This is perhaps reflected in the 
average treatment time of 60 days. Younger patients had better survival rates, a greater 
likelihood of resuming full oral nutrition after 1 year, but they also had more frequent 
readmission for HPN related sepsis compared with older subjects.  
 
A widening of the age spectrum of patients who started receiving HPN is seen, but the 
authors do not suggest an explanation for this finding. Younger patients generally had a 
better outcome, but the quality of the clinical outcome was good in all groups which 
made it reasonable to conclude that age per se should not disqualify anyone from HPN 
therapy. 
 
1.8.2 Indications for Paediatric HPN 
There is a general consensus in the literature that about 80 % of indications necessitating 
HPN in children are primary digestive (GI) diseases (247) including short bowel 
syndrome (SBS), Inflammatory Bowel Disease (IBD), Chronic Intestinal Pseudo-
obstruction (CIIP) and Intractable Diarrhoea (ID). Some of the primary non digestive 
diseases include immune deficiency, malignancy, cystic fibrosis and radiation enteritis. 
Indications for paediatric HPN have been reported to be the requirement for a return 
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home for a period of greater than 3 months and the wish to preserve the QoL for the child 
and the family (200).  
 
Table 1.3: Indications for HPN in Children  
Disease UK - 2006 (246) France – 2007 
(249) 
USA - 1987 (31) 
Primary GI Disease 86.5% 76% 79.5% 
SBS <5% 47% 33.3% 
IBD <5% 11% 21.5% 
ID 15.8% 26% 14.7% 
CIP 26.3% 10% 9.8% 
Gastroschisis 9.4% Within SBS data Within SBS data 
Autoimmune Enteropathy  8.4% Within ID data Within ID 
Malignancy <5% 2.3% 9.8% 
Immune Deficiency None reported 13.5% None reported 
Miscellaneous None reported 10.2% 10.7% 
 
Table 1.3 shows the latest published figures from the UK, France and the USA. The most 
recent reports from the USA do not distinguish clearly between adult and paediatric cases 
(176;250;251). The latest data from which conclusions can be drawn regarding the 
paediatric population was from 1987 (31). 
 
A review of the literature highlighted the difficulty in comparing different series. There 
are discrepancies in classification of indications. When broader criteria are used and 
specific subgroups are not indicated, for example SBS or ID, it is often possible that a 
disorder can be included in either criterion, for example Crohn’s disease can be included 
in both the SBS and IBD categories. 
 
Interestingly the UK experience appears to differ greatly from France and the USA, <5% 
being those with SBS and IBD. The authors of the report do not comment on this.    
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1.8.3 HPN in Cancer/Immune Deficiency 
HPN is a therapy considered for conditions where weight loss results primarily from 
increased catabolism, due to infections such as HIV or secondary malignant disease (11). 
In different clinical situations, a patient with cancer may benefit from HPN, for example, 
where a patient has a potentially curable cancer in which treatment may cause temporary 
bowel dysfunction, or where curative treatment has required massive bowel resection or 
abdominal radiation (252). Ethical problems start to arise when considering the terminal 
nature of untreatable malignancy.   
 
The primary purpose of cancer treatment is to improve the quality of patients’ lives by 
either curing their disease and/or ameliorating their worst symptoms for as long a period 
as possible (253). If a patient is expected to die earlier because of tumoral spread rather 
than starvation, there is no role for nutritional support (254;255).    
 
The use of HPN in malignancy and immune deficiency syndromes is often controversial; 
however it is not a new phenomenon. Copeland et al was the first group to initiate a TPN 
program for malnourished cancer patients, allowing those patients to withstand the 
inherent complications of intensive oncologic therapy (116). As early as 1970 authors 
report the use of TPN in 26 cancer patients (117) and from 1978 reports of the use of 
HPN for cancer in both adult and paediatric series started to emerge 
(31;156;176;177;182;225;250;256). The use of PN in active cancer was initially debated, 
due to questions regarding the potential for acceleration of tumour growth and possible 
septic complications (257), however further study demonstrated that PN was safe and 
efficacious in oncologic patients (258;259).  
 
HPN therapy in immune deficiency started to appear in the early 1990s, however the 
incidence of infection in relation to HPN treatment has been found to be high compared 
to other groups. This was explained by the special susceptibility of AIDS patients to 
infections and the frequent use of the nutritional catheter for antibiotic therapy or other 
purposes (260) and HPN use seems to have decreased due to more efficacious therapies 
(261). 
 56     
It is now well reported that the practice of providing HPN in malignancy differ 
throughout the world (11) and there are wide differences in culture on what is considered 
appropriate use for HPN. In the UK it is comparatively uncommon and it is seen more in 
North America (262) and other countries in Europe such as Italy (170). Violante (263) 
report that out of 140 patients studied, 88% of the HPN recipients had cancer.  
 
Jonkers-Schuitema (264) wrote an excellent editorial on the controversial use of HPN in 
palliative care, and presents both positive and negative points of pursuing this path. The 
terminal nature of malignant disease and AIDS means that patients usually only survive 
for short periods, and patient selection is very important (170). HPN is life prolonging, 
but only of value if the quality of life for both the patient and carers is also preserved. 
The current literature states that the majority of patients with incurable metastatic disease 
should not receive TPN at home (257;265-268). However Hoda et al (269) found that 
TPN can increase long term survival in very select patients with incurable cancer.  
Bozzetti et al (270) was the first to publish QoL data in a series of 69 advanced cancer  
patients receiving HPN, their main reason for nutritional support was the attempt to 
prevent an early death due to starvation in aphagic or obstructed patients. They concluded 
that it may benefit patients who survive longer than 3 months, yet in a further report go 
on to state that there is scarce accuracy of prediction on the length of survival in 
malignancy (271). In 2004 Orevall et al (272) found that the desperate and chaotic 
nutritional situation in the family led to a willingness to accept HPN and that it was 
viewed as a positive alternative. This study was followed up by further paper in 2005 
(273) which discussed the views and experiences of HPN in the same population. They 
conclude that physical, social and psychological benefits were gained from HPN. 
 
One of the main concerns of the use of HPN in malignancy is its fluctuating identification 
as a treatment or just basic care. Obviously some countries consider it a palliative type of 
medical intervention (263), while others believe wasting in malignancy appears to relate 
to a range of tumour induced metabolic disturbances, involving cytokines and appetite 
inhibiting peptides. Under these circumstances,  nutritional support may not effectively 
redress the wasting but does expose the patient to the risks associated with parenteral 
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nutrition (274). Experience reported in the literature states that the preservation of 
nutritional status from progressive deterioration is a more common outcome than its 
restoration to normal (270). 
1.9 Complications of HPN 
HPN is a complex procedure and complications, although not always fatal, can result in 
increased hospital readmissions and increased costs, thus resulting in a series of poor 
outcomes (275). This was recognised as early as 1969 in infants (127;276). The most 
common complications of HPN are catheter related sepsis, catheter occlusion, liver 
disease and metabolic bone disease. 
 
1.9.1 Catheter Related Sepsis 
Both adult and paediatric HPN patients can have fever from many causes, but if no 
symptoms or signs point to other causes, the chief concern becomes catheter related 
sepsis.  
 
Adult Catheter Related Sepsis  
Although septic events are rarely fatal, they are the most common type of catheter related 
problem (>80%) and the most frequent reason for hospital readmission, so prevention is 
an important issue (277). Prevention of a septic episode may be much less expensive than 
treating one (116). Catheter infections are generally secondary to touch contamination 
and patient education. Less commonly infection can result from the infusion of 
contaminated fluids (252). Nursing technical expertise and compliance monitoring are 
vital components for preventing infections (275). Aggressive antibiotic treatments are 
often initiated to salvage a patient’s catheter and prevent removal or replacement (278). 
Catheter sepsis rates have been shown to be decreased in very long-term HPN survivors 
(279) and in patients whose underlying disease was stable (12).  
 
In adults, the latest published data reports a range of 0.31-0.35 episodes of sepsis per 
patient year (76;170;280;281). Coagulase-negative staphylococcus is the most common 
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CVC infection in adult HPN patients followed by Klebsiella pneumoniae, 
Staphylococcus aureus, and Enterococcus (282;283). 
 
Paediatric Catheter Related Sepsis 
In paediatric HPN, catheter related sepsis no longer represents a major cause of death (4). 
It is difficult to assess whether sepsis is a result of poor training or execution, or is a 
consequence of a more complex underlying disease which facilitated the occurrence of 
infection (4) Catheter removal is necessary in case of fungal infection, exit site cellulitis 
or tunnel infection, secondary infection or unsuccessful antibiotic treatment (182). 
 
Sepsis occurs more in children than adults (224). Risk of CVC related infections in 
children has been found to be higher in children requiring HPN from early infancy than 
those started after the first year of life (196), higher in the first 2 years of HPN 
(224;284;285) and with SBS and neuromuscular intestinal disorders (286), and lower in 
patients with CIPS  (284) and intractable diarrhoea (287). Patients with SBS and 
neuromuscular disorders display a high frequency of intraluminal bacterial overgrowth 
due to dysmotility which may be responsible for the increased prevalence of sepsis (286). 
Staphylococcus aureus and coagulase negative staphylococcus are generally the most 
frequent bacteria found in positive cultures (285). The incidence of CVC related infection 
has been reported to be between 0.41 - 0.78 episodes per patient year (224;284). 
 
1.9.2 Catheter Occlusion 
Catheter occlusion is a common complication of central venous access devices (275) 
where the lumen of the catheter becomes blocked or occluded.  It may be caused by  
faulty catheter care, inappropriate infusion regimen (170) or secondary to drug 
thrombosis (288) It has been reported to occur at a rate of 0.071 episodes per patient year 
in adults and paediatric HPN (170) and is twice as common in those with congenital 
bowel disorders (289).  
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1.9.3 Venous Thrombosis 
Venous thrombosis is a result of fibrin deposition and venous clot formation (290) and 
may be associated with catheter sepsis (277). Richards et al systematic review of HPN 
found the overall rate in adult and paediatric HPN to be 0.027 episodes per catheter year 
(170). 
 
When a catheter is removed, local scar tissue develops resulting in the loss of an access 
site. Loss of venous access can ultimately result in higher rates of mortality in HPN (37), 
so preservation of venous access is of paramount importance. 
 
1.9.4 Liver Disease 
Hepatic complications can present as a broad spectrum of pathologic entities, including 
steatosis, cholestasis, steatohepatitis, fibrosis and cirrhosis (291-296). These 
complications are reported to occur in adults and children at a rate ranging from 15-85% 
(292;293;297-300).  The rate and extent of development of HPN related liver disease can 
be influenced by many factors including the presence of SBS (298;299), intestinal 
bacterial overgrowth and translocation. It is thought that one of the causes is when an 
excessive intake of glucose causes sugars to be transported to the liver and converted into 
fat that cannot then be transported to peripheral fat stores, resulting in massive steatosis 
of the liver (116). Mildly abnormal liver function tests are well documented in prolonged 
parenteral feeding, and in most patients these abnormalities remain stable. However in a 
few patients more serious hepatic dysfunction develops eventually progressing to 
cirrhosis if not treated (277). 
 
In 1979 the first documented case of TPN associated liver disease was in a premature 
infant who developed cholestasis (301). Patients with surgically induced intestinal failure 
are more likely to encounter HPN related liver disease (227), and it is more common in 
neonates who have recurrent episodes of sepsis and is reported to develop in 40-60% of 
infants on long term PN (200;302). In adults liver disease has been reported to occur in 
between 8-14% of patients (76;281) and is more common in SBS patients (277). 
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1.9.5 Metabolic Bone Disease 
Metabolic bone disease refers to the conditions that are characterised by a diffuse 
decrease in bone density and strength (303). It has been suggested that 40-60% of 
patients on HPN have histologic features of decreased bone density or metabolic bone 
disease (304), and that 40-100% of adults may have some degree of bone 
demineralisation (304-306). The incidence of  metabolic bone disease in the adult and 
paediatric HPN population remains unknown (303;307). In 2002 Pironi et al conducted 
an international multi-centred study on the prevalence of HPN bone disease and found 
that bone disease was present in most of the adults on HPN (84%) and that it was severe 
in half and symptomatic in one third of the population studied (305). The pathogenesis of 
HPN related bone disease is poorly understood, and is probably multi-factorial (308). 
Further research is needed to better understand its pathophysiology and treatment.  It is a 
debilitating complication which may render the patient immobile and cause substantial 
pain (37). 
 
1.9.6 Other Complications 
Other complications include both medical and psychosocial maladies (34). Renal 
dysfunction (309) and neuropathological problems (310) have also been described in 
patients on HPN. Metabolic complications are more frequent in patients who can not 
have any oral intake, in those receiving glucose and lipid infusion greater than 
6mg/kg/min and 3g/kg/day respectively and after long term administration of unbalanced 
formula (311-313). 
 
Children fed with prolonged HPN may experience difficulty in establishing oral feeding, 
but little attention has been focused on the major behavioural difficulties these infants can 
experience (314). Developmentally non-oral feedings, especially during infancy, may 
interfere with the association of eating as a pleasurable experience (315). 
 
HPN complications can be reduced with good training, meticulous aseptic technique, 
careful monitoring and prompt response to clinical indicators. There are several case 
reports which demonstrate the provision of HPN for over 25 years (316-318). 
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1.10 Survival / Outcome in HPN 
The introduction of parenteral nutrition has significantly improved the prognosis of 
patients with major abnormalities in which the use of the GI tract has been precluded for 
extended periods of time. HPN patient outcome is the result of several factors such as 
evolution of the underlying disease, general clinical condition, level of care and family 
and social support (263). The overall prognosis of HPN patients depends on the prognosis 
of the underlying disease (61). 
 
1.10.1 Adult Data 
All human beings will eventually die, and to properly assess or interpret mortality rates in 
a population you either need a critical comparison of a similar cohort, or you need to 
evaluate observed versus expected mortality. Unfortunately data of this nature was not 
available. A simple review of the literature demonstrated that HPN patients in the UK 
had varying observed total death rates (see table 1.4) over the various time periods 
studied. This table does not indicate total mortality, but highlights the fact that the 
majority of deaths in this cohort were unrelated to the HPN and could be attributed to the 
underlying diagnosis or another medical illness. It is however difficult to clearly define if 
a death is clearly due to HPN or not. For example if a patient on HPN commits suicide, 
could this be attributed to HPN therapy? In the Freshwater series, the one death related to 
HPN was due to septic central vein thrombosis (281). In the Lloyd series, 3 deaths were 
due to septicaemia resulting from CVC infection and two deaths were due to hepatic 
failure resulting from HPN related liver disease (76). The one HPN related death in the 
Green series was due to line sepsis (280) and the O’Hanrahan paper uses the term HPN 
related deaths, but does not elaborate on specific causes (225).          
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Table 1.4: Adult Death Rates in UK HPN Patients 
Paper Year N Study 
Period 
Total Observed Deaths 
(%) over the study period  
Deaths Stated to be 
clearly due to HPN (%) 
(76) 2006 188 1979-2003 55 (29) 5 (9) 
(280) 2008 88 1990-2004 12 (13.6) 1 (1.1) 
(281) 2005 23 1989-2002 9 (39.1) 1 (4.3) 
(225) 1992 400 1977-1991 69 (17) 15 (22) 
 
The latest data from the UK shows that overall probability of survival is 86%, 77%, 73% 
and 71% at 1, 3, 5 and 10 years. An almost 3 fold risk of death in patients starting HPN at 
>55 years compared to those starting at <54 was observed. Patients with SBS have the 
most favourable outcome, while GI dysfunction/dysmotility (pseudo-obstruction, 
radiation enteritis or systemic sclerosis) are associated with a threefold increase in 
mortality, and intestinal obstruction is associated with a six fold increase in mortality. 
Unsurprisingly survival is poor in those with an underlying diagnosis of neoplasia. No 
association between small bowel length and prognosis was found. Continued dependence 
on HPN was seen in 89%, 87% and 84% at 1, 3 and 5 years (76). 
 
1.10.2 Paediatric Data 
Although there are a number of articles which look at the outcome/prognosis of HPN, 
they lack specific details about the nutritional support received and do not clearly 
distinguish between adult and paediatric data (176;225;250;251), and have been excluded 
from the table 1.5 below. 
The recovery of enteral autonomy, if it occurs, is almost always within the first 2 years in 
adults, but in children recovery can take much longer (251). 
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Table 1.5: Outcome of Paediatric HPN  
Author Year Country N Still on 
HPN* (%) 
Weaned 
(%) 
Death 
(%) 
Death due to 
HPN (%) 
Vargas (31) 1987 USA 102 21 (21) 51 (50) 31 (30) 13 (41) 
Ricour (200) 1990 France 112 45 (40) 49 (44) 18 (16) 2 (11) 
Weber (83) 1991 USA 9 1 (11) 7 (77) 1 (1) 0 (0) 
Candusso (218) 1995 Italy 19 5 (26) 10 (52) 3 (16) 0 (0) 
Candusso (287)  2001 Italy 36 15 (42) 14 (39) 7 (20) 4  (57) 
Holden (202) 2001 UK 38 32 (84) 2 (5) 4 (10) 1 (2) 
Colomb (249)  2007 France 302 78 (26) 163 (54) 48 (16) 11 (24) 
BANs (246) 2007 UK 79 51 (65) 16 (20) 12 (15) 0 (0) 
Total - - 697 248 (35) 312 (44) 124 (17) 31 (4) 
* Patients who were still receiving HPN at time of publication 
 
There are 2 errors in the Vargas et al paper (31), the numbers of patients still on HPN, 
weaned and deceased add up to 103, yet the authors are reporting 102 patients. Also they 
state the number of patients on HPN for malignancy was 11, but this does not correspond 
with the table which only accounts for 10. 
 
It is of interest to note that the in Colomb series 13 patients underwent small bowel 
transplantation, of which 11 survived, although 5 patients had to restart HPN after 
transplantation failure (249). 
 
1.10.3 Significance of the Underlying Disease in Paediatric HPN 
To try and determine the significance of the underlying disease data regarding the cause 
of death was analysed from each of the papers from table 1.5.   
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Table 1.6: A Breakdown of all Causes of Paediatric HPN Mortality from Table 1.5 
Complication N (%) 
Underlying disease 79 (63.7) 
Catheter related sepsis 15 (12) 
TPN induced liver failure 12 (9.6) 
Unknown 9 (7.2) 
Other/Miscellaneous  6 (4.8) 
Haematological complication of lipid emulsion administration 1 (0.8) 
Nursing error  1 (0.8) 
Fluid overload 1 (0.8) 
Total 124 
 
The data in table 1.6 clearly shows that the biggest influence on survival is the underlying 
disease, the significance being sufficiently strong that broad international agreement has 
been reached to describe outcome in terms of the specific primary disease 
(176;261;319;320). 
 
The prognosis is poorer for patients treated for malignancy, immune deficiency disease 
(31) and intractable diarrhoea (249) and better for congenital short bowel syndrome 
(200;321) and IBD (249). Age also has an impact on survival, the younger the child at the 
start of HPN, the higher the risk of death (249). 
 
1.11 Cost Issues 
 
Clearly HPN is preferable to inpatient TPN both in terms of patient satisfaction and cost 
(225). There are studies from the UK (199;322), USA (323-327), Canada (328) and 
France (329), which examined the economic aspects of HPN and showed that HPN was 
between 65%-85% cheaper than alternative hospital treatment, making it considerably 
more cost effective and freeing beds in tertiary care facilities (210). However the data in 
these studies do not use the same methods to estimate costs, making it difficult to 
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compare when also taking into account different currencies, time scales and inflation. 
There will be difficulty interpreting the data until there is a consensus regarding 
expression of the result. 
 
The majority of economic appraisals of HPN use cost utility analysis, the 2 most cited 
cost utility studies are from Canada in1986 (328) and the UK in 1996 (322). Detsky et al 
showed HPN gave an estimated net saving of  Can $19,232 per patient over 12 years 
(328). The data from Richards et al suggested that HPN was more cost effective than 
hospital care, that the cost utility of treating younger patients was more favourable than 
treating older patients and that the estimated cost of HPN for an adult with benign disease 
in the UK was £36,000 per year after an initial £45,000 cost, with a calculated cost of 
£69,000 per quality of life year (322). To date there are no published extensive economic 
appraisals of paediatric HPN and several paediatric reviews are based on adult data 
(330;331). One study estimated that even in stable children on HPN the average cost was 
£159,000 over 30 months (332). 
 
Some of the typical costs of an HPN programme include clinic visits, drugs, laboratory 
tests, nursing visits, inpatient episodes, pumps, intravenous solutions (327) training of 
patients, consumable and disposable supplies (331).  
 
In France, Canada and the UK the financial burden of HPN is borne almost entirely by 
the NHS. In the USA third party carriers pay 80% of the costs with many patients finding 
it hard to pay the balance (331). In the USA to qualify for Medicare reimbursement HPN 
must be required for at least 3 months, fat malabsorption must be documented and enteral 
feeding must have failed (10). In the UK, often the obstacle in discharging patients home 
is organisation of the finance (199). However this may not be the case for much longer 
due to recent budget changes in the NHS, meaning that the hospitals will now only pay 
for the first 14 days of TPN and thereafter the primary care trusts are billed for the 
service.  Paediatric studies have found that financial savings to the acute hospital trusts 
can be made if the rate of CVC insertion is reduced (333). Costs are also reduced because 
of the change of the labour force from professionals to carers or parents (228). 
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1.12 Small Bowel Transplantation (SBTx) 
 
1.12.1 Adult Small Bowel Transplantation (SBTx) 
If successful, SBTx restores the ability of digestion and can result in weaning from HPN 
sometimes within as little as 4 weeks (334). Although Small Bowel Transplantation 
(SBTx) is seen as a relatively new discipline, intestines were actually one of the first 
organs transplanted in man (335), and the first attempts documented were in 1967 (336). 
However success with intestinal transplantation has lagged behind that of other solid-
organ transplants partly due to the advanced state of malnutrition and chronic illness seen 
in most patients referred (337). 
 
In the late 1990s the issue of SBTx started to emerge as it evolved from an experimental 
procedure to an invaluable treatment for patients with intestinal failure and life 
threatening complications of HPN (334). The early experience of SBTx was restricted by 
intense graft rejection. In 1989, a study of the use of immunosuppressant Tacrolimus 
(FK506) in intestinal transplant patients (3 adults and 6 children) (338) demonstrated 
improved outcomes. However, poor outcomes are still limiting the widespread 
application of this procedure and even in the most recent era, SBTx still does not match 
but approaches survival of adult patients dependant on TPN (320;339), and HPN is still 
considered the primary therapeutic option (44) for irreversible intestinal failure.   
 
In the UK the Department of Health, through the National Commissioning Group (NCG), 
recognises and funds 4 units for small bowel transplantation, 2 adult centres; 
Addenbrookes Hospital, Cambridge and John Radcliffe Hospital, Oxford, and two 
paediatric centres: Birmingham Children’s Hospital and King’s College Hospitals.   
 
1.12.2 Paediatric Small Bowel Transplantation (SBTx) 
 
Paediatric SBTx is feasible even in small infants and good intestinal function and 
independence from HPN has been achieved in children (340).  
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It has been recommended that children with chronic intestinal failure be identified and 
referred for assessment for SBTx early, in optimal nutritional status before liver 
dysfunction is established (341), as paediatric survival and recovery following combined 
liver and intestinal transplant is probably lower than following an isolated transplant. 
Also, recipients of an isolated intestinal allograft tend to wean from PN more quickly – 
median time 27 days, compared to 40 days for a combined liver and SBTx (342). A 
multidisciplinary approach to SBTx is thus vital, Beath et al (341) noted marked 
discrepancy between children referred for evaluation from centres with and without 
nutritional care teams, children coming from hospitals with multidisciplinary care teams 
were better nourished and had fewer CVC infections. 
 
One issue that may impede paediatric SB transplantation is donor recipient size 
incompatibility. Most candidates have had massive bowel resections with a subsequent 
reduction in the size of the peritoneal cavity. Therefore they often require donors who are 
50-75% smaller, thereby limiting the field of potential donors (43).  
 
Both HPN and SBTx can be highly effective treatments of intestinal failure, but each 
have a specific psychosocial impact and are capable of permitting children a normal 
participation in society (221). For approximately 6-12 months post transplantation, care 
routines of transplanted patients may include up to 15 daily medications, tube feedings, 
intravenous fluids and maintenance of the gastrostomy tube, jejunostomy tube, ostomy 
and central venous catheter. These routines decrease over time, but a mean of 7 daily is 
still required at >3 years (343). In a recent study the majority of parents state that caring 
for their post transplant child is easier than before transplant (221), although hostility and 
obsessive compulsive dimensions related to post operative adjustment have been reported 
in parents or carers in the postoperative period (344). It is interesting to note that in one 
study only six families (out of 14) said they would consider (paediatric) bowel 
transplantation (202) possibly suggesting that the majority were satisfied with HPN. 
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1.12.3 Indications for SBTx 
In September 1991 an Intestinal Transplantation (IT) program was initiated in Los 
Angeles USA (345). They were the first group to suggest criteria for SBTx and 
transplantation criteria continues’ to be debated. However the most recent adult and 
paediatric transplant criteria as defined by Medicare in the USA are (10): “failure of HPN 
therapy” by the development of one or more of the following complications: 
 Impending or overt liver failure 
 Thrombosis of major central venous channels (2 thromboses in subclavian, 
jugular or femoral veins)  
 Frequent CVC sepsis (2 episodes of systemic sepsis secondary to CVC infection 
per year, 1 episode of CVC related fungemia, septic shock or acute respiratory 
syndrome) 
 Frequent severe dehydration 
 
This is in contrast to the American Society of Transplantation paediatric guidelines which 
include patients at high risk of death from their primary disease or with high morbidity 
intestinal failure and which emphasise the need for preserving vascular access (342). 
 
The rate and the indications for adult and paediatric candidacy for transplantation differ, 
the rate being nearly twice as high in paediatrics and the indications being mainly related 
to the high risk of death related to the underlying disease (pre-emptive transplant), 
whereas in adults its mainly due to the failure of HPN (346).  
 
1.12.4 Adult and Paediatric SBTx Current Figures 
The Intestinal Transplant Registry is a collaborative effort among all centres performing 
intestinal transplantation which reviews the worldwide experience of SBTx 
(http://www.intestinaltransplant.org/). The Registry data is collected every two years 
from each centre and a report is produced. As of May 2009, there are 73 centres 
worldwide which have performed 2188 intestinal transplants in 2038 patients. The main 
condition leading to both adult and paediatric transplantation was short gut (58% and 
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68% respectively). Advances in surgical, clinical and immunosuppressive management 
since 1995 have improved patient survival and currently one year survival is 
approximately 80% and 5 year survival is approximately 50%. Waiting at home and 
being transplanted at a high volume centre are associated with superior survival rates, 
while the presence of a concurrent liver graft is associated with better long term survival 
(M. Marquez MD, Intestinal Transplant Registry Data November 2009, personal 
communication 3rd November 2010). 
1.12.5 QoL After Intestinal Transplantation 
If a patient on HPN has a satisfactory QoL, at which point should they be referred for 
SBTx assessment? QoL issues surrounding HPN and SBTx have been studied, but as yet 
no adult or paediatric study has clearly demonstrated a difference in the QoL between 
stable patients on HPN and transplant patients (277;342).  
 
Small bowel transplantation in adult and paediatric recipients offers a realistic alternative 
to HPN and often the choice of treatment is highly influenced by expected QoL 
outcomes.  
 
When intestinal failure is irreversible, and dependency on HPN becomes life long, SBTx 
can be a considered as an alternative treatment. Obviously if HPN treatment fails, then 
SBTx must be considered. This is a black and white picture as there is really no 
alternative and so often is considered as a last resort. Unfortunately this means that 
patients referred for transplantation are often very sick resulting perhaps in poorer 
outcomes.  
 
The issue of SBTx in patients who are well and managing on HPN is a greyer area. 
Whilst it would seem prudent to refer early, the poor outcome rates often halt this 
process. This is where the identification of QoL becomes essential. If a family and/or 
patient appears to be coping well with the HPN therapy, and QoL is deemed good, then is 
there a need for SBTx? Some authors suggest that most patients receiving HPN therapy 
do not develop life threatening complications and therefore have a prognosis superior to 
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that offered by SBTx (345). In practice, the Royal London Hospital tends to avoid 
referring patients for SBTx unless really necessary, as definitely, clinically HPN is 
considered a safer option. 
 
Fiscal evaluations of SBTx yield no clear economic conclusions. HPN is as good as 
transplant, but the balance between it and prolonged HPN in  terms of clinical and cost 
effectiveness and QoL remains equivocal (11). It is mandatory to assess carefully the 
respective costs of long term HPN and intestinal transplantation with the highest 
consideration for the best option in terms of QoL for both patients and their carers (347). 
 
 1.13 Definition and Origins of Quality of Life (QoL) Research 
The biggest problem faced by those wishing to measure and quantify QoL lies in the 
definition of the term. Many definitions are ambiguous and therefore do not allow 
consistent and obvious methods of measurement. The origin of QoL measurement is a 
relatively new concept, and it is an area which is still evolving.   
 
Politicians, philosophers, priests, psychologists, physicians and patients might all offer 
different definitions as to what constitutes QoL, and few of these descriptions would 
allow obvious and consistent methods of measurement (253).There is no consensus or 
absolute definition as QoL is conceptually a subjective term (253). But in 1993 the WHO 
defined QoL in relation to health as: 
 
The perception by individuals of their position in life, in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, standards 
and concerns (348). 
 
Previous generations understood very well that striving to keep people alive could be 
inappropriate. Historically medical workers have basked in the clear moral light of 
working to keep people alive (349). However it is in more recent times that issues 
surrounding the quality rather than quantity of life have arisen. 
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The concept and measurement of QoL entered medical research from two different 
sources – medical health status indices and social science population indices.  
 
The developments of functional status indexes were designed to examine non-biologic 
and objective aspects of patient daily behaviour. Functional health status was defined as 
the ability to perform routine self-care, to complete basic activities and on the basis of the 
level of independent living. The first functional classification scale for adults was 
published in 1937 (350). 
 
In 1948 the WHO defined health as: not only the absence of infirmity and disease, but 
also a state of complete physical, mental and social well being. This prompted 
governments to develop indexes designed to examine the social aspects of health, the 
personal impact and the steps taken to prevent illness, and the relation of medical care to 
other demographic variables. 
 
The first mention of quality of survival in a clinical trial was not seen until 1966 (351), 
and the term quality of life first entered medical literature in this year, although the 
literature contained no specific instruments for measuring QoL until 1970 (352;353). In 
1974, Social Indicators Research, a new journal which was dedicated to research on the 
QoL, was first published. The first QoL measure to gain popularity was Preistmans and 
Baums 1976 Linear Analogue Self Assessment Scale (354).  
 
For the next decade QoL instruments were appraised and developed. However in the mid 
1980s two events provided the impetus for measuring QoL in clinical trials. Firstly in 
1985 the Food and Drug Administration decided that QoL data was required as one of the 
key efficiency parameters in clinical trials. This resulted in the need for validated QoL 
instruments. The second event occurred when QoL data was for the first time a primary 
outcome in a clinical trial (355) to assess the QoL of patients taking one of 3 hypertensive 
medications. Soon it became obvious to pharmaceutical companies that their products 
could be promoted, not just for physiologic effects, but also for effects on QoL.     
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1.13.1 Types of QoL Measurement 
There are now a plethora of QoL instruments available to health professionals, which can 
be generic, disease specific or global. 
 
Generic instruments are used in general populations to assess a wide range of domains 
applicable to a variety of health states, conditions, and diseases.  
 
Disease specific questionnaires are designed to be used in populations with specific 
diseases. The questions are well defined and aim to detect aspects of the disease which 
are thought to have an impact on QoL. Disease specific questionnaires are also useful in 
determining the impact of interventions designed to influence symptoms of the disease.  
 
Global measures are those designed to measure QoL in the most comprehensive or 
general manner. This may be a single question that asks the respondent to rate their QoL, 
or an instrument such as the Flanagan QoL scale (356) that asks respondents to rate their 
satisfaction on 15 domains of life. 
 
The number of items in the questionnaire relates to the actual number of questions to be 
answered. The advantage of questionnaires with a small number of items is that people 
rarely mind completing them, however it is often harder to draw meaningful analysis 
unless you have a large sample size, and conclusions are very general due to the limited 
nature of questions. A questionnaire with a large number of items can be used to obtain 
more information, yet completion can often be poor meaning missing data has to be 
negotiated. 
 
Administration of the questionnaire is an important factor to consider in choosing the 
instrument. Questionnaires are designed to be completed by self administration, by an 
interviewer, or by telephone, and in rare cases to be used in group sessions. Weinberger 
et al (357) reported telephone and interviewer administration produced fewer missing 
data than self administration. It would be inappropriate to expect a respondent to 
complete a questionnaire on their own when it is designed to be administered by an 
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interviewer. Many of the questionnaires have been adapted for administration over the 
telephone. In these cases a strict script has been developed which must be adhered to. It is 
vital that the telephonist does not influence the respondents answers, as it may lead to 
over optimistic data (358). 
 
For some instruments there is a normative database available. A known database can be 
an essential method of comparison between different populations. Community norms are 
important as they provide a base level of results on the questionnaire (359). 
 
Time recall is the point in time upon which you are asking patients to rate their QoL. 
Many of the questionnaires try to illicit how a person currently feels, whereas others are 
more concerned with how a person has been feeling over a set period of time – for 
example over the last month. When choosing which instrument to use you must decide 
what time recall is appropriate for your population. 
 
A suitable QoL instrument should have been subjected to extensive studies of 
psychometric properties such as reliability, the tendency to answer questions in a 
consistent manner, and validity, the tendency for respondents’ answers to correspond 
with their other known characteristics. QoL evaluation is part of the skilful clinician’s 
armamentarium (360). 
 
1.13.2 QoL Measurement in Paediatrics 
Health Related QoL (HRQoL), health status and functional status are terms often used 
interchangeably to describe patients’ perceptions of their health, but HRQoL is 
considered the more comprehensive term (361;362). Much of the impetus for more 
formal measurement of child QoL has come from work in paediatric oncology and 
neonatal intensive care (363). The first formal attempt to measure paediatric QoL in 1985 
is often credited to Lansky et al whose measure remains in use today (364).   
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In paediatrics several issues, including cognitive development considerations complicate 
the decision regarding the best respondent for HRQoL assessment. Some measures allow 
for self report while others rely on a proxy such as a parent, teacher or clinician to rate 
the child’s HRQoL. However, self report and proxy report often do not agree. Research 
has demonstrated that children younger than 5 are not able to self report their health and 
well being (362). Parents have been shown to be better able to rate externalising 
(physical) compared to internalising (emotional or social) problems (365) and they may 
also be influenced by the development of other children they know, their expectations 
and hopes for their child, additional life stresses, their own mental health (366) and the 
burden of care giving (367). It has been shown that agreement is better between parents 
and chronically sick children compared with parents and healthy children (367).     
All currently available paediatric measures have some limitations (363), are few in 
number and still in the early stages of development (362). Among disease specific 
measures, asthma, cancer and epilepsy have received most attention. For children with 
other conditions it is only possible to rate QoL using generic measures (366).   
 
1.13.3 Quality of Life Instruments Database 
The success of QoL research greatly depends on the choice of appropriate instrument. In 
2002 the Quality Of Life Instruments Database (QOLID) project was initiated to provide 
a comprehensive and unique source of information on QoL measures, which is available 
through the internet (http://www.qolid.org/proqolid/). Its aims are to provide an overview 
of existing instruments, to assist in the choice of appropriate instrument and to facilitate 
access to instruments and their developers (368).    
 
A search engine allows criteria based queries to be made including type of instrument, 
pathology, target population, language and mode of administration. In 2008 the Quality 
of Life Instrument Database contained 72 adult generic instruments, 13 generic paediatric 
instruments and 33 instruments for digestive system diseases only one of which was 
designed for use in paediatrics. 
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1.13.4 Short Form 36 Questionnaire (SF36) 
The 36-item short-form questionnaire (SF36), see Appendix 1, was constructed to survey 
health status in the Medical Outcomes Study (369). The SF36 was designed for use in 
clinical practice and research, health policy evaluations, and general population surveys. 
It has excellent reliability, validity and responsiveness (370). The SF36 includes one 
multi-item scale (36 items) that assesses eight health concepts:  
 Physical Functioning (PF) - limitations in all physical activities including 
bathing and dressing due to health problems. 
 Role Physical (RP) - limitations in usual role activities because of physical health 
problems. 
 Bodily Pain (BP) – limitations due to pain. 
 General Health (GH) – evaluates personal health. 
 Vitality (VT) - evaluates energy and fatigue. 
 Social Functioning (SF) - limitations in social activities because of physical or 
emotional problems.  
 Role Emotional (RE) - limitations in work or other daily activities because of 
emotional problems. 
 Mental Health (MH) – evaluates feelings of nervousness and depression.  
Scores range from 0 – 100, the higher the score, the higher the QoL in that domain. 
The survey was constructed for self-administration by persons 14 years of age and older, 
and for administration by a trained interviewer in person or by telephone. 
Normative data (age and gender specific) for the UK population is produced by the 
Health Services Research Unit Oxford (371).   
 
1.13.5 Hospital Anxiety and Depression Scale (HADS) 
The HADS (see Appendix 2) is a brief  (14 item), self report measure of anxiety and 
depression developed by Zigmond and Snaith (372). It was developed for use in general 
medical outpatients clinics, but is now widely used in clinical practice and research (373). 
The Authors recommend that for the anxiety and depression scales alike, raw scores of 
less than 7 indicate no case, scores between 8 – 10 identify mild cases, 11 – 15 moderate 
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case, and 16 or above severe cases. However in 2001 normative data was produced for 
the UK from a large non clinical sample (374) which suggested a single higher cut off of 
10-11 should be used to categorise cases as only moderate or severe. 
 
1.13.6 EuroQoL 5 Dimensions Instrument (EQ5D) 
The EQ5D questionnaire (see Appendix 3) is a generic measure of health status (5 items) 
developed by the EuroQoL group (375), an international research network established in 
1987 by researchers from Finland, the Netherlands, Sweden and the UK. Health is 
defined in terms of 5 dimensions: mobility, self care, usual activities, (work, study, 
housework, family or leisure), pain or discomfort, and anxiety or depression. Each 
domain is subdivided into 3 categories which indicate whether the respondent has no 
problem, a moderate problem or an extreme problem in each dimension. Applicable to a 
wide range of health conditions and treatments, it provides a simple descriptive profile 
and a single index value for health status that can be used in the clinical and economic 
evaluation of health care as well as population health surveys. EQ5D has been specially 
designed to complement other quality of life measures such as the SF36, Nottingham 
Health Profile (NHP), Sickness Impact Profile (SIP) and some disease-specific measures. 
In 1998 normative EQ5D data was published using a large sample of 3395 UK 
individuals representative of the general population (376). 
 
1.13.7 The Ways Of Coping Questionnaire (WOCQ) 
Stress is experienced as a developing dynamic reciprocal transaction. This means that the 
individual’s interpretation with a stressor is neither a reaction nor a response, but rather a 
transaction between his or her appraisal of the level of threat to his or her well being. In 
other words, the individual feels stressed only when he or she assesses the event taxing 
his or her psychological resources. Coping involves the use of cognitive and behavioural 
strategies to deal with the demands imposed by the stressful experience (241). Mediators 
of stress are those behaviours, perceptions and resources persons use or posses to 
influence the experience and management of stressful experiences (228;377). 
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How individuals cope with stress, not stress per se, influences their psychological well-
being, social functioning and somatic health. The WOCQ was developed to provide 
researchers with a theoretically derived measure that could be used to explore the role of 
coping in the relationship between stress and adaptive outcomes (378). It is designed to 
be both interviewer and self administrated. 
 
The WOCQ (see appendix 4) consists of 66 items which aim to identify the thoughts and 
actions an individual has used to cope with a specific stressful encounter by measuring 
coping processes. The respondent is asked to think about the most stressful situation they 
have experienced within the last week. “Stressful” is defined as being a situation which 
was perceived as being difficult or troubling either due to the requirement of a 
considerable effort to deal with the situation or distress. It can include work, medical or 
car problems, discussion or confrontation, separation from someone you care about or 
something else. 
 
The 66 items represent thoughts and actions that can be used to deal with stressful 
situations. The respondent rates each item on a 4 point scale from “not used” to “used a 
great deal” (235). Adequate reliability and validity have been demonstrated for the use of 
the scale with parents of disabled children (379). The WOCQ is reported to have good 
internal consistency with Cronbach’s alphas for the subscales ranging between 0.61 and 
0.79 and also has a good construct and concurrent validity (241). 
 
Eight scales are derived from the responses: 
 Confrontive Coping (CC) – Describes aggressive efforts to alter the 
situation and suggests some degree of hostility and risk taking. 
 Distancing (D) – Describes cognitive efforts to detach oneself and to 
minimise the significance of the situation.  
 Self Controlling (SC) – Describes efforts to regulate one’s feelings and 
actions. 
 Seeking Social Support (SSS) – Describes efforts to seek informational 
support, tangible support and emotional support.  
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 Accepting Responsibility (AR) – Acknowledges one’s own role in the 
problem with a concomitant theme of trying to put things right. Accepting 
responsibility as a form of coping is more frequent in depressed people 
(241). 
 Escape Avoidance (EA) – Describes wishful thinking and behavioural 
efforts to escape or avoid the problem. Items on this scale contrast with 
those on the distancing scale, which suggest detachment. EA corresponds 
to increased depression, isolation and spousal relationship problems (380)   
 Planful Problem Solving (PPS) – Describes deliberate problem focused 
efforts to alter the situation, coupled with an analytic approach to solving 
the problem.  
 Positive Reappraisal (PR) - Describes efforts to create positive meaning 
by focusing on personal growth. It also has a religious dimension.     
 
There are 2 ways of scoring the WOCQ, raw and relative. Raw scores describe coping 
effort for each of the 8 types of coping, relative scores describe the proportion of effort 
represented by each type of coping. Relative scores are calculated from raw scores and 
describe the contribution of each coping scale relative to all of the scales combined. The 
relative scoring method controls for the unequal numbers of items within scales and for 
individual differences in response rates. 
Families who use a variety of coping strategies function more effectively than those who 
only use one strategy exclusively (212).    
 
1.13.8 The General Health Questionnaire (GHQ) 
The GHQ (see appendix 5) is a validated (381), internally consistent self administered 
screening questionnaire designed to detect those with diagnosable psychiatric disorder 
(382).  It assesses the respondent’s current state, asks if that differs from their usual state 
and is thus sensitive to short term psychiatric disorders. There are several versions of the 
GHQ (GHQ12, GHQ28, GHQ30 and GHQ60). The GHQ28 is the most used and popular 
version of the GHQ possibly because it provides a profile of scores whereas the other 3 
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only yield an overall total score. There are 4 subscales (each containing 7 items) and an 
overall total score: 
 Somatic Symptoms (SS) 
 Anxiety/Insomnia (AI) 
 Social  Dysfunction (SD) 
 Severe Depression (SevD) 
 Total Score 
Likert scoring is the most generally used method of scoring the GHQ28 producing a 
wider smoother score distribution for use when the severity is to be assessed. A suggested 
threshold (using the Likert scoring method) of greater or equal to 24 (out of a possible 
score of 84) identifies cases of positive psychiatric condition (381). There are no 
thresholds for individual subscales.  
 
1.13.9 Functional Status IIR Measure (FSIIR) 
The FSIIR - short version (see appendix 6) is a measure of child health status that is 
intended for use with children spanning the entire childhood range from 0-16 years old. It 
has particular strengths for the measurement of health status of children with chronic 
physical conditions who are not disabled. It uses a common core of 14 items which have 
been validated and shown to be internally consistent. It is designed to measure 
dysfunction only related to illness (383). It should be administered by an interviewer as it 
is divided into 2 parts. Part one is a series of questions asked to the parent or carer about 
how the child functions, for example, do they eat well? Do they sleep well? There are 3 
responses, never or rarely, some of the time and almost always. When part one is 
completed the interviewer returns to the questions which indicate a neutral or negative 
response and illicit if the poor functioning is due to illness. This is used to determine 
whether an illness related pattern of behaviour exists. Scores range from 0 – 100, the 
higher the score the better the perceived functional status of the child. 
In a sample of 732 children with and without a chronic physical condition, internal 
consistency testing showed a reliability coefficient of α=0.80 for all ages (383). 
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The authors of the FSIIR view behaviour as the final common pathway of health and 
defined the healthy child as one who exhibits age-appropriate physical, psychologic, 
intellectual and social behaviours (383). 
 
1.13.10 McMaster Family Assessment Device (FAD) 
The FAD (appendix 7) is a 60 item, self report, multidimensional measure of family 
functioning which has proven reliability and validity (384). All family members above 
the age of 16 are asked to complete the questionnaire in order to obtain an overall 
perception of how the family operates. When scores for multiple family members are 
obtained, results are averaged. The 7 dimensions of the FAD are: 
 Problem Solving (PS) – The family’s ability to resolve problems (issues which 
threaten the integrity and functional capacity of the family) at a level which 
maintains effective family functioning.   
 Communication – The exchange of information among family members, 
focussing on whether verbal messages are clear with respect to content and direct 
in the sense that the person spoken to is the person for whom the message is 
intended.  
 Roles – Does the family have established patterns of behaviour for handling a set 
of family functions which include provision of resources, providing nurturance 
and support. Supporting personal development, maintaining the family systems 
and providing adult sexual gratification.  
 Affective Responsiveness – assesses the extent to which individual family 
members are able to experience appropriate affect over a range of stimuli. Both 
welfare and emergency emotions are considered. 
 Affective Involvement – is concerned with the extent to which family members 
are interested in and place value on each others activities and concerns. The 
healthiest families have intermediate levels of involvement 
 Behaviour Control – assesses the way in which a family expresses and maintains 
standards for the behaviour of its members. Behaviour in situations of different 
sorts (dangerous, psychological and social) is assessed as well as different 
patterns of control. 
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 General Functioning – Assesses the overall health/pathology of the family.  
 
Scores range from 1-4 with 1 reflecting healthy functioning and 4 reflecting unhealthy 
functioning. The FAD differentiates between healthy and unhealthy family functioning 
and the authors have derived threshold/cut off scores for each domain. If the family 
scores above the threshold, this indicates some degree of family dysfunction in that 
dimension (384). 
 
1.14 Quality of Life (QoL) in Adult Home Parenteral Nutrition (HPN) 
HPN is a life saving, potentially life long therapy that allows patients with intestinal 
failure to be discharged from hospital and to live at home. However it is a therapy which 
can potentially seriously impair an individual’s mobility and social life. It can be 
expected that these patients will perceive QoL differently from those who have a terminal 
illness. The major therapeutic goal for most patients with a chronic illness is not a cure of 
the disease, but rather an improvement in function and life quality resulting from an 
alleviation of the symptoms of the illness (385). 
 
Initially HPN was reported to have a positive effect on patients’ well being which was 
attributed to the reduction of gastro intestinal symptoms, weight gain and an increase in 
strength and exercise tolerance (159). 
 
Early responses to permanent TPN  were examined by Price et al in 1979 (386) who 
showed anxiety, depression, fear, negative body image, and major adjustment problems 
centred on the loss of the basic function of eating in Canadian patients. The reasons for 
the initiation of TPN were varied and included CIP and SBS. Intravenous feeding forced 
patients to make multiple alterations to their life styles. The ability to cope with this 
intrusive procedure was related to the level of restitution of physical health, ego, strength, 
and the family and hospital support systems. Sexual function was decreased in most cases 
with only occasional patients noticing improvements.  
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In 1981 Ladefoged (387) conducted a psychosocial survey of Danish patients on HPN, 
and concluded that 9 out of 13 patients had a fair quality of life. However no validated 
QoL instruments were used. These interviews were repeated and revealed no systematic 
improvement or deterioration in QoL. 
 
Detsky et al published Canadian data which suggested moving patients from hospital to 
home resulted in a significant gain in QoL (and financial savings) (388). In 1986 Mughal 
and Irving (243) described data from the UK HPN register (200 patients). QoL was 
crudely assessed by categorizing patients into one of 4 categories: 1) at work full time or 
looking after family and home unaided. 2) At work part time or looking after home and 
family with help. 3) Unable to work but able to cope with HPN unaided. 4) House bound 
needing major assistance with HPN. They found that the majority of patients were fit and 
independent whilst on HPN. Grade 4 was classified as an unsatisfactory QoL, and the 
patients who fell into this group tended to be older. The authors concluded that QoL is 
generally good in those whose intestinal failure is due to a disease affecting primarily the 
GI tract (e.g. Crohn’s disease), but poor in those whose intestinal failure is a 
manifestation of a systemic disorder (e.g. scleroderma, malignancy and radiation 
enteritis). They also noted the tendency for QoL to deteriorate with time as the systemic 
disease advanced.  
 
Stokes et al 1988 (389) described 76 cases – some of which were included in Mughal and 
Irving’s UK data (243). They used the same 4-point system to assess QoL. They found 
that 35 of their patients fell into grades one and two, but did not discuss the patients who 
were in grades three or four. USA data from Burnes et al (390) (1992) found that age did 
not negatively impact on QoL, which is in contrast to O’Hanrahan and Irving’s findings 
that older patients did less well (225). A further study in 1993 used the 4 point Mughal 
criteria for assessing QoL and found HPN improved QoL by ameliorating the protein 
calorie nutritional status, allowing social rehabilitation and reducing the hospitalisation 
rate. Two thirds of their patients could be considered fully or partially rehabilitated.  
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The Canadian 1979 Price and Levine paper (391) comprehensively studied the 
psychological and social responses to the early stage of HPN. They found that the patient 
goes through a series of stages beginning with numbness, disbelief or denial, thereafter a 
period of pain, sorrow, eventually ending up with acceptance and adaptation to a new 
way of living. Depression, anxiety and body image comprised the early emotional 
reactions. Adaptation involved coming to terms with lack of control over body 
functioning and dependence on mechanical apparatus to sustain life. Resumption of 
normal activities was essential and included employment, sleep, marital relationships, 
sexual functioning and family involvement. 
 
The first study of QoL which used validated questionnaires was from the USA and 
published in 1993 by Smith (392). She described psychologic, social and fiscal aspects of 
HPN from both the patients and the caregiver’s perspective. Results indicated QoL, self-
esteem, life satisfaction, family cohesion and quality of the patient – caregiver 
relationship to be similar to population norms, and noted that family adaptability and 
coping scores were higher than population norms. Overall a low QoL score was 
associated with increasing length of time on HPN – for both patients and caregivers. 
Problems such as loss of friends, employment and depression were reported in two thirds 
of families.  
 
A UK study in 1997 by Richards et al (393) reported the extent to which opiate and 
benzodiazepine dependence affected outcomes for patients on HPN. Health status was 
measured using the SF36 and EuroQoL instruments. The data was from a series of 15 
patients; 5 dependent and 10 controls (not dependent), and although it is not possible to 
derive statistically significant results from such small numbers, it is possible to identify 
trends. Results indicated that the QoL experienced by dependent HPN patients was lower 
compared to controls.  
 
Another UK study by Egger et al (394) showed 51% of their HPN population to be 
moderately malnourished. Under-nutrition causes weakness, impairs immune function 
and reduces the ability to work (395). Jamieson et al (395) (UK) showed weight gain 
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significantly improved QoL scores in every category of the Nottingham Health Profile 
(NHP) in a group of previously malnourished patients. A further study by Richards and 
Irving (396) assessed the QoL of 51 patients on HPN using the same QoL instruments as 
the previous study (SF36 and EQ5D). Compared to earlier studies which suggested a 
large proportion of HPN patients were mostly independent and able to work 
(243;389;392), Richards and Irving found that 80% of patients reported that they were 
too ill to work. The SF36 scores were significantly lower than population norms in 6 (out 
of 8) domains: Physical Functioning (PF), Physical Role (RP), General Health (GH), 
Social Functioning (SF), Vitality (VT) and Bodily Pain (BP), and were at the lower end 
of the normal range for Mental Health (MH) and Emotional Role (RE). There was no 
difference seen between patients who were too ill too work or employed (although the 
number of patients actually employed was very small which prevented meaningful 
analysis). They found younger patients (<45) scored higher in PF, SF and RE than 
compared to older patients. No gender differences were observed. The EQ5D scores 
concurred with the SF36 scores. An Italian study of 30 HPN patients in 2001 (79) found 
that only the PF and GH were significantly lower than that of the general population 
which is in contrast to previous studies. 
 
HPN has also been found to result in a reduction in steroid intake in Crohn’s disease, and 
obviate the abdominal pain associated with eating. Decreased GI secretory activity can 
also result in a decrease in pain secondary to partial small bowel obstruction. Decreased 
stoma output or diarrhoea may lead to a marked improvement in social activity and 
general QoL (397). 
 
To date the majority of studies which have measured QoL in HPN patients have used 
generic QoL questionnaires including the  SF36 (79;327;393;396;398-402), EQ5D 
(393;396;400) and SIP (403;404).  The disease or treatment specific measures that have 
been used to measure QoL in HPN include the IBDQ (404), Quality of life 
instrument/inventory (405;406), Quality of life index (392;402) and the Rotterdam 
symptom checklist (270). However, although these measures are disease or treatment 
specific, none of them are designed to be used in, or specific to the HPN population. The 
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IBDQ was designed to measure the subjective health status of patients with inflammatory 
bowel disease. It examines symptoms related to the primary disease, social function, 
emotional state and systemic symptoms (361). The Quality of life instrument/inventory 
was designed for use in transplant patients and examines emotional state, social and 
physical functioning pain and discomfort, relationships and vocation. The quality of life 
index was designed to be used in healthy individuals and renal dialysis patients (407), but 
has also been used in liver transplant patients. It measures satisfaction with regard to 
health, socio-economic status, psychological/spiritual and family life. The Rotterdam 
symptom checklist was designed for use in cancer patients, and measures physical 
symptoms (pain, fatigue and gastrointestinal complaints) and psychological distress 
(408). Often these disease or treatment specific questionnaires fail to measure HPN 
symptoms such as sleep disturbance and the psychological effects of not eating and 
drinking are not normally addressed (409), and have highlighted the need for a HPN 
specific QoL questionnaire. 
 
Janet Baxter and her colleagues from the Scottish Home Parenteral Nutrition Managed 
Clinical Network, Ninewells Hospital and Medical School, Dundee, UK, have 
subsequently developed the HPN-QOL, a method of objectively assessing the QoL of 
patients treated with HPN. The HPN-QOL has been rigorously prepared and 
demonstrates psychometric and clinical validity to assess the QOL of long-term HPN 
patients (410). It is an exciting development in the field of HPN and results from clinical 
studies are eagerly awaited. 
 
1.14.1 QoL After Intestinal Transplantation 
In the 1990s small bowel transplantation was introduced as a possible alternative to HPN 
for the treatment of irreversible gut failure, but a mortality of 40 – 50% after 3 years was 
ascribed to initial attempts (406;411). In 1998 DiMartini and Rovera et al published two 
studies which compared QoL in HPN patients with those who had received intestinal 
transplantation. In the first study (406) both intestinal transplantation and HPN patients 
were retrospectively asked to rate their QoL over time. In the second study (405) analysis 
was confined to current assessment of QoL. They concluded QoL in post transplant 
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patients was similar to that of HPN patients, although QoL in the transplanted group 
improved over time with decreasing anxiety as they adjusted in the post transplant period. 
A study by Van Gossum et al of 228 HPN patients showed that only 8% of their 
population claimed a willing for intestinal transplantation, while it was considered by the 
medical team in 10% of the patients (412). The decision whether to refer a patient for 
consideration of small bowel transplantation may be difficult if the QoL on HPN is 
satisfactory (221). 
 
In 1996 DiMartini et looked at psychiatric evaluations of small intestine transplantation 
patients (335). Faced with the complicated postoperative course, transplant recipients 
develop a range of endogenous and organic psychiatric disorders. They reported, 30 
adults and 33 children who had undergone intestinal transplantation. Early in their 
program it became evident that psychiatric evaluation, support and treatment would often 
be necessary in the post operative phase. Half of their adult patients required psychiatric 
intervention at some point in the transplant process. Five patients developed adjustment 
disorders with anxious and depressive features in response to their prolonged 
hospitalisations and medical/surgical complications. Two patients required psychiatric 
intervention for delirium at later points during their hospitalisations. Patients with 
Crohn’s may have a higher incidence of depression. It is extremely difficult to define or 
anticipate the amount of pain an individual is or should be experiencing, especially in this 
highly sensitive area. As knowledge advances they state they will be better able to serve 
the psychological needs of intestinal transplant candidates and recipients. 
 
1.14.2 A Systematic Review 
In 1997 a systematic review of HPN was published (170). The objective was to locate, 
appraise and summarise evidence from scientific studies on HPN in order to answer 
specific research questions on the effectiveness of this technology. The authors conclude 
that QoL is reasonable for patients with benign disease. Fifty six studies met the inclusion 
criteria, 13 of which attempted to measure QoL. However only five studies measured 
QoL using validated instruments, although it is not clear which studies these are.  
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1.14.3 Comparison of Adult HPN Patients and Different Patient Groups 
 
QoL was compared between Home Enteral Nutrition (HEN) and HPN by Reddy et al in 
1998 (327). They found no significant difference between the SF36 scores of HPN and 
HEN patients, although both groups scored significantly lower scores than the general 
population in 5 (out of 8) of the domains.  As with other studies MH and RE were seen to 
be closer to population norms, but this study showed that BP was not significantly 
different.  SF36 scores were also compared with patients on renal dialysis (413) because 
the patients were believed to experience similar interference with daily living. End stage 
renal disease and HPN patients both have chronic long term conditions and dependence 
on IV access, which interrupts their daily routine.  No statistical differences were found 
between the two groups in any of the 8 domains. 
 
Richards and Irving (396) compared SF36 scores of HPN patients (with Crohn’s Disease) 
with age matched type II diabetics and patients with congestive cardiac failure. They 
reported lower scores in the HPN patients than both comparison groups in all 8 domains, 
however the diagram in the paper does not the support text – according to the graph 
(Figure 4 p.221), those with congestive cardiac failure have the lower SF36 scores than 
HPN patients. 
 
Smith (392) found Quality of Life Index (QoLI) mean scores of HPN patients to be 
similar to those reported in groups of chronically ill patients requiring haemodialysis, 
peritoneal dialysis, liver transplant and chemotherapy. 
 
1999 Jeppesen et al (404) studied QoL using the generic Sickness Impact Profile (SIP) 
and disease specific Inflammatory Bowel Disease Questionnaire (IBDQ).  HPN patients 
were compared with 36 patients who had either anatomical or functional short bowel not 
on HPN. The HPN patients scored worse overall in both the SIP and IBDQ. The 
exception being the HPN had fewer problems with bowel symptoms.  In agreement with 
Carlsson et al (399) the presence of a stoma was not associated with lower QoL scores 
and the authors postulate the impairment in physical, emotional and social function in the 
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HPN group may be related to the complex technology required for the nutritional support, 
rather than the inconvenience and bowel symptoms that accompany intestinal failure. 
They also agreed that QoL in HPN compares well with that reported in chronic renal 
failure. 
 
A further study by Cuerda (403) also used the SIP  to measure QoL, however only six 
patients were measured, and showed QoL scores were slightly decreased compared with 
normative data. 
 
The most recent study published on QoL and HPN was in 2003 (399). Its primary aim 
was to assess QoL in patients with short bowel syndrome – 8 of whom were on HPN. It 
agrees with other studies in that patients receiving HPN rated lower QoL scores than 
those with intestinal dysfunction not on HPN. Fear of becoming a burden was the most 
frequently expressed concern. 
 
Patients with ulcerative colitis have been shown to have better QoL scores than patients 
with Crohn’s disease - none of whom were treated with HPN (385), thus illustrating the 
impact of the underlying disease. 
 
From the above text it is clear that there have been many efforts to evaluate QoL in 
people treated by HPN. The most influential factors appear to be age, underlying disease 
(243), social circumstances (392), opiate dependence (393) general malnutrition (395), 
length of time on HPN (405), ability to work (392;396) and perhaps the presence of a 
stoma (399;404). Price (386) proposes that the earliest stages of HPN are the most 
difficult. QoL of HPN patients has been compared to patients with functional and 
anatomical short bowel syndrome, type II diabetes and congestive cardiac failure. 
However there seems to be agreement that end stage renal disease is an appropriate 
comparison.  
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1.14.4 Longitudinal QoL Data  
Most studies have reported QoL data from a single time point 
(250;327;388;392;393;396). Jamieson et al (395) used the NHP to evaluate HPN patients 
for up to 4  years. They saw an improvement in QoL scores in group 1 (BMI < 20), 5 of 
which were receiving HPN. Another study asked patients to retrospectively compare their 
QoL before and after HPN dependence, which can not be classified as a longitudinal QoL 
study. In 2002 Malone reported longitudinal QoL in HPN patients on two occasions 3 
years apart (414). It is unclear whether her sample was of 12 or 13 HPN patients. SF36 
scores did not change over the time period. There has been no longitudinal QoL study 
which specifically identifies patients newly discharged on HPN. 
1.15 QoL in Adult Pseudo-Obstruction 
People suffering with pseudo-obstruction may require nutritional input including oral 
nutritional supplementation, enteral and parenteral nutrition or a combination of these 
therapies. Symptoms can be episodic or continuous and include abdominal pain, 
distension, constipation and vomiting, and this may have an impact on QoL. 
 
A literature review revealed 3 abstracts and 2 original communications related to this area 
of research. 
 
In 2000 Iwarzon et al (415) assessed pseudo-obstruction patients self-reported symptoms, 
functional status and health related QoL (HRQoL) using the Gastrointestinal Symptoms 
Rating Scale (GSRS), the sickness impact profile (SIP), the Swedish QoL questionnaire 
(SWED-QUAL) and the psychological general wellbeing index. They found that 
compared to healthy controls, pseudo-obstruction patients had poor QoL and poor general 
well being. There was a strong correlation between severity of symptoms and QoL, the 
main determinants of poor QoL being abdominal pain, indigestion and diarrhoea. In 2004 
Chambers et al (416) used the SF36 and HADS to identify that 23 pseudo-obstruction 
patients had significantly lower role physical (RP) and general health (GH) scores when 
compared to a healthy population, and that clinically significant levels of anxiety and 
depression levels were seen in 20% and 17% of the population respectively. In 2006 
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Keller et al published an abstract which used the SF36 to evaluate QoL in 6 patents with 
pseudo-obstruction. They found that QoL was decreased in pseudo-obstruction patients 
when compared with healthy controls. 
 
Iwarzon et al published a further article in 2009 which compared health related QoL and 
symptom severity between 28 patients with pseudo-obstruction and 26 with enteric 
dysmotility (ED) using the GSRS, SWED-QOL and SIP questionnaires (417). Patients 
with pseudo-obstruction reported a greater impairment of functional status and HRQoL 
than did patients with ED. Abdominal pain severity was found to be the only independent 
predictor of HRQoL. 
 
The latest report which discusses QoL in pseudo-obstruction states that near total small 
bowel resection caused an improvement in QoL in six patients, however it was not stated 
how QoL was evaluated, merely that it improved (418). 
 
1.16 QoL in Paediatric HPN 
Initial research into the effects HPN had on lifestyle were concerned with the restoration 
of productive life (for example returning to school or participating in physical/peer group 
activities) and growth and development (see table 1.7), the general consensus being that 
HPN allowed infants to have normal psychological development and lifestyle. QoL was 
acknowledged in many of these papers, but no formal assessment was undertaken. In 
1990 Ricour et al evaluated QoL using medical and psychological interviews, however 
they fail to report the results in any detail, but state that HPN provides a remarkable 
improvement in QoL (200). Howard et al (1995) was the first group to recognise that a 
more sophisticated QoL assessment of either the patient or a close family member was 
required (176). 
 
The 1997 systematic review of HPN (170) highlighted the lack of proper QoL 
assessments in paediatric studies. Further reviews come to the same conclusions that 
there was a distinct lack of studies which assessed the QoL in paediatrics (221;247;248). 
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Candusso et al published 2 papers looking at outcome and QoL in paediatric HPN, 
however, disappointingly they did not even attempt to study the QoL of children on HPN 
but merely state that long term patients suffered from psychological disability, that QoL 
is not easy to determine (287), and that QoL still needed to be evaluated (4). 
The first study which tried to evaluate both the child’s (by proxy) and caregivers QoL 
was published in 2003. Engstrom et al used an un-validated HPN questionnaire, the Child 
Behaviour Checklist (CBCL) and the Interview Schedule for Social Interaction (ISSI). 
Results from 20 families suggest that the children on HPN (mean age 7, range 3-15 years) 
were significantly less socially competent and that they had more psychological and 
emotional problems when compared to (Swedish) population norms – more specifically, 
demanding a higher level of attention, expressing distress about being alone and often 
crying. Their parents also felt they were anxious, shy, sensitive, they often showed bad 
temper and emotions that fluctuated rapidly (205). 
 
In 2005 a French group used the Qualin questionnaire for children <3, the Auquei 
questionnaire for children age 3-11 years, and the OK.ado questionnaire for adolescents, 
and found that QoL of HPN dependent children is not different from that of healthy 
children. They postulate that the lack of difference is because the children on HPN have 
not had a healthy life with which to compare, and they are accustomed to the HPN (231). 
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Table 1.7: Studies of QoL/Functional Status in Paediatric HPN 
Author Year Title QoL 
Assessment 
Outcome 
Dudrick (126) 1969 Can intravenous 
feeding as the sole 
means of nutrition 
support growth in the 
child and restore 
weight loss in an 
adult? An affirmative 
answer 
Clinical 
parameters 
Normal growth and 
development and 
faster restoration to 
productive life 
Filler (127) 1969 Long-term total 
parenteral nutrition in 
infants 
Clinical 
parameters 
Reduced length of 
hospital stay and 
acceptable growth 
Strobel (177) 1978 Home parenteral 
nutrition: results in 34 
pediatric patients 
Ability to 
pursue normal 
peer group 
activities 
The majority 
attended full time 
classes and resumed 
relatively normal 
lives and had an 
improved state of 
general well being  
Strobel (129) 1979 Home parenteral 
nutrition in children 
with Crohn's disease: 
an effective 
management 
alternative 
School 
attendance and 
participation in 
peer group 
activities 
Improved QoL on 
HPN 
Byrne (179) 1979 Home parenteral 
nutrition 
Clinical 
parameters and 
participation in 
peer group 
activities 
All patients showed 
sufficient growth, 
school attendance    
improved and 
patients were able to 
lead relatively 
normal lives at home 
Farmer (419) 1979 Prognosis of Crohn's 
disease with onset in 
childhood or 
adolescence 
Medical 
interviews 
2/3rds considered they 
were functioning in a 
suboptimal state of 
health 
Cannon (180) 1980 Home parenteral 
nutrition in infants 
Neurological 
examinations, 
sequential 
developmental 
assessments and 
Gesell 
evaluations 
Appropriate 
developmental 
milestones can be 
expected during the 
1st 2 years of HPN 
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Continued…Table 1.7: Studies of QoL/Functional Status in Paediatric HPN 
Author Year Title QoL 
Assessment 
Outcome 
Wolfe (174) 1983 Experience with 
home parenteral 
nutrition 
Ability to 
function as 
outpatients 
Depressive 
symptoms  were 
common and 
satisfactory growth 
and development was 
maintained on HPN 
Ralston (223) 1984 Somatic growth and 
developmental 
functioning in 
children receiving 
prolonged home TPN 
Sequential 
developmental 
assessments and 
Gesell 
evaluations 
Majority of children 
experienced adequate 
somatic and 
behavioural growth 
over the first 3 years 
of life 
Farmer (420) 1985 Long-term follow-up 
of patients with 
Crohn's disease. 
Relationship between 
the clinical pattern 
and prognosis 
Telephone 
interviews 
It is not clear how 
many of these were 
paediatric cases. QoL 
tended to be 
suboptimal among 
operated patients and 
was better in those 
with segmental 
involvement of the 
colon/ileum. 
Ricour (35) 1985 Enteral and parenteral 
nutrition in the short 
bowel syndrome in 
children 
None stated Patients QoL is near 
normal on HPN 
Amarnath 
(421) 
1987 Home parenteral 
nutrition in chronic 
intestinal diseases: its 
effect on growth and 
development 
Medical 
notes/interviews 
Psychological 
problems were noted. 
All patients had 
improved stamina 
and general sense of 
well being.  
O’Connor 
(422) 
1988 Intellectual and 
Perceptual-motor 
performance of 
children receiving 
prolonged home total 
parenteral nutrition 
Wechsler               
Preschool and 
primary scale of 
intelligence, 
Beery 
Buktenica 
developmental  
test of visual 
motor 
integration 
Children had average 
intelligence with 
perceptual-motor 
delays and some 
problems of attention 
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Continued…Table 1.7: Studies of QoL/Functional Status in Paediatric HPN 
Author Year Title QoL 
Assessment 
Outcome 
Ricour (200) 1990 Home parenteral 
nutrition in children: 
8 years of experience 
with 112 patients 
Medical and 
socio-
psychological 
interviews 
Remarkable 
improvement in QoL 
Weber (83) 1991 Short-bowel 
syndrome in children. 
Quality of life in an 
era of improved 
survival 
None stated Excellent growth, 
development and 
QoL  
Bisset (199) 1992 Home parenteral 
nutrition in chronic 
intestinal failure 
Griffith’s 
mental 
development 
scale and the 
Wechsler pre 
school and 
primary scale of 
intelligence 
Patients were able to 
grow and develop 
normally after 
discharge home 
O’Hanrahan 
(225) 
1992 The Role of HPN in 
the Management of 
Intestinal Failure. 
Report of 400 Cases 
School 
attendance and 
development 
Patients appear to 
enjoy a satisfactory 
lifestyle.  
Candusso 
(218) 
1995 Long-term HPN in 
children 
None 
specifically 
stated 
Parents and patients 
all had behaviour 
disorders 
(depression) 
Leonberg 
(423) 
1998 Long-term growth 
and development in 
children after HPN 
Neurologic 
examination, 
assessment of 
expressive and 
receptive 
language, 
auditory   
memory and 
visual motor 
function   
Development was 
normal, some 
discrepancies were 
seen between 
language and 
perceptual motor 
performance 
Candusso 
(287) 
2001 Home parenteral 
nutrition in children: 
outcomes and quality 
of life 
None Long term patients 
suffer from 
psychological 
disability 
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Continued…Table 1.7: Studies of QoL/Functional Status in Paediatric HPN 
Author Year Title QoL 
Assessment 
Outcome 
Candusso (4) 2002 Outcome and quality 
of life in paediatric 
home parenteral 
nutrition 
None Disability especially 
if the treatment was 
started at birth 
Engstrom 
(205) 
2003 Psychological distress 
associated with HPN 
in Swedish children, 
adolescents and their 
parents: preliminary 
results 
HPN 
questionnaire 
(not validated), 
CBCL and ISSI 
More psychological 
and emotional 
problems than 
population norms 
Gottrand (231) 2005 Satisfaction in 
different life domains 
in children receiving 
HPN and their 
families 
Qualin 
questionnaire, 
the Auquei 
questionnaire 
and the OK.ado 
questionnaire 
QoL of HPN 
dependent children is 
not different from 
that of healthy 
children 
Colomb (249) 2007 Long-term outcome 
of children receiving 
HPN: a 20 year single 
centre experience in 
302 patients 
None stated Repeat 
hospitalisations has a 
serious impact on 
QoL 
 
Table 1.7 illustrates the lack of proper validated methods of determining QoL in children. 
One of the important measured outcomes of HPN has been QoL. These studies have 
revealed that HPN reduces QoL for recipients to the same extent experienced by patients 
on home dialysis for renal failure (404) 
 
A major aim of providing parenteral nutrition in the home setting is to minimise 
morbidity and maximise survival and QoL (2). Clinicians understand that HPN is a 
complex and time consuming procedure and attempts have been made to allow patients 
(and carers) a more normal lifestyle during the day, for example, feeding at night (over 
10-14 hour periods ) (177). 
1.17 Telemedicine 
The term 'telemedicine' is a composite word derived from the Greek 'tele' meaning 'at a 
distance' and the word 'medicine' which itself derives from the Latin 'mederi' meaning 'to 
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heal'. Telemedicine has numerous definitions, Murphy (424) first coined the term in the 
1970s, referring to health care delivery in which physicians examine distant patients 
through the use of telecommunications technologies. The European Commission’s health 
care telematics programme defines telemedicine as: "rapid access to shared and remote 
medical expertise by means of telecommunications and information technologies, no 
matter where the patient or relevant information is located." 
There are many other definitions ranging from simple one-line statements to full reports. 
The World Health Organisation offers a holistic definition of telemedicine: "The delivery 
of healthcare services, where distance is a critical factor, by all healthcare professionals 
using information and communication technologies for the exchange of valid information 
for diagnosis, treatment and prevention of disease and injuries, research and evaluation, 
and for the continuing education of healthcare providers, all in the interests of advancing 
the health of individuals and their communities". Broadly defined, telemedicine is the 
transfer of electronic medical data (i.e. high resolution images, sounds, live video and 
patient records) from one location to another. This transfer of medical data may utilize a 
variety of telecommunication technologies, including, but not limited to: ordinary 
telephone lines, ISDN, ATM, the Internet and satellites.  
The idea of performing medical examinations and evaluations through a 
telecommunication network is not new.   
1.17.1 History of Telemedicine  
There are differing views about the origin of telemedicine. Some say that telemedicine 
came about with the introduction of the telephone. Dr Alexander Graham Bell used his 
invention when he was feeling ill to call his friend Watson for help. Some believe that the 
early stages of telemedicine actually began in the 1920s when several countries offered 
offshore medical advice from hospitals to their fleet of trade ships by using the Morse 
alphabet. Others say that telemedicine originated not long after the introduction of 
television.  
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The initial idea behind telemedicine was, and is, to overcome time and distance barriers. 
From inception, the focus has been on physical diagnosis and prognosis. Physical 
diagnosis usually requires visual information, hence one needs a device that would enable 
the physician to ‘see’ the patient.  
An example of an early application of telemedicine involved the Papago Native 
American tribe in the late 1950s. Space Technology Applied to Rural Papago Advanced 
Health Care (STARPAHC) (425) delivered health care to residents living in remote areas 
of the Papago Indian Reservation in Arizona. This was a joint effort between Lockheed, 
the National Aeronautics and Space Administration (NASA), and the US Public Health 
Service. The project lasted about 20 years. 
In 1959, another attempt at telemedicine was made at the University of Nebraska. Dr. 
Cecil Wittson was in charge of the first two-way video link between the institute and 
Norfolk State Hospital which was 112 miles away. They used this link for education 
purposes, as well as consultations between specialists and general practitioners. In 1971, 
the institute was linked with three other facilities. 
Telemedicine was utilised in the early 1960’s when NASA first put men in space. 
Physiological measurements of the astronauts were telemetered from both the spacecraft 
and the space suits during NASA space flights. These early efforts were enhanced by the 
development of satellite technology which fostered the development of telemedicine. 
NASA was not the only one to experiment with the integration of telecommunications 
systems into the practice of medicine. During the late 1960s and early 1970s, others were 
also experimenting with telemedicine. 
The first telemedicine system in which there was a regular interaction between physicians 
and patients was installed in Boston in 1967. A radiologist set up a diagnostic ‘shop’ in 
the Logan airport health centre. Physicians were invited to bring X-rays and patient data. 
The X-rays were illuminated by an ordinary light box, scanned by a black and white 
television camera and the images transferred to a video monitor in Massachusetts General 
Hospital’s (MGH) radiology department. The physician could discuss the case with MGH 
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radiologists via an ordinary telephone line. These early experiments demonstrated that it 
was possible to undertake remote diagnosis through interactive television and that the 
transmission of medical data (e.g., X-rays) could be accomplished successfully without 
any significant loss of information in terms of its quality and detail. 
Most of these projects used some form of video (black-and-white television, colour 
television, slow-scan transmission) to complement the most basic unit of telemedicine 
equipment, the telephone. 
The use of telemedicine grew out of a need to provide medical diagnoses for patients in 
remote areas who were unable to travel. There also was a need to help small towns by 
providing doctors with technology that would allow them to keep abreast of advances in 
medicine and to consult with other physicians. 
From these beginnings, the interest in telemedicine has continued to grow. Today, 
telecommunications networks are being developed to transmit information about patients 
to doctors and information from doctors to patients, faster than ever before, and 
eventually from any location. These same networks can be used to provide access to on-
line patient records and medical libraries, to facilitate communications among medical 
specialists around the country, and make available standardised medical information and 
insurance data more readily. Telemedicine technology is advancing and will continue to 
do so. Although much of the more sophisticated technologies such as virtual reality are 
still expensive, the cost of some technologies is dropping, so that telemedicine should 
become more affordable to more people, regions and countries than ever before. 
1.17.2 Clinical Uses of Telemedicine 
A Pubmed search in April 2004 using the subject heading “Telemedicine” retrieved 
approximately 6300 citations dating back to 1974. When this search was repeated in 
2008, over 10,000 citations were returned illustrating how this technology is a rapidly 
expanding field. Telemedicine is and has been used in a growing number of medical 
specialties such as: cardiology, homecare, radiology, emergency care, surgery, 
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dermatology, psychiatry, oncology, pathology, ophthalmology, haematology, ENT, renal 
medicine and pre-hospital care.  
 
The technology has improved and the cost of equipment has decreased in the past ten 
years, resulting in an increase in the number of telemedicine research projects and 
increase in the scope of those projects. The Telemedicine Information Exchange (1997)  
(http://tie.telemed.org/default.asp) lists over 130 telemedicine research sites. 
 
At present there is limited nurse led published evaluation of nursing initiatives with 
telemedicine in the UK compared to other countries i.e. USA and Australia.  
 
The use of providing patients a telephone contact with the primary HPN centre has been 
shown to minimise separation and disruption in families, discouraged a feeling of total 
dependence on, or insecurity of being at home, and encouraged a sense of self sufficiency 
and ability to carry on in a normal environment even in the face of HPN adjustments or 
complications (13). 
1.18 Recruiting Controls in Paediatric Populations 
Obviously when undertaking a clinical study it is important to have a control population 
with which to compare to the diseased population. However identifying and recruiting 
controls in paediatric studies can be problematic. Selection bias occurs when controls are 
not a representative sample of the population from which the case emerged. The potential 
for sample bias can be minimised by maximising the probability that a representative 
sample will be selected ideally by random sampling or some other kind of unbiased 
sampling (426). There is very little in the literature on recruiting paediatric controls, even 
though this can be the weak point in a paediatric study design. We hoped to ask parents 
with children on HPN to rate their own and their child’s QoL by proxy. We therefore 
needed to recruit a control population with which we could compare these results.   
 
This subject was discussed in detail at the 2003 European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) QoL working group. 
Historically, in the UK it is very common for studies to recruit paediatric controls from 
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the children of people who work at the hospital, from children who have another 
(sometimes less severe) illness or from children from GP practices in the same 
geographical area as the case group (Dr. A Thomas, personal communication, August 
2003). There was consensus that each of these methods of obtaining a paediatric control 
population resulted in the introduction of some degree of bias.  
 
The aforementioned methods of recruiting paediatric controls do not take into account 
socio-economic status, education (parental and child), social grade or geographical area. 
For example, the parents of children who work at the hospital may live in a different area, 
may contain a higher percentage of people who have attended further or higher education, 
and potentially have a higher income than a case population. Also a hospital worker may 
become somewhat over-sensitised or desensitised to certain types of illness if they are 
dealing with it on a daily basis. Trying to compare a case group with children who have 
another illness can also be inappropriate as the illnesses may not be comparable with 
respect to pain, disruption of daily living, social stigma and the amount of care and 
treatment required. Recruiting paediatric controls from GP practices in the same 
geographical area as the case group considers geographical area, but none of the other 
social or educational parameters. 
 
Using any of these methods to recruit a paediatric control population would thus result in 
some sort of bias. There is little evidence to support other methods of recruitment, so a 
consensus was reached at the 2003 ESPGHAN QoL working group to devise a novel 
approach for recruiting a paediatric control population. It was discussed in great detail, 
and decided that the parent (or main carer) of the case child would be asked to nominate 
or suggest a healthy control family. More specifically, a family who they felt were the 
same in numbers of children, ages of children, who lived nearby or in the same area and 
had a similar income. Examples to be provided to the case family included - the family of 
someone who went to the same school or nursery as their child, the family of a friend of 
their child, a sibling or close friend or colleague’s family who have children of similar 
ages as their own. 
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It was considered that the parents with a child on HPN might feel embarrassed or might 
not want to ask another family to undertake something of this nature. For this reason a 
blank envelope with all the information for the control family was sent to the case family. 
If they did not want to pass this on to a nominated family, then they did not have to. 
 
It was hoped that this approach would minimise selection bias as the case family would 
be suggesting a control family that they felt in some ways were similar. Generally, it is 
more probable that siblings or friends or families who live in a similar area, whose 
children attend the same schools, are more likely to be matched on one or more social, 
economic or educational parameters and are to some extent representative of the case 
population. As this is a novel way of recruiting a paediatric control group the type and 
amount of bias would be unknown. There is always a danger that the case families could 
fail to nominate a family, or nominate an inappropriate family (which would be difficult 
to detect), or that the control family would be unresponsive. Moreover, this type of 
control sample selection is not random or unbiased. But in the absence of a better or more 
robust alternative method of selecting controls, I decided to test this approach, firstly to 
see if it was accepted by the case and control families and secondly to identify if it caused 
any problems or obvious confounding variables. This method is new and therefore 
requires validation. 
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2.0 Aims and Objectives 
The objectives of the 3 studies presented were to investigate and compare aspects of QoL 
in adult patients who require HPN, in adult patients who have chronic intestinal pseudo-
obstruction and in carers of and children receiving HPN. 
 
The specific aims of the studies were to: 
 Recruit adult patients being newly discharged on HPN, in order to define and 
quantify longitudinal changes in SF36 scores, EQ5D scores and HAD scales at 
the time of discharge home on HPN and over the first year after discharge home 
and to compare this with a normative population. To document prospectively the 
number of visits to hospital outpatient clinics (nutrition, or other), the number of 
admissions to hospital and days in hospital during the course of the first year of 
treatment. To compare the results of the above in patients receiving standard care 
and those in contact with a nutrition nurse specialist (NNS) via telemedicine. 
 Contact patients diagnosed with pseudo-obstruction with the intention of 
identifying a cross sectional measurement of SF36 scores, EQ5D scores and HAD 
scales. To document method of nutritional intake and other clinical indications. 
To compare the above QoL results with the clinical features and a normative 
population. 
 Identify families with a child under 5 years old on HPN with the purpose of 
determining cross sectional measurements of the functional status of the child 
(FSIIR), the GHQ28 score, WOCQ score and HAD scale of the main carer of the 
child and to asses the level of family functioning. To compare the above 
measurements with a case controlled group. 
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3.0 Materials and Methods 
3.1 Hypothesis Testing 
3.1.1 Study 1 QoL in Adult HPN and Telemedicine 
Null Hypotheses: SF36, EQ5D and HAD scores in patients on HPN are not affected by 
clinical parameters, do not alter over the first year on HPN and are the same as the 
general population. Telemedicine has no effect on the QoL of patients on HPN 
Alternative Hypotheses: SF36, EQ5D and HAD scores in patients on HPN are affected 
by clinical parameters, change over the first year on HPN and are different from the 
general population. Telemedicine has an effect on the QoL of patients on HPN. 
3.1.2 Study 2 QoL in Pseudo-obstruction 
Null Hypothesis: SF36, EQ5D and HAD scores of pseudo-obstruction patients are not 
affected by method of nutritional intake and other clinical factors and are not different to 
a normative population. 
Alternative Hypothesis: SF36, EQ5D and HAD scores of pseudo-obstruction patients 
are affected by method of nutritional intake and other clinical factors and are different to 
a normative population. 
3.1.3 Study 3 QoL of Children on HPN and their Carers 
Null Hypothesis: There is no difference in WOCQ, FAD, GHQ28, HAD and EQ5D 
scores in parents who have a child on HPN compared with parents who do not have a 
child on HPN. FSIIR scores are not different in children who do or do not receive HPN.  
Alternative Hypothesis: There is a difference in WOCQ, FAD, GHQ28, HAD and 
EQ5D scores in parents who have a child on HPN compared with parents who do not 
have a child on HPN. FSIIR scores are different in children who do or do not receive 
HPN. 
 
In order to meet the aims and objectives of the studies, consenting patients or their 
parents who were eligible were recruited into one of three studies.  
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3.2 Study 1: QoL in Adult HPN and Telemedicine 
3.2.1 Study Design 
This was a multi centred, randomised, controlled, longitudinal (prospective) trial. Patients 
were recruited by the Nutrition Nurse Specialists (NNS) in the participating centres 
before discharge. When the patient was discharged the NNS contacted the trial 
coordinator. 
 
All patients received standard care and follow up according to his/her centres usual 
protocol. The control group had telephone links with the NNS, whilst the telemedicine 
group had telemedicine contact with the NNS at the specified time points:  
 Weekly for the 1st month 
 Fortnightly for the 2nd month 
 Once monthly for the next four months 
 At least once every 3 months for the remainder of the study 
Subjects were advised by the NNS that after discharge they would receive a telephone 
call from the trial coordinator on 4 occasions where they would be asked a series of QoL 
questionnaires. Questionnaire data collection was carried out two days after discharge 
home and then 6, 12 and 18 months from discharge. At the end of the first year all 
patients in the trial were offered telemedicine as an incentive for them to participate in 
the trial and further data was collected for a maximum of one year for each patient. 
 
HPN patients were randomised to receive telemedicine or telephone follow up from each 
centre, therefore I was interested not in the direct effect of the specific (but various) 
underlying diseases which result in IF and the need for HPN, but in the overall QoL of 
these patients as a group and how this was influenced by time and telemedicine contact 
with the base hospital. Our intervention was not designed to affect physical symptoms 
caused by either the underlying disease or the HPN and therefore a disease specific 
questionnaire was not used. The majority of studies which have measured QoL in HPN 
patients have used the  SF36 (79;327;393;396;398-402) and these studies have illustrated 
that the SF36 is able to detect significant differences in this population when different 
parameters are compared. Using the SF36 allowed comparisons with other adult HPN 
 105     
series. EQ5D and HAD were employed to supplement and if possible amplify our 
understanding of any changes observed.  
 
3.2.2 Inclusion/Exclusion Criteria 
The inclusion criteria were any consenting patient that was starting home parenteral 
nutrition de novo and who were being sent home with Calea (a private homecare 
company). Calea was providing and funding a telemedicine service, at a time when other 
homecare companies were not consistently offering this service. The exclusion criteria 
were failure to consent, using another homecare company for supplies, being under 18 
years old, unprepared or unable to use telemedicine and unable to respond to 
questionnaire by telephone. 
 
3.2.3 Randomisation  
A centre specific four block randomisation process, restricted by centre, was applied, 
which was only enacted after a signed consent form was received. 
 
3.2.4 Telemedicine Installation 
Telemedicine requires installation of an ISDN line. In practice this took between 1 and 3 
weeks to be completed. After the line had been installed, a videophone was delivered to 
the patient who was given a tutorial on how to use the equipment. Each of the 
participating HPN centres had telemedicine installed at the beginning of the study. 
Initially a PC with a camera and conferencing device was provided, but it was felt the 
added benefits of the PC would be a confounding factor. The protocol was changed so 
that a videophone was to be provided instead. None of the trial patients received a PC, 
but some of the HPN centres did. 
3.3 Study 2: QoL in Pseudo-obstruction 
3.3.1 Study Design 
This was a single centred observational, cross sectional study. A detailed retrospective 
analysis of the case notes by 2 investigators (Dr. Emma Grieg and Professor Jeremy 
Powell-Tuck), identified cases of pseudo-obstruction based on radiological, manometric 
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and histological reports. Eligible patients were contacted by letter to explain the study 
and invite them to participate. Written consent was obtained. Researchers then contacted 
patients to answer any further questions about the study and arrange an appointment for 
the telephone questionnaire. 
 
Information from the patient’s notes were recorded and put into a database by Alison 
Chambers which allowed comparison of the QoL data with clinical features, manometric, 
histological and radiological findings. 
 
The SF36 was chosen to measure QoL as pseudo-obstruction patients often need 
nutritional support including EN and HPN. There are studies using the SF36 which have 
measured QoL in HPN patients (79;327;393;396;398-402) and enterally fed patients 
(327;427;428) and these studies have illustrated that the SF36 is sensitive enough to 
detect significant differences in these populations when different parameters are 
compared. As with study 1, EQ5D and HAD were employed to supplement and if 
possible amplify our understanding of any changes observed.  
 
Age 
To date there are no published studies which have identified age as a predictor of QoL in 
pseudo-obstruction patients. Evidence was sought from the literature to see if age had any 
impact on QoL in HPN and enteral nutrition, as many patients suffering with pseudo-
obstruction receive this type of nutritional support.  In 1997 Richards and Irving observed 
significantly lower scores in physical functioning, social functioning and emotional role 
SF36 domains in HPN patients who were older than 45 years old (396). Jeppesen et al 
observed that HPN patients below the age of 45 scored significantly better on the overall, 
physical and psychosocial dimensions of the sickness impact profile (404). Patients on 
enteral nutrition who were younger than 45 years old have been found to have 
significantly higher SF36 physical functioning scores (428). In light of the above studies, 
the pseudo-obstruction data was subdivided and compared in patients who were older and 
younger than 45 years old.  
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Diarrhoea 
One of the symptoms consistently recorded in the medical records was the absence or 
presence of diarrhoea. However this was not an objective measure and purely reflected 
the patient’s perception of diarrhoea. GI function exhibits a wide range of normal 
objective parameters and can be highly variable overtime both within and between 
individuals. The term diarrhoea means different things to different people and is 
commonly used by the general public to describe a change in bowel habit, but the extent 
to which this term correlates with objective measures of diarrhoea is not clearly known. 
The vast majority of anecdotal reports of diarrhoea are actually transient fluctuations in 
stool consistency and are of little or no clinical significance (429).  Moreover, previous 
studies have revealed a discrepancy between recalled and recorded bowel habits (429-
431). It may be misleading to rely on patients recall as it is often imperfect (432) and 
people tend to exaggerate bowel frequency (433). In light of these findings, our patient’s 
perception of suffering with diarrhoea was not compared to QoL outcomes. 
 
Full thickness small bowel biopsy:  
Full thickness specimens or biopsies of the small intestine were obtained laparascopically 
or during surgical intestinal resection. Full thickness biopsies only were included in this 
analysis to allow examination of the smooth muscle layers and nerve plexuses by 
Professor Joanne Martin who has a specialist interest in this area of intestinal pathology. 
Multiple levels of the sections were stained, to include haematoxylin and eosin, elastic 
van Gieson, alpha smooth muscle immunohistochemistry, periodic Schiff, CD45 and 
CD117 immunohistochemistry. Categorisation into “normal”, “myopathy”, “neuropathy”, 
“non specific partial actin deficiency”, or “abnormal indeterminate” was done blind to 
manometric diagnosis. 
 
Intestinal Manometry: 
24 hour ambulant intestinal manometry was performed by a perfused tube placed through 
the pylorus using radiographic control. This uses 5 sensors in the proximal small bowel 
with contractions identified by computer and artefact eliminated. Diurnal, nocturnal and 
meal-related patterns of the migrating motor complex (MMC) were studied in patients in 
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whom drug therapy, particularly opiate analgesia and smooth muscle relaxants were 
stopped or curtailed prior to investigation. Patterns may be seen which can be divided 
into being suggestive of (a) neuropathy in which the contractions are uncoordinated but 
of normal amplitude and (b) myopathy in which contractions are coordinated but of low 
amplitude. Interpretation of the traces was principally computer-based using automatic 
comparison of the patient’s recordings with a control database in respect of cycle length, 
duration, median amplitude, frequency of contractions in phases II and III and also 
velocity of phase III. Temporal analysis also included day cycles, night cycles, 
contraction incidence and cluster frequency. In addition subjective assessment by two 
experienced observers - Professor David Wingate and Professor David Evans, following 
international guidelines contributed to an overall broad categorisation into myopathy, 
neuropathy, abnormal indeterminate or normal. Final categorisation was done blind of 
histopathological diagnosis by Professor David Evans. 
 
Gastric Emptying 
Rates of gastric emptying were measured using gamma scintigraphy and/or electrical 
impedance tomography following previously described techniques (434-436). 
 
Radiological assessment 
This relied on the recorded radiologist’s reports in each case. The principal abnormality 
sought was small bowel dilatation in the absence of mechanical obstruction. 
 
3.3.2 Inclusion/Exclusion Criteria 
Inclusion criteria were any adult patient who had presented to Bart’s and the London 
NHS Trust Intestinal Failure Clinic between its inception in 1989 and 1st May 2005 who 
had been diagnosed with pseudo-obstruction. Exclusion criteria were patients who failed 
to consent, who were unable to respond to the telephone questionnaire or who were 
diagnosed with secondary pseudo-obstruction due to scleroderma or HIV. 
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3.4 Study 3: QoL of Children on HPN and their Carers 
3.4.1 Study Design  
This was a multi centred observational, cross sectional, case control study. Subjects and 
their families were identified by the paediatric NNS in each participating centre, who 
provided the trial coordinator (Alison Chambers) with their contact details. An 
information pack was then sent inviting them to participate in the research project. If the 
family was interested in participating they were asked to complete a family information 
sheet, consent and assent forms and send them back to the researcher in a stamped 
addressed envelope. The families were then contacted within 1 week to arrange a 
convenient time to complete the telephone questionnaire. During this telephone interview 
the researcher fully discussed the process by which controls were recruited and asked the 
main carer if they could nominate a control family. After the telephone questionnaire 2 
postal questionnaires were then sent to the family. See appendix 8 for organisation chart.  
 
In order to obtain families of similar age, background and geographical setting, controls 
were recruited from families recommended by the subject’s families. The researcher sent 
a letter to the subject’s family which they were asked to pass to another family who they 
felt they were similar to in age, number of children, social class and race and who lived 
nearby. This contained an information pack explaining the study and inviting them to 
take part in the research. If the control family were interested in participating they were 
asked to complete the family information sheet, consent and assent forms and send them 
back to the researcher in a stamped addressed envelope. After receiving the completed 
forms the families were contacted within 1 week to arrange a convenient time to 
complete the telephone questionnaire, after which 2 postal questionnaires were sent to the 
families. See appendix 8 for organisation chart. 
 
Several measures were used to identify QoL and functional status in this population. It is 
hypothesised that having to care for a child on HPN can be stressful and the WOCQ was 
used to try to assess the coping strategies used by these carers. The GHQ28 was chosen 
for its use as a screening questionnaire, as we hoped to identify any psychiatric disorders 
present in carers of children on HPN. The FSIIR has particular strengths for the 
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measurement of health status of children with chronic physical conditions – who are not 
disabled and is thus appropriate for use in children on HPN. Finally, the FAD was used to 
try to detect any effects on the whole family of having a child on HPN. 
 
3.4.2 Inclusion/Exclusion Criteria 
The inclusion criterion for the subjects was any consenting parents or guardians caring 
for a child who has been receiving HPN for greater than 6 months. Exclusion criteria 
were failure to consent and the inability to respond to either the telephone or postal 
questionnaire. The only specified exclusion criteria for the control families were if they 
had a child with a chronic illness. 
3.5 Administration of Questionnaires 
In all 3 studies, telephone questionnaires were administered by Alison Chambers (trial 
coordinator) not involved with the patients’ care. In study 1, a week before the next 
questionnaire was due a letter was sent out reminding patients of the date and time of the 
telephone call. If a patient was unable to be contacted the trial coordinator made 3 
attempts at contacting the patient by telephone and if unsuccessful sent a further 
reminder. In study 3 postal questionnaires were sent to the participating families, who 
were asked to complete them and return them in the stamped addressed envelope. 
 
3.5.1 Analysis of Questionnaires 
Once the questionnaire scores from all 3 studies had been collected, the raw data was 
entered into specially designed Microsoft Excel spreadsheets. From the raw data, QoL 
scores were calculated. The SF36 normative data is gender, culture and age specific. 
Normative data was adjusted to match our population by taking mean age and gender 
scores from published general population data (359). 
 
3.5.2 Medical Record Data Collection 
At the end of each study the trial coordinator visited hospitals which had recruited 
patients to the trials. Full medical records were analysed in an attempt to determine 
factors contributing to developmental outcome. Clinical information obtained from 
medical records included diagnosis, date of admission and discharge from the HPN 
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centre, date of CVC insertion, presence of a stoma, use of opiates, no. of outpatient 
clinics, no. of inpatient episodes and days, no. of  CVCs and whether they were still 
receiving HPN. Patients were contacted and asked to confirm hospital visits where 
possible. 
3.6 Participating Centres 
The subject populations in studies 1 and 3 consist of patients recruited from 15 UK 
centres. All major centres in the UK who provide an adult and or paediatric HPN service 
were approached to participate in the studies. Several centres declined to be in the studies 
for two main reasons. Firstly because they felt their HPN population was too small. 
Secondly because the NHS Trust had contracts with specific HPN providers not involved 
with study 1.  
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Table 3.1: Centres Which Participated in the Research Projects 
Centre Geographical Area Study 
Hope Hospital Manchester Study 1 
Saint Marks Hospital Harrow Study 1 
The Royal London Hospital London Study 1,2 &3 
Leeds General Infirmary  Leeds Studies 1&3 
Dudley NHS Trust  Birmingham Study 1 
The John Radcliffe Hospital Oxford Studies 1 & 3 
Ninewells Hospital Dundee Study 1 
Leicester Royal Infirmary  Leicester Study 1 
Queens Medical Centre Nottingham Study 1 
Booth Hall Hospital Manchester Study 3 
Birmingham Children’s Hospital Birmingham Study 3 
Yorkhill Hospital Glasgow Study 3 
Great Ormond Street Hospital London Study 3 
Bristol Royal Hospital For Children Bristol Study 3 
University Hospital of Wales Wales Study 3 
3.7 Ethical Consent 
The system of obtaining ethical consent in the UK is constantly evolving and changing. 
Ethical consent was obtained for 3 separate research projects (over 5 years), but because 
consent was sought at different time points, the processes and committees differed 
slightly.  
 
For study 1- the HPN, telemedicine and QoL study, multi centred ethical approval was 
obtained from the London MREC (Multi-centred Research Ethics Committee), and 
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ethical authorisation was acquired from the Local Research Ethics Committees (LREC) 
at each participating centre. Subjects were approached and interviewed by a member of 
the nutrition team, and asked if they would like to participate in the study. Information 
sheets and consent forms were provided. On agreement the consent form was signed and 
faxed to the trial coordinator. Upon receiving the consent form, patients were randomised 
within 24 hours.  
 
With the pseudo-obstruction study (study 2), ethical approval was also obtained from the 
London MREC, although this was not a multi centred study. Patients were introduced to 
the study by letter and asked to return a signed consent form if they wanted to participate. 
A telephone questionnaire was arranged then a subsequent audit of the case notes was 
translated into an anonymous database which allowed comparison of the clinical features 
with radiological, manometric and histological findings.  
 
The paediatric HPN study (study 3) required COREC (Central Office for Research Ethics 
Committee) ethical approval which was obtained from the South West MREC (Multi-
centred Research Ethic Committee). LREC (Local Research Ethic Committee) and R&D 
approval was then acquired for each participating centre. Participating centres then sent 
the researcher contact details for all the families who were eligible for inclusion. Subjects 
were then sent a letter and information sheets and consent forms were provided. Upon 
receiving the consent form, the parent or guardian was contacted within 1 week to 
arrange a time for the telephone questionnaire. 
 
In all 3 research projects, confidentiality was maintained by allocating patient record 
numbers known only to the trial coordinator and patients were not provided any 
compensation for participation in these studies. 
 
3.8 Comparison and statistical analysis 
The 2 types of data represented in these studies are: 
 Categorical (qualitative) ordinal data, e.g. HAD Scale and EQ5D 
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 Numerical (quantitative) continuous data, e.g. SF36, WOCQ, FAD and GHQ28 
Questionnaire data is derived data. This is an arbitrary value, but can be treated as 
continuous variables (437). 
 
The SF36 manual provides estimates of sample sizes necessary to detect differences 
between two groups in SF36 average scores, and to detect differences overtime within 
one group (longitudinal measures).These estimates assume alpha = 0:05 and power = 
80%. The SF36 outcome score is from 0-100, and the sample size needed to detect a 
difference of 20 points (on a 100 point scale) varies between each domain see table 3.2. 
 
Table 3.2 Sample Size Needed to Detect a Difference of 20 Points in Average SF36 
Scores 
 Sample size needed to detect a difference of 20 points 
SF36 Domain Between 2 Groups 1 Group Over time 
Physical functioning (PF) 22 15 
Physical role (RP) 47 30 
Bodily pain (BP) 23 15 
General health (GH) 17 11 
Vitality (VT) 18 12 
Social functioning (SF) 21 14 
Emotional role (RE) 44 28 
Mental health (MH) 14 9 
 
All statistical data analysis was done using Intercooled STATA 8 package 
 
3.8.1 Study 1 – QoL in Adult HPN and Telemedicine 
Comparisons were made between SF36 and EuroQol scores and HAD to determine if the 
results were substantiated. The control population was compared with those who received 
telemedicine upon discharge. It would have been ideal to further subdivide our study 
population by opiate use, presence of stoma, employment status, and gender, however the 
 115     
limited number of subjects prevented this and analysis would not be meaningful. The 
HPN population was compared to normative population data (359). 
 
If you expect the variability to be similar in two groups, then provided you have a 
reasonable number in each group (paired analysis), t-tests will be sufficiently accurate. 
The data does not have to be normal. If the data is significantly not normal and the 
sample size is less than 15 then it is possibly better to use a non parametric test. However 
the non parametric tests require the groups to have similar shaped distributions 
(Statistician Enid Hennessy, personal communication 20th April 2009). We expected the 
variability to be similar in two groups and had a reasonable number in each group 
therefore it was assumed that t-tests would be sufficiently accurate. The statistical tests 
applied were t-tests and Pearson correlations. The level of significance was set at p<0.05. 
 
Pearson Correlations: measures the degree of association between 2 variables.  
SF36, HAD, and clinical outcome data were compared using paired and unpaired t-tests 
as appropriate. Pearson χ2 testing was used for EQ5D data. 
 
3.8.2 Study 2 – QoL in Pseudo-obstruction 
The same statistical analysis was applied as in the first study.  
 
3.8.3 Study 3 – QoL of Children on HPN and their Carers 
Data Distribution 
Non parametric tests (sometimes referred to as distribution free tests or rank methods) are 
particularly useful when the sample size is small (so that it is impossible to assess the 
distribution of the data) and when the data are measured on a categorical scale (HAD & 
EQ5D). But non parametric tests are generally wasteful of information and consequently 
have less power of detecting a real effect.   
In fact, scores on the 8 subscales were probably not all normally distributed because of 
the small size of the sample.  
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Wilcoxon signed-rank test was chosen as the sample size is small (12 matched pairs) and 
we were therefore unable to determine the distribution of our data. The Wilcoxon signed-
rank test was chosen over the sign test as it takes into account the ranks of the data as 
well as the sign of the data and is thus more powerful (437). 
 
Obviously the protocols for sending a patient home on HPN differ between centres and to 
a large extent depend on the experience of the centre. For this reason centres are not 
identified for comparative purposes in publication as this was a worry voiced by some of 
the smaller centres when planning these studies. 
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4.0 Results 
4.1 Study 1: QoL in Adult HPN and Telemedicine 
4.1.1 Study Sample Characteristics 
A total of 30 subjects were recruited to the study from 8 out of the 9 centres involved 
between March 2001 and June 2003. Fourteen subjects remained on HPN for one year. 
Reasons for HPN being discontinued were death (7), bowel adaption (8), and one subject 
was lost to follow up. Acute diagnosis was classified as short bowel syndrome occurring 
suddenly or a result of bowel infarction, chronic intestinal disease was classified as 
Crohn’s disease or pseudo-obstruction. Functional short bowel was defined as the 
functional loss of extensive segments of small intestine so that absorptive capacity was 
severely compromised. Clinical information was collected for 29 of the subjects, and we 
were unable to obtain a full medical history for one subject as their notes were lost in the 
post. The mean age was 46 years old, 19 (63%) had a stoma, 15 (50%) used opiates and 
11 (37%) had an acute onset of disease resulting in the need for HPN. 
 
Table 4.1: Study 1 - Population Diagnosis  
Diagnosis Total Telemedicine Control 
Ischaemic bowel disease 6 4 2 
Crohn’s disease 6 3 3 
Functional short bowel 4 1 3 
Pseudo-obstruction 3 3 0 
Radiation enteritis 2 0 2 
Volvulus 2 0 2 
Adenomatous polyposis 1 1 0 
Neuropathy 1 1 0 
Raynauds phenomenon 1 1 0 
Sclerosing encapsulating peritonitis 1 1 0 
Syringomyelia 1 0 1 
Ulcerative colitis 1 0 1 
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4.1.2 Differences between the Telemedicine (TM) and Control Groups 
The subjects in our sample were randomised into 2 groups – standard care follow-up 
(control), or standard care follow-up with telemedicine. Table 4.2 shows the demographic 
and clinical differences between the 2 groups. 
 
Table 4.2: Study 1 -Differences between the TM & the Control Group 
 TM (%) SD Control (%) SD P Values 
Male 8 (50) 0.5 5 (35) 0.5 0.448 
Female 8 (50) 0.5 9 (65) 0.5 0.448 
Mean Age 44 12.7 46 13.8 0.752 
Presence of Stoma 11 (73) 0.5 8 (57) 0.5 0.377 
Opiate Use 9 (60) 0.5 6 (43) 0.5 0.374 
Acute diagnosis 4 (27) 0.5 7 (50) 0.5 0.381 
 
The telemedicine group contains a higher number of patients with stomas (p=0.377), a 
greater percentage of opiate users (p=0.374) and a lower percentage of subjects with an 
acute diagnosis (p=0.381) when compared to the control group although these differences 
were not significant. The mean time of hospitalisation over the first year was 31.7 and 26 
days which corresponds to 9 and 7% of the year for the telemedicine and control group 
respectively. 
 
It was postulated that telemedicine might facilitate earlier initial discharge from hospital 
by perhaps providing an enhanced method of communication. The patients receiving 
telemedicine had a mean of 75 days, whilst the control group had a mean of 65 days as an 
inpatient before their initial first discharge, although a t-test comparison indicated that 
this difference was not significant (p=0.29). Further analysis suggested that there was no 
significant correlation between the number of days as an inpatient before initial discharge 
and opiate use (p=0.33) or acute diagnosis (p=0.99). Patients who had a stoma spent on 
average 27 more days in hospital before initial discharge than those without a stoma 
(although this was not significant - p=0.073), which may explain why the telemedicine 
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group (which contained a higher number of patients with a stoma) had a longer mean 
number of inpatient days before their initial first discharge. 
 
4.1.3 Comparison of QoL Scores between HPN Population and Normative Data  
 The study population was compared to adjusted normative population data. 
Table 4.3: Comparison of Mean Total HPN Cohort SF36 Scores with Normative 
Data  
Domain (n) HPN (SD) Norms (SD) P value 
PF 2 Days (27) 33.7 (26.6) 86.7 (6.2) < 0.001 
PF 6 Months (21) 57.9 (32.1) 86.1 (6.7) < 0.001 
RP 2 Days (27) 3.7 (9.1) 85.8 (6.7) < 0.001 
RP 6 Months (21) 33.3 (42.8) 85.1 (5.5) < 0.001 
BP 2 Days (27) 38.6 (27.5) 77.9 (4.7) < 0.001 
BP 6 Months (21) 45.9 (29.7) 77.1 (5.1) < 0.001 
GH 2 Days (27) 35.5 (22.3) 70.6 (3.3) < 0.001 
GH 6 Months (21) 33.1 (23.2) 70.4 (3.2) < 0.001 
VT 2 Days (27) 28.3 (21.2) 57.8 (2.5) < 0.001 
VT 6 Months (21) 43.3 (24.8) 57.6 (2.5) 0.015 
SF 2 Days (27) 21.3 (27.7) 82.4 (2.1) < 0.001 
SF 6 Months (21) 47.0 (33.3) 82.3 (2.0) < 0.001 
RE 2 Days (27) 49.4 (44.7) 85.6 (2.2) < 0.001 
RE 6 Months (21) 71.4 (43.8) 85.2 (2.3) 0.164 
MH 2 Days (26) 57.2 (20.5) 72.0 (2.6) 0.001 
MH 6 Months (22) 65.5 (23.7) 72.2 (2.6) 0.200 
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
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Upon initial discharge, in all domains except Role Emotional and Mental Health the 
study population had significantly lower scores (indicating lower QoL) than the normal 
population. RE and MH however were not significantly different at 6 months post initial 
discharge.  
 
Table 4.4: Comparisons of Mean Total HPN Cohort HAD Scores with Normative 
Data 
HAD Score HPN Mean (SD)  UK Normative Data Mean (SD) 
Anxiety 2 Days 7.1 (3.9) 6.1  (3.8) 
Depression 2 Days 6.3 (3.5) 3.7  (3.1) 
Total Score 12.5 (7.0) 9.8  (6.0) 
Anxiety 6 Months 7.0 (4.5) 6.1  (3.8) 
Depression 6 Months 6.5 (4.2) 3.7  (3.1) 
Total Score 6 Months 9.4  (8.6) 9.8  (6.0) 
 
The HAD scale authors (372) suggest cut offs for anxiety and depression. Raw scores of 
<7 indicate no case, scores between 8–10 identify mild cases, 11 – 15 moderate case, and 
16 or above severe cases. According to these guidelines the HPN mean population scores 
imply the anxiety and depression scores are not clinically relevant. 
Crawford et al (374) also suggest the addition of the anxiety and depression scores to 
yield a Total Score which measures general psychological distress. This tends to produce 
higher scores, however, there are no published cut offs for the total score.  
 
It was not possible to obtain normative data adjusted to our population therefore I was 
unable to determine the significance of differences seen. 
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Table 4.5: Comparison of EQ5D Scores between TM, Control & Normative Data 
EQ5D 
Domain 
% of TM group 
reporting any 
problem 
% of Control 
group reporting 
any problem 
Mean % of Study 
Population 
reporting any 
problem 
% of Normal 
Population with 
any Problem 
MB 2 Days 71.4 76.9 74.1 18.4 
MB 6 Months 50.0 61.5 57.1 18.4 
SC 2 Days 57.1 30.8 44.4 4.2 
SC 6 Months 25.0 30.8 28.6 4.2 
UA 2 Days 92.9 92.3 92.6 16.3 
UA 6 Months 75.0 69.2 71.4 16.3 
PD 2 Days 78.6 69.2 74.1 33.0 
PD 6 Months 75.0 84.6 81.0 33.0 
AD 2 Days 42.9 46.2 44.4 20.9 
AD 6 Months 50.0 38.5 42.9 20.9 
 
Table 4.5 shows the percentage of the study population who had any problem with 
Mobility (MB), Self Care (SC), Usual Activities (UA), Pain and Discomfort (PD) and 
Anxiety and Depression (AD). Results from UK normative data (376) are also shown.  
 
There is little difference between the TM and control group in any of the domains, and 
comparison with the normative data reveals the HPN population report more “any 
problem” scores in each domain than normal. 
 
At both 2 days and 6 months the HPN populations report more moderate or extreme 
problems than the normal population.  
 
4.1.4 Longitudinal QoL Scores  
Repeated measures were taken at several time points throughout the duration of the study, 
allowing the observation of time on QoL scores. QoL scores were measured at 2 days, 6, 
12 and 18 months post discharge. By one year the sample size had become too small to 
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allow for meaningful analysis, so statistical analysis was performed between 2 days and 6 
months. As no significant differences in SF36 scores or any other parameters measured 
between the telemedicine and control group were observed, the two groups were pooled 
together for the remainder of the analysis. 
 
Table 4.6: Comparison of Mean Total HPN Cohort SF36 Scores between 2d & 6m 
SF36 Domain (n) 2 Days (SD) 6 Months (SD) P Value 
PF (19) 38.9 (25.5) 50.5 (31.7) 0.021 
RP (20) 3.75 (9.2) 30.0 (41.0) 0.011 
BP (20) 37.3 (28.5) 39.5 (27.6) 0.592 
GH (20 35.6 (22.5) 31.5 (22.4) 0.184 
VT (20) 28.75 (21.6) 41.0 (24.0) 0.059 
SF (20) 22.5 (29.1) 44.4 (31.8) 0.006 
RE (20) 48.3 (46.5) 68.3 (44.5) 0.055 
MH (20) 57.4 (22.3) 64 (24.5) 0.117 
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
 
The data indicates that there is a significant increase in PF, RP and SF. There is a trend 
for QoL to be higher at 6 months in VT and RE. This increase in QoL is not observed in 
MH or BP. 
 
Table 4.7: Comparison of Mean Total HPN Cohort HAD Scores between 2d & 6m 
 2 Days (SD) 6 Months (SD) P Value 
Anxiety  7.1 (4.2) 7.0 (4.5) 0.940 
Depression  6.2 (3.7) 6.5 (4.2) 0.690 
Total Score 12.5 (7.0) 9.4 (8.6) 0.033 
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There are no significant changes in anxiety or depression over between 2 days and 6 
months of HPN therapy. There is a significant reduction in Total HAD score (p=0.033) 
indicating a reduction in psychological distress between 2 days and 6 months. 
 
Table 4.8: Comparison of Total HPN Cohort EQ5D Scores between 2d & 6m 
 % of respondents 
reporting any problem 
at 2 Days 
% of respondents 
reporting any problem 
6 Months 
%  of Normal 
Population reporting 
any problem 
MB  74.1 57.1 18.4 
SC  44.4 28.6 4.2 
UA  92.6 71.4 16.3 
PD  74.1 81.0 33.0 
AD  44.4 42.9 20.9 
Key: MB=Mobility, SC=Self Care, UA=Usual Activities, PD=Pain and Discomfort, AD=Anxiety and Depression 
 
Figure 1: Percentage of HPN Patients Reporting Any Problem at 2d & 6m 
Compared with Normative Data 
Number of Patients Reporting Any Problems at 2 Days and 6 Months, Compared with Normative Data
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I was unable to analyse the EQ5D in the same way as the SF36 and HADS, because the 
normative data is expressed differently and it was not possible to apply standard tests of 
hypothesis. However the graphical representation clearly shows that in all domains 
(except pain and discomfort), the number of HPN patients reporting any problems (either 
moderate or extreme) reduces over the first 6 months of HPN and is starting to approach 
the normative data values. It would be of interest to see if this continues or stabilises over 
an extended period of time.  
 
4.1.5 Comparison of SF36 Scores by Opiate Use, Acute Diagnosis, Presence of a Stoma 
and Use of Telemedicine     
Student t test comparisons of SF36 scores between those who do and do not use opiates, 
between those who had a stoma and between those who had an acute or chronic onset of 
disease were performed.   
 
Table 4.9: Comparison of Mean Total HPN Cohort SF36 Scores by Opiate Use 
Domain Opiate (SD) N No Opiate (SD) n P Value 
BP 2 Days 23.2 (25.9) 14 50.3 (23.4) 12 0.011 
BP 6 Months 26.2 (26.6) 12 62.8 (22.4) 9 0.007 
RP 6 Months 16.7 (38.9) 12 55.6 (39.1) 9 0.036 
VT 6 Months 30.4 (21.3) 12 59.4 (20.1) 9 0.006 
SF 6 Months 32.3 (27.4) 12 66.7 (31.3) 9 0.015 
MH 6 Months 55.3 (24.2) 12 77.3 (18.3) 9 0.035 
Key: BP=Bodily Pain, RP=Role Physical, VT=Vitality, SF=Social Functioning, MH=Mental Health 
 
Not all the analysis is shown, but SF36 scores were significantly higher in those who do 
not use opiates in RP, BP, VT, SF and mental health. 
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Table 4.10: Comparison of Mean Total HPN Cohort SF36 Scores by Acute Onset 
Domain Acute (SD) n Chronic (SD) n P Value 
BP 6 Months 66.0 (30.4) 8 33.5 (22.1) 13 0.011 
GH 2 Days 52.2 (24.8) 11 26.3 (15.9) 15 0.015 
GH 6 Months 56.0 (25.3) 8 21.7 (15.1) 13 0.007 
VT 6 Months 60.0 (25.1) 8 34.2 (22.7) 13 0.091 
Key: BP=Bodily Pain, GH=General Health, VT=Vitality 
 
Those who were diagnosed with an acute form of intestinal failure had significantly 
higher QoL scores in BP and GH domains. There was weak a trend for those with chronic 
intestinal failure to have lower vitality scores.   
 
There were no significances observed between those who did and did not have a stoma. 
Telemedicine use had no statistically significant impact on SF36 scores.  
 
Table 4.11: Comparison of Mean Anxiety HPN Cohort HAD Anxiety Scores at 2 
Days by Opiate Use, Acute Onset, Presence of a Stoma and TM 
HAD ANXIETY (n) Mean Anxiety 2 Days (SD) P value 
Opiate (15) 7.7 (4.7) 
No Opiate (12) 6.5 (3.0) 
0.460 
Acute onset (12) 5.3 (3.0) 
Chronic onset (15) 8.6 (4.1) 
0.031 
Stoma (18) 7.3 (4.4) 
No Stoma (9) 6.9 (3.2) 
0.816 
Telemedicine (14) 7.6 (4.7) 
No Telemedicine (14) 6.6 (3.1) 
0.530 
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Table 4.12: Comparison of Mean Anxiety HPN Cohort HAD Anxiety Scores at 6 
Months by Opiate Use, Acute Onset, Presence of a Stoma and TM 
HAD ANXIETY (n) Mean Anxiety 6 Months (SD) P value 
Opiate (11) 7.9 (5.0) 
No Opiate (9) 6.0 (4.0) 
0.369 
Acute onset (10) 6.1 (4.7) 
Chronic onset (10) 8.0 (4.6) 
0.369 
Stoma (13) 7.2 (4.8) 
No Stoma (7) 6.9 (4.5) 
0.895 
Telemedicine (8) 7.2 (4.9) 
No Telemedicine (13) 6.9 (4.4) 
0.840 
 
At 2 days, those whose disease onset was chronic had significantly more anxiety than 
those whose disease onset was acute. This difference has diminished by 6 months.  
 
Table 4.13: Comparison of Mean HAD Depression Scores at 2 Days by Opiate Use, 
Acute Onset, Presence of a Stoma and TM 
HAD DEPRESSION (n) Depression 2 Days (SD) P value 
Opiate (15) 7.3 (3.2) 
 No Opiate (12) 5.3 (3.5) 
0.135 
Acute onset (12) 5.4 (3.5) 
Chronic onset (15) 7.3 (3.2) 
0.169 
Stoma (18) 6.6 (3.2) 
No Stoma (9) 6.2 (4.1) 
0.817 
Telemedicine (14)  6.7 (3.7) 
No Telemedicine (14) 5.9 (3.3) 
0.520 
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Table 4.14: Comparison of Mean HAD Depression Scores at 6 Months by Opiate 
Use, Acute Onset, Presence of a Stoma and TM 
 
At 6 months there is a trend for those on opiates to be more depressed.  
 
Table 4.15: Comparison of HAD Total Scores at 2 Days by Opiate Use, Acute Onset, 
Presence of a Stoma and TM 
HAD TOTAL (n) Total HAD Score 2 Days (SD) P value 
Opiate (15) 15.0 (7.0) 
No Opiate (14) 10.1 (6.5) 
0.063 
Acute onset (12) 10.8 (5.6) 
Chronic onset (17) 14.0 (7.8) 
0.229 
Stoma (19) 13.1 (7.1) 
No Stoma (10) 11.8 (7.3) 
0.645 
Telemedicine (16) 12.5 (5.4) 
No Telemedicine (14) 12.5 (8.3) 
1.000 
 
HAD DEPRESSION (n) Depression 6 Months (SD) P value 
Opiate (11) 8.4 (3.6) 
 No Opiate (9) 4.9 (3.9) 
0.052 
Acute onset (10) 5.9 (4.1) 
Chronic onset (10) 7.7 (3.9) 
0.332 
Stoma (13) 7.2 (4.3) 
No Stoma (7)   6.1 (3.8) 
0.607 
Telemedicine (8) 6.4 (4.6) 
No Telemedicine (13) 6.5 (4.1) 
0.930 
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Table 4.16: Comparison of HAD Total Scores at 6 Months by Opiate Use, Acute 
Onset, Presence of a Stoma and TM 
HAD TOTAL (n) Total HAD Score 6 Months (SD) P value 
Opiate (15) 11.9 (9.5) 
No Opiate (14) 7.0 (7.1) 
0.129 
Acute onset (12) 10.0 (7.3) 
Chronic onset (17) 9.2 (9.7) 
0.820 
Stoma (19) 9.8 (9.2) 
No Stoma (10) 9.1 (8.0) 
0.843 
Telemedicine (16) 6.8 (9.1) 
No Telemedicine (14)     12.4 (7.1) 
0.072 
 
No significant differences were observed.  
 
Data on patients who extended beyond 6 months were analysed although the sample size 
was small, however no trends were detected. 
 
4.1.6 Comparison Hospital Contact by Clinical Parameters 
Student t tests were used to compare number of outpatient clinics, inpatient episodes, 
inpatient days, nutrition clinics and CVCs at one year by opiate use, acute diagnosis, 
presence of a stoma and telemedicine use.   
 
Table 4.17: Hospital Contact at 1 Year by Opiate Use 
Variable at 1 Year Mean opiate (SD) N Mean nil opiate (SD) n P Value 
Outpatient clinics 6.3 (5.1) 15 6.4 (2.8) 14 0.952 
Nutrition clinics 4.9 (4.1) 15 4.4 (2.5) 14 0.734 
Inpatient days 39.8 (25.6) 14 18.1 (38.7) 14 0.092 
Inpatient episodes 3.3 (2.9) 14 1.2 (1.1) 14 0.018 
CVCs 2.0 (1.0) 14 1.1 (0.4) 14 0.007 
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There were no significant differences in outpatient clinic or nutrition clinic attendances or 
inpatient days between the two groups (table 4.17). Significant differences were found in 
the number of inpatient episodes and number of CVCs. The group who used opiates had 
more inpatient episodes and required CVC replacement more often. 
 
Table 4.18: Comparison of Hospital Contact by Acute Diagnosis 
Variable at 1 Year Mean Acute (SD) n Mean Chronic (SD) N P Value 
Outpatient clinics 6.7 (3.0) 12 6.2 (4.8) 17 0.759 
Nutrition clinics 5.0 (2.8) 12 4.4 (3.8) 17 0.653 
Inpatient days 20.7 (27.0) 12 35.3 (38.1) 16 0.270 
Inpatient episodes 1.0 (1.0) 12 3.2 (2.7) 16 0.013 
CVCs 1.3 (0.7) 12 1.8 (1.0) 16 0.221 
 
There were no significant differences in outpatient clinics, nutrition clinics or number of 
inpatient days between the two groups (table 4.18). A Significant difference was found in 
the number of inpatient episodes. The group who had chronic diagnosis had statistically 
more inpatient episodes.  
 
Table 4.19: Hospital Contact at 1 Year by Stoma 
Variable at 1 Year Stoma (SD) n No Stoma (SD) n P Value 
Outpatient clinics 5.9 (4.3) 19 7.3 (3.7) 10 0.392 
Nutrition clinics 4.6 (3.4) 19 4.8 (3.6) 10 0.871 
Inpatient days 32.8 (37.0) 18 22.2 (28.5) 10 0.441 
Inpatient episodes 2.6 (2.5) 18 1.6 (2.0) 10 0.287 
CVCs 1.7 (1.0) 18 1.3 (0.7) 10 0.230 
 
No significant differences seen. 
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Table 4.20: Comparison of Hospital Contact by TM 
Variable at 1 Year Mean Telemedicine (SD) n Mean Control (SD) n P Value 
Outpatient clinics 5.7 (4.3) 15 7.1 (3.7) 14 0.392 
Nutrition clinics 4.3 (3.4) 15 5.1 (3.6) 14 0.530 
Inpatient days 31.7 (37.0) 14 26.3 (28.5) 14 0.681 
Inpatient episodes 2.2 (2.5) 14 2.3 (2.0) 14 0.940 
CVCs 3.8 (1.0) 14 4.7 (0.7) 14 0.675 
 
Telemedicine had no significant effect on hospital contact. 
 
4.1.7 Multivariate Analysis 
It is possible that there are dependent relationships between certain variables. For 
example opiate use may be dependent on the onset (acute or chronic) of the disease 
necessitating HPN therapy. Multivariate analysis would be a way to determine and 
interrogate the presence and or nature of such relationships. However the literature does 
not provide a consistent answer to the sample size required to perform multivariate 
analysis. There seems to be a general consensus that to yield statistically meaningful 
results, the sample size needs to be greater than n=50. 
 
Although the sample size in this study was only n=29, a pair-wise correlation was 
performed to determine the presence, the strength and direction of any correlations 
between any 2 variables. The outcome correlation coefficient ranged from -1 to +1, with -
1 indicating a perfect negative correlation, +1 indicating a perfect positive correlation, 
and 0 indicating no correlation at all. However the results indicated no highly positive or 
highly negative correlations, negating the need for further multivariate analysis. I suggest 
that the small sample size of the study (n=29) could be a reason that no correlations were 
observed. 
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4.2 Study 2: QoL in Pseudo-obstruction 
4.2.1 Study Sample Characteristics 
A total of 42 subjects were recruited to the study from 60 patients invited (response rate 
of 70%). Characteristics of the study sample can be seen in table 4.21 Clinical 
information was collected for 42 of the subjects. Presence of stoma and acute diagnosis 
were not recorded. 
 
Table 4.21: Study 2: Characteristics of the Study Sample 
Variable No. of Males (%) No of Females (%) Total (%) 
Gender (n=42) 7 (17) 35  (83) 42 (100) 
Mean Age (n=42) 53 42 44 
Age Range (n=42) 21-69 19-69 19-69 
Opiate Use (n=42) 5 (71) 19 (54) 24 (68) 
Oral Nutrition (n=32) 2 (29) 17 (49) 19 (45) 
Enteral Nutrition (n=32) 2 (29) 12 (34) 14 (33) 
Parenteral Nutrition (n=32) 3 (42) 16 (45) 19 (45) 
 
The majority of our cohort was female, males only representing 17%. The male 
population was older and contained a higher percentage of opiate users (5 out of the 7 
men – or 71%). 
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Table 4.22: Summary Table of Clinical Investigations/Findings 
Clinical Investigation/Event Findings/Incidence (%) 
Histology (n=23) Normal = 8 (34.8) 
Actin Deficiency = 5 (21.7) 
Neuropathy = 2 (8.7) 
Myopathy = 5 (21.7) 
Abnormal Indeterminate = 2 (8.7) 
Actin Deficiency/Neuropathy = 1 (4.4) 
Manometry (n=20) Normal = 3 (15) 
Neuropathy = 5 (25) 
Myopathy = 0 (0) 
Abnormal Indeterminate = 12 (60) 
Resection (n=32) 15 (46.9) 
Dilated SB (n=32) 10 (31.2) 
Delayed Transit (n=15) 11 (73) 
Gastric Emptying (n=24) Delayed = 14 (58.3) 
Rapid = 4 (16.7) 
Normal = 6 (25)   
Abnormal Oesophageal Manometry (n=8) 7 (87.5) 
Hysterectomy (n=28) 11(39.2) 
Abnormal Uro-Dynamics (n=6) 4 (66.7) 
Urinary Symptoms (n=32) 7 (21.8) 
 
Information regarding clinical investigations and findings were obtained from medical 
records. Obviously not all patients had all investigations which is why (n) is not constant.  
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Table 4.23: Current Symptoms of the Study 2 Sample 
Current Symptoms No. of Males (%) No of Females (%) Total (%) 
Abdominal Pain (n=32) 4 (100) 26 (93) 30 (94) 
Vomiting (n=32) 4 (100) 20 (71) 24 (75) 
Constipation (n=32) 1 (25) 24 (86) 25 (78) 
Bloating (n=32) 4 (100) 17 (60) 21 (66) 
Diarrhoea (n=32) 0 (0) 11 (39) 11 (34) 
Reflux (n=32) 1 (25) 4 (14) 5 (15) 
Dysphagia (n=32) 0 (0) 3 (10) 3 (9) 
 We were able to obtain information about current symptoms from 32 members of the 
study population. Due to the fact that the majority of the cohort suffered with abdominal 
pain, vomiting, constipation, no reflux and no dysphagia, we were unable to statistically 
analyse the stratified data and correlate it with QoL scores. For example 30 out of 32 
suffered with abdominal pain (94%), so we’d be comparing the results of 30 people with 
the results of 2 people. QoL comparison was only made if n ≥10 in each of the groups 
being analysed. 
 
4.2.2 Analysis of SF36 Scores  
Table 4.24: A Comparison of Mean CIIP SF36 Scores with Normative Data 
SF36 Domain Mean CIIP Score 
(SD) 
Mean Normal 
Score (SD) 
t-test p value 
PF 44.5 (31.0) 85.8 (5.5) < 0.001 
RP 19.6 (33.4) 85.3 (4.6) < 0.001 
BP 30.2 (25.2) 76.8 (3.9) < 0.001 
GH 27.9 (16.1) 70.2 (2.6) < 0.001 
VT 26.2 (19.3) 56.8 (1.7) < 0.001 
SF 41.5 (28.2) 81.7 (1.4) < 0.001 
RE 68.3 (43.5) 84.6 (1.9) 0.019 
MH 60.7 (23.9) 71.1 (2.4) 0.008 
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
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Highly statistically significant results demonstrate that those with pseudo-obstruction 
have a poorer QoL than the normal population as ranked by every SF36 domain. 
 
Table 4.25: Comparison of Mean CIIP SF36 Scores by Age  
SF36 Domain Up to 44 years old 
Mean Score (SD) 
Over 45 years old 
Mean Score (SD) 
t-test P value 
PF 48.3 (29.6) 40.7 (32.5) 0.432 
RP 17.9 (31.8) 21.4 (35.6) 0.733 
BP 26.7 (22.0) 33.7 (28.2) 0.375 
GH 26.2 (16.3) 29.6 (16.0) 0.502 
VT 26.7 (21.0) 25.7 (17.9) 0.875 
SF 45.4 (24.6) 37.6 (31.6) 0.376 
RE 76.2 (39.6) 60.3 (46.7) 0.241 
MH 60.6 (23.8) 60.8 (24.5) 0.980 
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
 
SF36 scores were correlated with age, no statistical differences were found in those older 
or younger than 45 years old, which is in contrast to the results found from other studies 
of HPN patients (396;404) and home enteral nutrition patients (428).  
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4.2.3 Comparison of Clinical Information 
Table 4.26: Comparison of Mean CIIP SF36 Scores by Opiate Use 
SF36 Domain Opiate use n=24 
(SD) 
Nil Opiate Use n=18 
(SD) 
t-test p value 
PF 33.1 (28.2) 59.7 (28.5) 0.005 
RP 9.4 (23.1) 33.3 (40.2) 0.019 
BP 16.1 (11.2) 48.9 (26.7) < 0.001 
GH 22.9 (12.6) 34.6 (18.1) 0.018 
VT 21.3 (18.7) 32.8 (18.6) 0.054 
SF 32.5 (26.1) 53.6 (27.0) 0.014 
RE 66.7 (45.0) 70.4 (42.6) 0.790 
MH 58.0 (24.7) 64.2 (22.9) 0.410 
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
 
Those who use opiates report statistically significant lower levels of physical role, 
general health, physical and social functioning, and worse bodily pain. There was a trend 
for those on opiates to have poorer VT scores. Interestingly opiate use does not appear to 
affect emotional role or mental health.    
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Table 4.27: Comparison of Mean CIIP SF36 Scores by Oral Nutrition 
SF36 Domain Oral Intake n=19 
(SD) 
 No Oral Intake n=23 
(SD) 
t-test p value 
PF 54.2 (30.4) 36.5 (29.8) 0.065 
RP 26.3 (41.2) 14.1 (24.8) 0.244 
BP 30.8 (27.8) 29.7 (23.5) 0.886 
GH 29.7 (16.5) 26.4 (15.9) 0.515 
VT 22.4 (20.4) 29.3 (18.1) 0.248 
SF 46.2 (30.0) 37.7 (26.7) 0.334 
RE 59.7 (47.9) 75.4 (39.2) 0.249 
MH 54.5 (28.9) 65.7 (17.9) 0.131 
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
 
Oral intake does not appear to have any impact on SF36 outcomes, although the data 
suggests there is a trend for higher physical functioning scores in those who are able to 
eat. 
 
Table 4.28: Comparison of Mean CIIP SF36 Scores by Enteral Nutrition 
SF36 Domain Enteral Intake n=14 
(SD) 
No Enteral Intake n=28 
(SD) 
t-test p value 
PF 32.1 (31.1) 50.7 (29.5) 0.066 
RP 17.9 (28.5) 20.5 (36.0) 0.810 
BP 25.6 (13.9) 32.5 (29.3) 0.410 
GH 25.8 (14.9) 28.9 (16.8) 0.557 
VT 29.6 (18.7) 24.5 (19.7) 0.419 
SF 35.9 (30.6) 44.4 (27.1) 0.364 
RE 76.2 (38.0) 64.3 (46.2) 0.411 
MH 67.1 (18.6) 57.4 (25.8) 0.218 
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
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Enteral nutrition does not appear to have any impact on SF36 outcomes, although as with 
oral intake, physical functioning scores are higher in those who do not require enteral 
nutrition support.  
 
Table 4.29: Comparison of Mean CIIP SF36 Scores by Parenteral Nutrition 
SF36 Domain PN  n=19 
(SD) 
No PN  n=23 
(SD) 
t-test p value 
PF 41.8 (30.8) 46.7 (31.6) 0.616 
RP 18.4 (29.9) 20.7 (36.7) 0.832 
BP 30.8 (25.8) 29.7 (25.2) 0.886 
GH 26.8 (16.4) 28.7 (16.1) 0.708 
VT 27.1 (20.1) 25.4 (19.0) 0.784 
SF 39.6 (29.0) 43.1 (28.1) 0.698 
RE 75.5 (41.3) 62.3 (45.3) 0.337 
MH 63.2 (20.0) 58.6 (26.9) 0.545 
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
 
Parenteral nutrition does not appear to have any impact on SF36 outcomes.  
 
Table 4.30: Comparison of CIIP SF36 Scores by Resection 
SF36 Domain Resection n= 15 
(SD) 
No Resection n=17 
(SD) 
t-test p value 
PF 42.0 (30.1) 47.4 (33.4)               0.640  
RP 6.7 (20.0) 38.2 (41.6)               0.010  
BP 27.5 (24.2) 35.4 (27.8)               0.400  
GH 30.3 (17.9) 30.0 (16.3)               0.960  
VT 28.0 (17.6) 29.29 (18.4)               0.930  
SF 41.9 (22.0) 43.1 (26.5)               0.860  
RE 68.9 (44.5) 85.8 (30.8)               0.080  
MH 63.5 (19.3) 65.9 (20.3)               0.890  
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
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Patients who had undergone a previous intestinal resection reported a significantly worse 
physical role (RP) and there was a weak trend for them to have a poorer emotional role 
(RE). 
 
Table 4.31: Comparison of CIIP SF36 Scores by Dilated Small Bowel 
SF36 Domain Dilated SB n= 10 
(SD) 
No Dilated SB n=19 
(SD) 
t-test p value 
PF 53.5 (27.9) 42.1 (34.3 0.370 
RP 35.0 (42.8) 19.7 (34.9) 0.310 
BP 40.9 (32.8) 26.4 (22.2 0.170 
GH 27.8 (20.7 31.1(16.1) 0.640 
VT 35.5 (17.1 29.3(18.4 0.930 
SF 56.4 (26.5) 43.1(26.5 0.860 
RE 66.7 (47.1) 85.8(30.8) 0.080 
MH 68.0 (22.4 65.9 (20.3 0.890 
Key: PF=Physical Functioning, RP=Role Physical, BP=Bodily Pain, GH=General Health, VT=Vitality, SF=Social Functioning, 
RE=Role Emotional, MH=Mental Health 
 
Table 4.32: A Summary of Statistically Significant Results/Trends Identified 
 
SF36 
Domain 
Oral Intake Enteral 
Intake 
Resection Dilated 
Small Bowel 
Opiate Use 
PF 0.065 0.066 - - 0.005 
RE - - 0.080 0.080 - 
RP - - - - 0.019 
BP - - - - 0.000 
GH - - - - 0.018 
VT - - - - 0.054 
SF - - - - 0.014 
 
Physical functioning appears to be the domain most affected by method of feeding. 
Opiate use has a negative impact on nearly every SF36 domain, but it is postulated that 
this may be due to the fact that these patients are sicker and have more pain – resulting in 
the depressed score.   
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4.2.4 Comparison of CIIP HAD Scores by Clinical Parameters 
Table 4.33: Comparison of CIIP HAD Scores by Clinical Parameters 
 
Clinical 
Parameter 
Mean  
Anxiety 
Score (SD) 
P value Mean 
Depression 
Score (SD) 
P value Mean Total 
Score (SD) 
P value 
Male (n=7) 7.9 (5.6)   9.3 (5.7) 17.1 (10.6) 
Female (n=35) 7.9 (4.4) 
0.976 
7.8 (4.8) 
0.473 
15.7 (8.4) 
0.696 
Older than 45 
(n=21) 
8.6 (5.4) 7.9 (5.0) 16.5 (9.7) 
Younger than 45 
(n=21) 
7.2 (3.5) 
0.316 
8.2 (4.9) 
0.853 
15.4 (7.7) 
0.675 
Opiate (n=24) 8.0 (4.6) 9.3 (4.9) 17.4 (9.1) 
No Opiate (n=18) 7.7 (4.6) 
0.826 
6.3 (4.5) 
0.049 
14.1 (8.0) 
0.224 
Oral (n=19) 8.7 (5.0) 8.5 (5.1) 17.2 (9.5) 
No Oral (n=23) 7.3 (4.2) 
0.320 
7.7 (4.8) 
0.573 
14.9 (8.0) 
0.399 
Enteral (n=14) 6.9 (4.8) 7.4 (4.8) 14.4 (8.6) 
No Enteral (n=28) 8.4 (4.5) 
0.333 
8.4 (5.0) 
0.571 
16.8 (8.8) 
0.406 
Parenteral (n=19) 7.6 (5.0) 7.9 (5.2) 15.5 (8.5) 
No Parenteral 
n=(23) 
8.2 (5.0) 
0.679 
8.1 (4.8) 
0.906 
16.3 (9.0) 
 0.776 
CIP Mean Score 
(n=42) 
7.9 (4.6) 8.0 (4.9) 15.9 (8.7) 
Normal 
Population 
(n=1792) 
6.1 ** 
0.016 
3.7 ** 
< 0.001 
9.8 ** 
< 0.001 
Resection (n=15) 8.2 (4.5) 8.5 (5.0) 16.7 (8.5) 
No Resection 
(n=17) 
6.4 (4.3) 
 0.245 
6.1 (4.5) 
0.169 
12.5 (8.1) 
0.163 
Dilated Small 
Bowel (n=10) 
7.3 (4.5) 7.4 (4.1) 14.7 (7.9) 
No Dilated Small 
Bowel (n=19) 
7.1 (4.6) 
0.915 
7.4 (5.4) 
0.987 
14.5 (9.4) 
0.949 
   
** = Standard deviation of normative data is unavailable 
Opiate users report significantly higher levels of depression. We compared our cohort 
with normative data from a large non clinical sample (374) and found that those suffering 
with pseudo-obstruction report significantly (highly) more anxiety and depression.   
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4.2.5 Comparison of EQ5D Scores with Normative Data  
EQ5D scores were analysed and the percentage of the study population who had any 
problem with Mobility (MB), Self Care (SC), Usual Activities (UA), Pain and 
Discomfort (PD) and Anxiety and Depression (AD) is shown in table 4.34. Results from 
UK normative data are also shown (376). I was unable to analyse the EQ5D in the same 
way as the SF36 and HADS, so the EQ5D is expressed differently.  
 
Table 4.34: Comparison of CIIP EQ5D Scores with Normative Data  
 Mean Study 
Population (%) 
Normal Population with any 
Problem (%) 
MB 64.3 18.4 
SC 40.5 4.2 
UA 83.3 16.3 
PD 90.5 33.0 
AD 40.5 20.9 
Key: MB=Mobility, SC=Self Care, UA=Usual Activities, PD=Pain and Discomfort, AD=Anxiety and Depression 
 
Comparison with the normative data reveals the pseudo-obstruction population report on 
average more “any problem” scores in each domain than the normal population.   
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Figure 2: Percentage Pseudo-obstruction Patients Reporting Any Problem at 2d & 
6m Compared with Normative Data 
Percentage of CIIP Patients Reporting ANY Problem EQ5D Score Compared to Normative Data
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4.3 Study 3: QoL of Children on HPN and their Carers 
4.3.1 Study Sample Characteristics 
A total of 23 families were invited to participate in this study. Of those, 12 patients (7 
female and 5 male) were recruited from 4 UK centres between September 2005 and April 
2007. Twelve control families were recruited in the same time period. 
Age at diagnosis was birth for 83% of the cohort (10 out of 12). The only 2 patients not 
diagnosed at birth were diagnosed at 2 and 7 months. Follow up was recorded for a mean 
of 4.5 years per child. The number of CVCs required was 50 and there was a mean of 4.1 
or median of 3 catheters per child used.  
 
In the case group, reasons for intestinal failure include (n): CIIP megacystis (2), 
Hirschsprung’s (1), hollow visceral myopathy (1), gastroschisis (3), tufting enteropathy 
(2), protracted diarrhoea (1), phenotypic diarrhoea (1) and short gut syndrome (1). A 
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stoma was present in 4 and none of the children were classified as being opiate 
dependent. Full clinical information was collected for 11 of the patients, and limited data 
was collected for 1 patient.   
 
Table 4.35: Study 3: Characteristics of the Study Sample 
Case Diagnosis Age No of Days 
monitored 
IP Episodes IP Days OP 
Episodes 
CVCs Nutrition 
1 CIIP Megacystis 4 1757 12 50 23 3 PN + EN 
2 CIIP Megacystis 5 2286 22 316 20 5 PN + EN 
3 Hirschsprung’s 2 850 5 27 6 2 PN + EN 
4 Hollow Visceral Myopathy 5 2357 21 30 52 2 PN  
5  Short Gut Gastroschisis 5 2331 16 47 41 3 PN + EN 
6 Gastroschisis 5 2021 31 267 13 4 PN + EN 
7 Tufting Enteropathy 5 2595 32 395 52 10 PN + EN 
8 Protracted Diarrhoea 2 955 12 225 33 3 PN + EN 
9 Phenotypic Diarrhoea 2 1145 29 209 25 8 PN + EN 
10 Tufting Enteropathy 3 1174 -  -  -  3 PN + EN 
11 Short Gut Syndrome 1 569 1 12 2 3 PN + EN 
12 Gastroschisis 4 1841 11 310 19 4 PN 
 
Table 4.36: Comparison of Case & Control Subjects 
Parameter Case (SD) Control (SD) P value 
No. Recruited 12  12 - 
Mean Age 4 (1.5) 4 (1.8) 1.000 
Male 5 (0.5) 4 (0.5) 0.689 
Total No. Siblings 6 (1.0) 11 (1.1) 0.338 
Mean Age of Main Carer 30 (8.7) 34 (5.6 0.173 
 
 The age of the main carer in the case group is older than in the controls, although this 
was not significant. The control children had more siblings.  
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4.3.2 Comparison of QoL Scores Between the Case and Control Groups 
QoL data was collected for both the case and control group.  
 
Table 4.37: Comparison of WOCQ Raw Scores between Case & Control Groups  
WOCQ Domain Case Mean (SD) Control  Mean (SD) Wilcoxon Signed-rank 
Confrontive Coping 1.5 (0.8) 0.9 (0.5) 0.102 
Distancing 0.9 (0.5) 1.3 (0.7) 0.221 
Self Controlling 1.3 (0.6) 1.1 (0.5) 0.444 
Seeking Social Support 1.7 (0.6) 1.0 (0.5) 0.014 
Accepting Responsibility 1.1 (0.7) 1.2 (0.9) 1.000 
Escape Avoidance 1.2 (0.9) 0.8 (0.7) 0.356 
Planful Problem Solving 1.9 (0.7) 1.5 (0.8) 0.203 
Positive Reappraisal 1.3 (0.8) 0.7 (0.5) 0.051 
See section: 1.13.7 for information on WOCQ.    
 
The case group used the coping mechanism Seeking Social Support significantly more 
than the control group. There was a trend for the case group to use the coping mechanism 
Positive Reappraisal more than the controls.    
 
Table 4.38: Comparison of WOCQ Relative Scores between Case & Control Groups 
WOCQ Domain Case Mean (SD) Control  Mean (SD) Wilcoxon Signed-rank 
Confrontive Coping 13.9 (5.6) 9.8 (5.0) 0.075 
Distancing 8.3 (4.3) 16.8 (6.7) 0.028 
Self Controlling 11.7 (3.0) 13.8 (6.2) 0.508 
Seeking Social Support 16.3 (4.9) 14.2 (9.6) 0.721 
Accepting Responsibility 10.2 (4.8) 12.1 (6.9) 0.575 
Escape Avoidance 10.1 (6.6) 8.5 (5.5) 0.508 
Planful Problem Solving 17.7 (6.6) 17.0 (10.7) 0.879 
Positive Reappraisal 11.9 (5.6) 8.0 (6.2) 0.114 
The control group used significantly more distancing as a coping mechanism, and there 
was a weak trend for them to use less Confrontive Coping than the case group.  
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Table 4.39: Comparison of GHQ28 Scores between Case & Control Groups 
GHQ28 Domain Case Mean (SD) Control  Mean (SD) Wilcoxon Signed-rank 
Somatic Symptoms 7.7 (4.3) 3.4 (2.6) 0.038 
Anxiety Insomnia 7.2 (5.2) 3.4 (2.4) 0.012 
Social Dysfunction 6.9 (2.8) 5.8 (2.0) 0.360 
Severe Depression 2.7 (3.1) 0.4 (0.5) 0.129 
Total 24.4 (12.3) 13.0 (5.2) 0.021 
 
The GHQ28 yields sub scores and a total score. The higher the GHQ28 sub scores, the 
more severe the condition. Total scores can be compared to threshold values, the default 
cut off indicating a positive psychiatric condition being a score of 23/24. The case group 
had significantly higher scores in the Somatic Symptom and Anxiety/Insomnia domains. 
The mean total score exceeds the threshold for a positive psychiatric condition in the case 
group and is significantly higher than the control mean score.  
 
Table 4.40: Comparison of HADS Scores between Case & Control Groups 
HAD Case Mean Control  Mean Wilcoxon Signed-rank 
Anxiety 8.9 (4.1) 3.8 (3.3) 0.007 
Depression 4.8 (3.8) 2.9 (2.2) 0.135 
  
  Case 
Anxiety 
Control 
Anxiety 
Case 
Depression 
Control 
Depression 
No case <7 3 10 9 11 
Mild Case = 8-10 4 2 2 1 
Moderate Case = 11-15 5 0 1 0 
Severe Case = >16 0 0 0 0 
 
The case group to have significantly more anxiety than the control group (p=0.0074) and 
exceed the level of clinical relevance. 
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Table 4.41: Comparison of FSIIR Scores between Case & Control Groups 
 Case Mean (SD) Control  Mean (SD) Wilcoxon Signed-rank 
FSIIR Score 75.3 (10.5) 96.7 (5.9) 0.003 
 
As would be expected the children on HPN scored significantly lower than the healthy 
controls.  
 
Table 4.42: Comparison of FSIIR and Transformed GHQ28 Scores 
FSIIR (Mean) GHQ28 (Mean) Wilcoxon Signed-rank 
86.0 (13.8) 81.3 (10.9) 0.059 
 
We used Wilcoxon Signed Rank to correlate the GHQ28 and FSIIR and found that there 
was a nearly significant correlation between the 2 measures. The lower the FSIIR score – 
the higher the GHQ28 score suggesting that a poor functional status of the child has a 
negative impact on the general health of the parent.  
 
Table 4.43: Comparison of FAD Scores between Case & Control Groups 
FAD Domain Case Mean (SD) Control  Mean (SD) Threshold Wilcoxon Signed-rank 
Problem Solving 1.6 (0.5) 2.0 (0.4) 2.2 0.124 
Communication 1.8 (0.5) 2.0 (0.2) 2.2 0.502 
Roles 2.2 (0.4) 2.1 (0.4) 2.3 0.553 
Affective Responsiveness 1.9 (0.3) 1.7 (0.3) 2.2 0.091 
Affective Involvement 1.8 (0.4) 1.8 (1.8) 2.1 0.814 
Behaviour Control 1.6 (0.3) 1.6 (0.3) 1.9 0.969 
General Functioning 1.6 (0.4) 1.7 (0.3) 2.0 0.813 
 
Scores range from 1-4 with 1 reflecting healthy functioning and 4 indicating unhealthy 
functioning. None of the families (either in the case or control groups) scored above the 
threshold, indicating no degree of family dysfunction. There were also no significant 
differences observed between the case and control groups.  
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5.0 Discussion 
The purpose of this thesis was to try and determine the impact that intestinal failure had 
on QoL. Thus data was collected from 3 distinct population groups: Adult patients newly 
discharged on HPN; patients with pseudo-obstruction; and children on HPN (and their 
carers). For each group, separate studies were undertaken involving collection of QoL, 
clinical and demographic data. This gave a comprehensive set of results from which 
inference can be drawn. 
 
New definitions of intestinal failure were introduced in 2008 by the Strategic Framework 
for IF and HPN Nutrition Services for England. This new definition excludes some of the 
adult patients that have been included in this body of work, who were previously 
classified as having IF (but did not require HPN); however, the majority of subjects 
studied suffered with type III intestinal failure and they all had impaired (often severe) 
intestinal function. From a diagnostic perspective, disease definitions are invaluable and 
aid clinical practice and epidemiological research. It is important that definitions are 
updated when necessary in response to research and scientific consensus. Although some 
of the patients studied were no longer classified as having IF, they still suffered with 
gastrointestinal symptoms and treatments associated with intestinal failure (for example 
stoma’s, nutritional support, pain and GI motility problems) and the results gained from 
these individuals are still valuable. 
 
Because the majority of the questionnaires were administered via telephone, missing data 
was minimal and not significant.  
 
5.1 Development of a Disease or Treatment Specific QoL Questionnaire 
 
Using a generic questionnaire can have the advantages that derived data is comparable 
with other diseased populations and in many cases, normal population data exist for 
comparison (as in the case of the SF36). The main disadvantage of using a generic 
questionnaire is the potential lack of sensitivity to the problems encountered by a specific 
population. QoL assessments need to include emotional, social, occupational and 
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physical parameters (438). The generic questionnaires employed in these studies 
encompass all these factors, but they were not specifically designed for use in patients 
with intestinal failure. During the period that these studies were undertaken, there were 
no validated intestinal failure or HPN specific questionnaires available.  
 
Disease or treatment specific questionnaires if designed well and properly validated, are 
better at focusing on the issues of particular concern to the patients with the disease 
(439), however there is less scope to compare the results with various other diseases or 
normal population data.  
  
Designing and validating a disease or treatment specific QoL questionnaire is a highly 
involved process, and can take time and resources. There are recognised published 
guidelines on how to develop a QoL questionnaire (440). Briefly, initially there is a 
literature search to identify issues in the population from which categories and questions 
are derived. Then interviews with patients and health care professionals pre-test the 
questionnaire for content validity and acceptability. After this, there are a variety of 
methods for examining the validity of measurement scales to confirm that the scores 
appear to be consistent with their intended purpose. The questionnaire should appear to 
give consistent (reliable) and repeatable results when applied to patients who are believed 
to be in a stable condition. The scores must be sufficiently sensitive or responsive to be 
able to detect differences between treatments or patients (439). This process can take a 
long time to complete, and can involve many editions before it is considered to be 
acceptable.  
 
Intestinal failure can be the result of a plethora of diseases. Specifically, the HPN 
population comes from a variety of different backgrounds and medical experiences, 
which can impact on their perspective and opinion of the treatment. This can make QoL 
measurement in this population difficult and the sensitivity of generic and disease 
specific QoL tools used are starting to be questioned in this population (441). This has 
prompted the development of an HPN therapy specific instrument.  
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The HPN-QOL is a 48 item questionnaire that focuses on physical, emotional, and 
symptomatic issues (442). The questionnaire contains functional and symptom scales. 
The functional scales include general health, ability to holiday (vacation) or travel, 
coping, physical function, ability to eat and drink, employment, sexual and emotional 
function. The symptom or problem scales include body image, immobility, fatigue, sleep 
pattern, gastrointestinal symptoms, other pain, presence or absence of a stoma, financial 
issues, and weight. Two questions relate to nutrition teams and the availability of an 
ambulatory pump for infusion of HPN, in which a high score represents a good outcome. 
 
Hopefully the HPN-QOL will provide a more focused assessment of QoL in this 
population. Ideally QoL needs to be measured periodically or routinely, to identify any 
patterns over different stages of the treatment or disease. In study 1, SF36 social 
functioning scores of HPN patients significantly improved over the first 6 months. Future 
repeated measures with an instrument specifically designed for the HPN population may 
reveal additional aspects of QoL and health status, that up to now have not been 
emphasised. It would be a remarkable achievement if this instrument could eventually be 
incorporated into clinical practice, providing clinicians and health care providers with an 
enhanced understanding of the social, emotional and symptomatic issues faced by this 
population. 
5.2 Study 1 QoL in Adult HPN and Telemedicine 
Thirty patients were recruited who were newly starting on HPN. These patients were 
prospectively followed over the first year of HPN and their QoL scores were also 
documented. I also wished to ascertain if telemedicine had an affect on their QoL.  
 
The study population consisted of patients with a broad range of age (22-68) and primary 
diseases necessitating HPN, enabling me to draw conclusions which represent an array of 
experiences. The mean percentage of time spent as an inpatient corresponds with 
previously published data (412).  
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5.2.1 Comparison of HPN Population QoL with Normative Data  
At 2 days post initial discharge the HPN population report significantly lower QoL scores 
than the normal population in every SF36 domain. This may be due to the fact that 
patients have gone through a series of initial responses to the loss of intestinal function 
including denial, sorrow and grief, as reported by Price & Levine (386) and also this 
could be due in part, to reliance on the pump and the need to be in close proximity to a 
bathroom (327). The results at 6 months post discharge are in agreement with Richards 
and Irving (396) in that patients on HPN had significantly lower scores in 6 out of 8 SF36 
domains compared to normative data (359). The Mental Health (MH) and Role 
Emotional (RE) domain scores although lower, were not significantly different from 
normative data suggesting that either the loss of intestinal function or the initiation of 
HPN has a more social and physical QoL impact, whilst the mental and emotional state of 
the patient remains comparable with someone who does not suffer with intestinal failure. 
The improved results at 6 months perhaps suggest an emotional or mental acceptance and 
adaptation to the HPN. These findings agree with previously published data (386;396), 
but also disagree with other researchers who claim QoL is satisfactory in an HPN 
population (387;388). 
 
There is no doubt that the physical symptoms of intestinal failure can cause considerable 
and chronic stress. The poor SF36 outcomes in the physical domains may in fact be a 
disclosure of the severity of the underlying disease, for example pain or weakness.  One 
group reported that quantitatively these are comparable with the quality of life problems 
related to patients requiring haemodialysis, peritoneal dialysis liver transplant and 
chemotherapy (392). 
 
Social rehabilitation is often a considered parameter for QoL, and indeed in many of the 
earlier HPN QoL studies it was the only proxy marker used. QoL has been correlated 
negatively with distress (anxiety, somatisation, depression), hopelessness and social 
detachment, and positively correlated with social integration (443).The social aspects of 
the SF36 aim to assess how well integrated into society a person is feeling, examples 
include questions about work/usual activities and about visiting friends and relatives. The 
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results from this study indicate that certainly during the first 6 months social 
rehabilitation is not fully achieved, but whether this is due to the HPN or the underlying 
disease remains uncertain. SF36 scores were significantly higher at 6 months compared 
to 2 days post initial discharge (p=0.06), but were still significantly lower than 
populations norms (359) Time could be a factor and it may be the case that after a 
protracted period of time an acceptable or better level of social rehabilitation can be 
achieved.  
 
An attempt was made to compare the HPN population HAD scores with HAD UK 
normative data (374). However the normative data only supplies an average mean for 
anxiety, depression and total HAD score. It was thus not possible to obtain normative 
data adjusted to our population in order to perform analysis. Percentile charts are 
available, but these yield no interpretable results and were thus not utilised. The UK 
normative mean scores are marginally lower than our population (indicating less anxiety 
depression and psychological distress), and while it is not possible to calculate the 
significance of this, it is possible to identify a trend suggesting that the HPN population 
suffers with more anxiety and depression than the normal population. The total scale 
score indicates a higher level of general psychological distress in the HPN group.  
 
The EQ5D questionnaire is a qualitative questionnaire which makes numerical analysis 
and comparison to a normal population less appropriate. Without exception, when 
compared to normative data (376) the HPN population report double the amount of 
moderate or severe problems in every EQ5D domain at 2 days and 6 moths past initial 
discharge. 
 
The 3 QoL instruments used in this study describe many aspects of the HPN populations 
QoL in comparison to a normative population. The HAD and EQ5D scales concur that 
there is increased anxiety and depression. The EQ5D broadly agrees with the SF36 in that 
both scales demonstrated a reduction in physical functioning including mobility and self 
care, a reduction in social functioning and usual activities (for example work and social 
engagements) and an increased level of bodily pain and discomfort. The SF36 and HAD 
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both detect poorer general health, but are at odds concerning psychological distress and 
mental/emotional health. The SF36 highlights the relatively satisfactory mental health 
and emotional role achieved by the HPN patients, whereas the HAD does not. This may 
emphasise the fact that neither the HAD or EQ5D are sensitive enough or able to assess 
these parameters considering our SF36 results are in harmony with other published work 
(396). 
 
5.2.2 Longitudinal QoL Scores 
If transition to oral nutrition has not been effected within a two year period, intestinal 
failure is usually deemed permanent in adults (78). This may influence QoL scores in 
patients who are disappointed that they are not only on HPN for a limited period. HPN is 
a complex, high risk therapy for an individual to accept, however we propose that as the 
patient becomes more experienced, they will feel more at ease and this may have an 
impact on QoL scores. The data set was too small to analyse at one year, so we compared 
QoL scores at 2 days and 6 months post discharge, which showed significant 
improvement in PF, RP, VT, and SF in SF36 domains. Significant differences in the 
separate anxiety and depression were not detected by the HAD scale, but at 6 months the 
total HAD score (indicating general psychological distress) was statistically lower than at 
2 days which supports the SF36 result. 
 
There is little published data which analyses longitudinal QoL in HPN patients. The 
majority of current research offers cross sectional measurements. Smith (1993) states that 
overall a low QoL score was associated with increasing length of time on HPN (392), and 
Malone reports no change (414). Our data does not support previous findings, but this 
may be related to our study population being newly discharged and not established on 
HPN. Jeppesen et al (404) found that patients who had been receiving HPN for less than 
2 years scored worse than those with a longer duration of HPN. It may be important to 
adjust for the length of time on HPN in future HPN and QoL studies.  
 
 
 152     
5.2.3 Comparison of QoL of the HPN Population by Clinical Parameters  
 
Opiate use  
SF36 scores were compared between those who do and do not use opiates. At 2 days and 
6 months opiate users reported significantly more bodily pain. This is perhaps to be 
expected, as opiates are used in the management of malignant and non-malignant chronic 
pain, and it could be postulated that those who require opiates have a more severe disease 
(and are sicker). 
 
At 6 months opiate users also have less vitality and poorer physical role, social 
functioning and mental health scores. Again it is unclear whether this is due to opiate use 
or disease severity. At 6 months HAD depression scores were higher in opiate users. And 
although opiate users had higher HAD anxiety scores this was not statistically significant.    
 
It would be useful to analyse the data regarding opiate use with and without codeine 
phosphate as in general codeine phosphate is taken as an anti-motility agent rather than 
an analgesic and it may not be suggestive of the amount of pain experienced. However 
due to the data collection process this was not possible. When I collected the data, I 
recorded if opiates were being prescribed, but not the type of opiate prescribed. This was 
an oversight in my data collection process.  
 
It would not be ethically appropriate to stop opiate use for medical research to see if this 
impacted on QoL scores, however this data illustrates that prudence must be shown 
before prescribing opiate analgesics as they are associated with a poorer QoL. However 
the quality of life of someone suffering continuous pain will not be high in the first place, 
and is unlikely to be improved by inappropriately withholding opiates. We do not have 
data on the effect of prescribing opiates on QoL in such patients. 
 
Richards et al (393) reported the extent to which opiate and benzodiazepine dependence 
negatively affected outcomes for patients on HPN, with which our data concurs. Van 
Gossum et al (412) reports that at least a third of their HPN population used opiates. Our 
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sample had 50% opiate users, which has a negative effect on outcome. It is not surprising 
that QoL suffers in opiate users. Morale is often low, and anxiety and depression are 
common. (393) 
 
Acute Diagnosis 
A patient’s initial response to HPN can be positive or negative depending on their 
medical circumstances. A patient who develops sudden intestinal infarction for example 
moves from a state of normality, both of intestinal function and nutrition, to one of 
intestinal failure and HPN-dependence very quickly. Depending upon medical 
management, such a patient may never experience malnutrition but will suffer the marked 
contrast between normality and their newly acquired state. By contrast a patient gradually 
becoming malnourished and weak as a result of perhaps painful chronic disease might 
notice the benefits of improved nutrition as HPN is started, but continue to suffer the 
effects of the chronic underlying disease. A patient with chronic intestinal failure is more 
likely to start HPN with a greater degree of malnourishment than a patient with acute 
intestinal failure. Therefore gradual correction of nutritional deficiencies may result in a 
slow improvement in health and vitality. However their continued intestinal symptoms 
may tend to negate this effect. If intestinal failure develops slowly the initial response to 
HPN has been reported to be more positive (277), however this difference in response has 
been shown to even out after 1 year when confidence in life is restored to all patients 
(438). Our study did not support these findings and showed that those with a chronic 
diagnosis suffered with more pain (at 6 months), had poorer general health (at 2 days and 
6 months) and had less vitality (at 6 months), presumably as a consequence of their 
underlying disease. It would be interesting to see if this phenomenon still existed at 1 
year and 18 months to see when or if QoL measurements plateau.  
 
Presence of a Stoma 
Intestinal failure is often associated with disabilities such as high output stomas causing 
abdominal distension, vomiting and pain. We subdivided our sample by stoma incidence. 
In our cohort 63% of patients had a stoma in situ at the time of the questionnaires. The 
results indicate that the presence of a stoma did not affect QoL in any of the SF36 
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domains or HAD scale domains. There are 2 main studies with which my data concurs. 
Richards et al (396) observed no differences in 51 HPN patients SF36 scores between 
those with and without a stoma. Carlsson et al (399) looked at 28 patients (8 on HPN) 
with short bowel syndrome and they also found no significant differences in SF36 scores 
associated with having a stoma. Jeppesen et al (404) found no significant QoL differences 
in non-HPN patients suffering with anatomical or functional short bowel who had a 
stoma, whereas in HPN patients with a stoma, QoL was significantly worse. This may be 
due to the fact that the IBDQ was used to rate HRQoL in this cohort – which may suggest 
that this disease specific instrument is more accurate at detecting issues surrounding the 
presence of a stoma and stoma care than the SF36.  
 
Use of Telemedicine 
The TM and control group were demographically compared to each other. Some 
differences between the telemedicine and control group were observed, possibly because 
randomisation was only restricted by centre. However our sample size was too small to 
allow for further limitation of randomisation. 
 
There were no differences found between the telemedicine and control groups SF36 or 
HAD scores at 2 days and 6 months post discharge. From this data it is possible to 
conclude that telemedicine has no effect on QoL.  
 
An attempt was made to determine the extent of TM use, and how it was utilised, 
although missing data meant analysis would have been meaningless.   
 
5.2.4 Comparison of Hospital Contact by Clinical Parameters 
We found that those who used opiates had significantly more inpatient episodes, more 
inpatient days (although this did not reach significance p= 0.09) and needed more CVC 
replacements Those who had an acute diagnosis had significantly less inpatient days and 
there was a trend towards less CVC replacements. The presence of a stoma had no effect 
on hospital contact or CVC replacement.  
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Richards et al (393) found that opiate dependent patients had more episodes of  CVC 
sepsis (p=0.0007) and longer periods of inpatient care (p=0.004), with which our results 
broadly agree. The authors do not present an explanation for this. I postulate that opiate 
users have a more severe underlying disease resulting in the need for additional hospital 
contact, exposing the HPN patients to the nosocomial environment which has been 
shown to increase sepsis rates and CVC replacements (176). Currently there are no 
studies which compare the onset of the disease with hospital visits and number of CVCs. 
I suggest that those who suffer chronic intestinal failure may be more undernourished and 
generally sicker (with poorer immunity) which may explain the increased inpatient visits 
and increased CVC replacements. This information may be useful in the future for 
budgeting purposes.   
 
5.2.5 Telemedicine Use and Hospital Contact 
Dispersion of patient management may have made HPN more universally available, but it 
has also had the adverse effect of leaving HPN patients more isolated (210). In the UK 
there are only two nationally funded referral centres, which potentially means patients 
may find themselves a considerable distance from their specialist centres when they 
return home (444), some as far as 400km (445), meaning long distances to travel to 
attend hospital appointments. Indeed it has been reported that patients feel that they need 
increased accessibility to the PN team to answer their questions or help when they are 
having problems (210), patients also wish to have more locally available high quality care 
similar to that which they receive in more remote centres (175). These problems were 
confirmed and highlighted by a questionnaire study of British people dependent upon 
HPN conducted by the patients group PINNT in 2001 (response rate 48% of 200) and 
highlighted at a BAPEN workshop that year (BAPEN workshop on Home parenteral 
Nutrition: Ensuring Equity of care)  Harrogate November 2001 (446).  
  
It was proposed was that telemedicine may have a positive benefit for HPN patients, 
namely to; 
 Reduce the frequency of hospital outpatient visits – by interchanging visits with 
telemedicine consultations.  
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 Reduce the number of inpatient episodes – by allowing the visual identification 
of problems via telemedicine, decreasing the incidence of patients being 
unnecessarily admitted for only one or two days.   
 Facilitate earlier discharge – by providing an enhanced method of 
communication, any problems could be explained and discussed via the 
videophone.  
 Reduce the number of CVC replacements – by permitting nurses to view the 
CVC, enabling early detection of problems, reducing the requirement for 
replacement. 
 
However, our data suggests that telemedicine has no impact (either negative or positive) 
on outpatient and inpatient visits, post discharge inpatient days, nutrition clinics or CVCs.  
 
Telemedicine is a new technology and patients and nurses alike may feel apprehensive 
about replacing it for a face to face or outpatient visit. Some of the recurring issues 
surrounding telemedicine are that of barriers to introduction, risk analysis, economic 
viability and innovative use of this fast evolving application to healthcare (unpublished 
Clare Archer). Nurses have reported not feeling confident about making a clinical 
judgement just by seeing an image of the patient, and will often advise that the patient be 
admitted anyway. The picture quality is improving as bandwidth increases, but the 
quality of the image is still an area which could be improved.     
 
While technologies like telemedicine rapidly evolve, it is still the human factors that tend 
to determine failure or success. Telemedicine has much to offer in the management of 
patients who are either in a high dependant state needing specialist advice or for those 
who may live a distance from the specialist centre (447). 
 
We can thus reject the null hypothesis that SF36, EQ5D and HAD scores in patients on 
HPN are not affected by clinical parameters, do not improve over the first year on HPN 
and are the same as the general population. We can accept the null hypothesis that 
telemedicine has no effect on the QoL of patients on HPN.  
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5.3 Study 2 QoL in Pseudo-obstruction  
Pseudo-obstruction is a term which includes many different rare clinical conditions. Our 
study group was defined by histology, manometry, history of surgical procedures, 
motility study information and other clinical parameters and symptoms. Forty two 
subjects who were diagnosed with pseudo-obstruction were asked a series of telephone 
questionnaires in order to establish their QoL. We achieved a response rate of 70%. 
Acceptable questionnaire response rates are considered to be in the range of 60–70%, 
with response rates of over 70% described as very good (448).  
 
The study population consists of patients with an age range of 19-69. The majority of our 
population was female (83%) and 68% of our cohort were opiate users. Presence of 
stoma and acute diagnosis were not recorded.  
 
5.3.1 Comparison of Pseudo-Obstruction QoL Scores with Healthy Controls  
The pseudo-obstruction population reported significantly lower QoL scores than the 
normal population in every SF36 domain and HAD scale, indicating that pseudo-
obstruction has a negative impact on all aspects of quality of life, which is also supported 
by the EQ5D results. It is interesting to note that although these results are similar to the 
HPN cohort (study 1); the pseudo-obstruction patients, who are often clinically regarded 
as having a major psychological component to their illness, do not report higher levels in 
SF36 mental health and emotional role scores. Furthermore non-significant small 
differences only were noted for anxiety and depression between the HPN and pseudo-
obstruction cohorts.  
 
5.3.2 Comparison of the Pseudo-obstruction Population QoL Scores by Clinical 
Parameters  
We stratified our pseudo-obstruction population by age, opiate use, oral nutrition, enteral 
nutrition, parenteral nutrition, diarrhoea, resection and dilated small bowel to try to 
identify if any of these factors were accountable for the vastly reduced SF36 scores when 
compared with normative data.  
 
 158     
Age and parenteral nutrition had no effect on SF36 and HAD scores. Oral intake had a 
higher (nearly significant) effect on SF36 physical functioning scores (p=0.06), while 
there was a trend for enteral nutrition to lower SF36 physical functioning scores (p=0.07). 
 
Opiate use had a significantly negative impact on the SF36 domains physical role, bodily 
pain, general health and vitality, physical and social functioning. Opiate users also 
reported significantly more depression (but not anxiety) on the HAD scale. As with study 
1, the data collection method was flawed, as only the use and not specific type of opiate 
use was recorded.  
 
We recorded if any of the pseudo-obstruction patients had had any intestinal resections 
and found that this had a negative impact on physical role. No differences were seen in 
HAD scores.  
 
Overall the comparisons of SF36 and HAD scores by small bowel dilation did not yield 
any statistically significant results, although those suffering with a dilated small bowel 
tended to have lower mental health scores. 
 
There is only one previous study which examines QoL in pseudo-obstruction (417). They 
report greater functional impairment and poorer general health in pseudo-obstruction with 
which our results concur. Interestingly they state that abdominal pain severity was the 
only independent indicator of QoL. We measured the presence of abdominal pain, but not 
the severity. Ninety four percent of our cohort had abdominal pain, so when we tried to 
stratify by abdominal pain, we did not have sufficient numbers in both groups to derive 
meaningful results.    
 
We can partly accept the null hypothesis that SF36, EQ5D and HAD scores of pseudo-
obstruction patients are not affected by method of nutritional intake and other clinical 
indications. Opiate use and previous intestinal resections negatively affected QoL scores. 
But we must reject the null hypothesis that pseudo-obstruction patients QoL scores are 
not different from a normative population.     
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Obtaining the clinical information was achieved by going through medical notes (often 
over 9 volumes) and searching the Royal London Hospital’s electronic record systems. 
This was an extremely time consuming process. We believe we managed to extract the 
majority of clinically relevant data, but this process identified the need for a pseudo-
obstruction database, which is currently being developed. Further analysis of the data 
suggested that for research purposes, more detailed information regarding clinical tests 
and severity of symptoms would be useful.   
5.4 Study 3 QoL of Children on HPN and their Carers 
Twelve families who had a child on HPN were recruited from 4 UK centres. Twelve 
control families were recruited in the same time period. Both groups completed WOCQ, 
FAD, GHQ28, HAD and FSIIR questionnaires in order to determine the impact that 
having a child on HPN has on family functioning and QoL. 
 
We attained a response rate of 53%, but due to NHS privacy and confidentiality protocols 
we were unable to access any further medical or demographic information on the families 
who declined to participate, and are thus unable to establish the type and extent of bias 
this created. The study design reduces the possibility of centre bias that may be observed 
in single centre studies.  
 
The majority of children (83%) were diagnosed with intestinal failure at birth. The only 2 
patients not diagnosed at birth were diagnosed before they were a year old. The number 
of CVCs required were 50 (average CVC life 398 days and 4.1 catheters per child).  
 
5.4.1 Comparison of Case and Control Demographics 
A novel, un-validated method of selecting a paediatric control group was used in this 
study. The families of a child on HPN (interviewed by Alison Chambers) were asked to 
suggest a control family. All case family carers could think of a suitable family and were 
happy to pass on the information to the control family. Without exception, all of the 
control families were willing to participate and data was collected. When I suggested 
nominating a control family (by telephone after I had finished the questionnaire), there 
was no resistance or negative reaction to this suggestion. Some of the case carers asked 
 160     
me to clarify certain points such as the appropriateness of siblings or friends who had 
moved away. One carer said she had a close friend whose child suffered with cystic 
fibrosis – and asked if this was ok. I then explained the notion of healthy controls, and 
she immediately could think of someone else.  
 
From a logistical point of view, this method of recruiting paediatric controls appears to 
work, and received a positive reaction from both the case and control families. If 
anything, the control families were more willing to participate as they felt they were 
taking part as a favour to their friend, relative or colleague. On several occasions the 
main carer of the control family told me that they would be available for any other 
questionnaire based studies of this nature, and that they were more than happy to 
participate. 
 
The recruitment of controls in paediatric studies is always difficult as each method will 
result in some form of bias including differences in socioeconomic status, geographical 
area, education level, cultures/religion and family values. Recruiting controls from 
hospital workers may not be suitable as socioeconomic status, education and 
desensitising of illness as a result of exposure to the nosocomial environment will 
probably differ from the cases. Recruiting children with another illness can confound 
results as the aspects of the illness need to be taken into consideration. Some studies 
recruit from GP surgeries which mean at least the geographical area will be similar, 
however many other variables may not be. It is generally considered that where possible, 
controls should be selected from the same source as cases. The use of neighbourhood 
controls may ensure that the case and controls are from similar backgrounds (437).      
 
The method we chose to use was discussed and approved at the 2003 ESPGHAN QoL 
working group meeting and was consensus rather than evidence based. It has not been 
used in other published studies, and thus data on bias is lacking. However it was felt that 
by using this method bias would be reduced as the controls would be to some extent a 
representative sample of the population from which the cases emerged. It is impossible to 
say if this has been achieved, however parents chose families who they considered to be 
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similar, both in a social status, numbers and ages of children. A comparison between the 
case and control groups reveals that the mean age between the children in each group was 
identical although the parents of the control group were slightly older. In the cases where 
the geographical area was different, this was due to a sibling of the main carer being 
chosen. The biggest difference seen was the control children had more siblings. The 
sample size in this study was small and a bigger study would be required to determine the 
extent and type of bias created by this method of recruitment. 
 
In this study the main carer of the case family was verbally asked to nominate a control 
family. A basic script was prepared for this request, and some of the carers needed further 
clarification of different points. Therefore it is not certain how applicable this method 
would be in large scale studies where the cases do not have access to an interviewer. This 
is an important point, because if there is no opportunity for the case subject/family to ask 
questions, there may be a greater incidence of inappropriate controls being nominated.     
 
To conclude, this novel approach appears to have been fully accepted by both the case 
and control families. I was unable to identify any obvious confounding variables between 
the case and control groups. As a method of selecting paediatric controls it did not cause 
any unforeseen problems. Logistically this method appears to work, but it needs to be 
validated and interrogated further in a larger sample to highlight the type and/or extent of 
bias created. 
 
5.4.2 Comparison of QoL Scores between the Case and Control Group  
 
Ways of Coping Questionnaire (WOCQ) 
Psychological well-being, social functioning and somatic health are influenced by how 
individuals cope with stress, not stress per se. Psychological and marital distress caused 
by caring for a chronically sick child are well described (220). It is postulated that the 
physical and social complications of providing HPN require an intensive effort, high 
level problem solving and constant adaptation. By using the WOCQ we hoped to elicit if 
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the carers with a child on HPN differed in their coping styles from a carer who did not 
have a child on HPN. 
 
We present both the raw and relative WOCQ scores as the different methods of scoring 
highlight different aspects, the raw score shows which coping mechanisms were 
employed, the relative scores show the percentage contribution of each mechanism in 
coping with the stressful experience.  
 
The results indicate that the carers of a child on HPN significantly seek more social 
support (p=0.01) and use more positive reappraisal (p=0.05).   
 
Seeking Social Support is a technical term which describes efforts to seek informational 
support, tangible support and emotional support. This method of coping is also highly 
employed in parents caring for a child with cancer (236-238), autism (240)  type 1 
diabetes (241) and cystic fibrosis (242;449). Engstrom et al found that social interaction 
in parents caring for a child on HPN, which deals with superficial and simple social 
contacts (including caregivers of different kinds), is high, whereas attachment, which 
deals with deeper, emotional relations, is affected. Families tend to be in contact with 
more people than usual because of the complex medical situation of their child providing 
less time for deeper relationships with partners, relatives and friends (205) and this may 
be the case with our cohort.    
 
The ability of the primary care giver to recruit support and child care resources may be 
crucial to participation in the labour force and in the determination of well being and 
QoL. Employment (or the decision to quit) may affect not only family finances but also 
maternal mental health (229). 
 
Positive Reappraisal describes efforts to create positive meaning by focusing on personal 
growth, enabling parents to draw on their own resources and focus on the positive aspects 
of their situation. Parents of children with Type 1 diabetes also exercise this coping 
strategy (241). It is postulated that the main carer of a child on HPN aims to find some 
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positive elements of the artificial nutrition. This can be illustrated by the response of one 
mother who implied that although the HPN was demanding, it was better than having her 
child permanently resident in hospital. 
  
Distancing describes cognitive efforts to detach one-self and to minimise the significance 
of the situation or stressor. When looking at the percentage contribution of the coping 
mechanisms, distancing contributes significantly less in parents with a child on HPN 
(p=0.02). This may be due to the fact that HPN therapy requires vigilance on the part of 
the parent to recognise complications, and the use of distancing as a coping mechanism 
may put their child at undue risk. The control parents do not have to be prepared for the 
potentially life threatening situations that can be caused by PN.  
 
As with type 1 diabetes (241), the biggest contribution of coping strategy used by parents 
caring for a child on HPN was planful problem solving (18%) which describes a major 
form of problem-focused coping, consisting of rational techniques such as “I knew what 
had to be done, so I doubled my efforts to make things work”. This strategy can virtually 
be considered opposite to distancing. It implies focus and action on the factor causing the 
stress, for example coping with pyrexia. Parents are constantly on alert for a crisis 
because of uncertainty about the child’s illness and prognosis (228).      
 
It is interesting to recognise that parents caring for children with autism (240), cancer and 
HIV (241) scored higher in coping behaviours of distancing and escape, whereas the 
parents of HPN, type 1 diabetics and cystic fibrosis do not appear to elicit escape 
avoidance strategies. Perhaps this is because these chronic illnesses are not usually as 
imminently fatal as cancer or HIV.  
 
A number of mothers caring for a child with CF expressed the belief that they had lost 
their identity as individuals, and a sense that sacrifices had been endured as a result of 
their child’s diagnosis was frequently voiced (449). Some parents with children suffering 
from cancer described the feeling that they had had to cope during the active phase of 
treatment and their own feelings had been set aside. Mothers’ appraisals of the strain of 
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illness-related demands and their confidence in their own ability to deal with these were 
related to distress (235). 
 
Our results demonstrate that the typical parent of a child on HPN tends to cope by 
seeking more social support that will usually be from health professionals or people 
involved with their child’s care/health, and by constantly re-evaluating the situation and 
focusing on a solutions then methodical problem solving.   
 
General Health Questionnaire (GHQ28) 
Levels of anxiety and depression are experienced by parents of children with disabilities 
at home potentially caused by physical and emotional overburden on the carer (228). We 
used the GHQ28 to detect if any psychological disorders existed.  
 
From our series, the mean total GHQ28 score (24.4) exceeded the threshold for 
psychiatric morbidity and a further breakdown of the data revealed that a diagnosable 
psychiatric disorder could be detected in 5 parents (41%) who care for a child on HPN. 
None of the control families exceeded the threshold, and the mean was significantly 
lower (p=0.02).   
 
Analysis of the subscales revealed that parents with a child on HPN have significantly 
more somatic symptoms (p=0.03) and anxiety and insomnia (p=0.01). No statistically 
significant differences were observed in social dysfunction and severe depression.     
 
Our results are in line with Wong et al (219) who identified the problems faced by 
parents with a child on HPN. They studied 11 families, 7 exceeded the threshold (Likert 
score >24) for psychiatric morbidity, and a significant deterioration of social life, family 
life, sex life and work compared with controls was seen.   
 
Hospital Anxiety and Depression Scale (HADS) 
The case group have significantly more anxiety than the control group (p=0.007). Using 
the thresholds it can be deduced that the mean score of the case parents indicates a mild 
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anxiety. There was no significant difference seen between depression scores. These 
results concur with the GHQ28 scores in that anxiety is present, but no clinically relevant 
depression is reported. 
 
The fact that a substantial proportion of the case groups endorsed a number of anxiety 
items is not surprising. A large scale survey has reported that between 30 and 40% of the 
general population suffer from anxiety to an extent that would benefit from clinical 
intervention (374) and it is likely that caring for chronically ill, technologically dependant 
child could provoke feelings of nervousness. We postulate that high levels of anxiety 
seen in the case group could be due to the need for parents to be constantly on alert for a 
crisis. 
 
Functional Status IIR (FSIIR) scores 
It has been reported that proxy respondents appear to underestimate the full effect of 
chronic illness on functional status (360), so we elected to employ the FSIIR in order to 
enumerate this parameter.  
 
Because children younger than 5 are not able to self report their health or functional 
status (362) we had no option but to obtain data by proxy. The FSIIR was chosen as it is 
sensitive to the interface between children who are “normal” and those with severe 
dysfunction (383), and therefore was applicable to both case and control groups. Studies 
suggest that parents are better able to rate physical problems (365) and the FSIIR mainly 
measures behavioural manifestations of illness that interfere with performance (383). As 
would be anticipated, the children on HPN scored significantly lower (p=0.0025) than the 
healthy controls. It would be expected that children without ongoing medical problems 
should score higher than children with ongoing medical problems.   
 
A study looking at families of a child assisted by technology found that children had 
poorer health status (indicated by lower FSIIR scores) and mothers reported a lower 
mental health SF36 score (229). Correlation between good paediatric glycaemic control 
and health outcomes in the parents of children with type 1 diabetes has been 
 166     
demonstrated (450) and associations involving change in symptoms and change in 
caregiver QoL was significant in parents who cared for children with mild wheeze (451). 
The design of this study is cross-sectional so we are unable to apply this principle as a 
function of time/change to our data. However, we compared FSIIR scores and 
transformed GHQ28 scores from all responders (case and controls) using the Wilcoxon 
signed-rank method to determine if there was any correlation. The results indicate that the 
FSIIR scores correlate with GHQ28 scores, although this was not significant (P=0.059) 
i.e. the poorer the perceived functional status of the child, the poorer the reported general 
health of the parent. 
 
Family Assessment Device (FAD) scores 
Given the intrusiveness and chronicity of HPN therapy, it was postulated that the case 
families would be at a higher risk of family dysfunction than the control families. 
Families both affect and are affected by the presence of a chronically ill child (450), 
however there were no significant differences observed between the case and control 
groups, and none of the families (case or control) surpassed the thresholds indicating poor 
family functioning. Other studies of family functioning with a chronically sick child 
which did not demonstrate differences from controls include type 1 diabetes (450), 
children with chronic sleep disturbance (452) and paediatric liver transplant (453). A 
study looking at family functioning in children with food refusal demonstrated that in all 
FAD subscales the mean score was significantly lower than the control group (454). 
 
5.4.3 Comparison of Clinical Information 
Coping with a child’s chronic illness is a complex process that can be influenced by the 
child’s gender. It is not known whether, within a family, the mother’s and father’s use of 
coping strategies vary as a function of the child’s gender. For example, mothers have 
been reported to be more likely to perceive girls with type 1 diabetes as being more 
vulnerable than boys (241).  There was a fairly equal spread of female and male children 
in the case group (58% and 42% respectively) which reduces the possibility of gender 
bias within the case sample. There were a higher percentage of girls in the control group 
(66%). This may be a confounding factor with respect to analysis.    
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The average (4.2) and median (3) number of CVCs required per child was much higher 
than reports from other groups. Ricour et al and Colomb et al report means of 1.25 and  
2.6 respectively (200;224). There are 2 reasons postulated for the comparatively high 
number of CVCs required: 1) Two patients required a total of 18 CVCs (36%) mainly for 
repeated CVC infections which skewed results. However, removing these outliers from 
the analysis still resulted in a median of 3 CVCs per child. 2)The vast majority of the 
children in our cohort were started on HPN shortly after birth and it is known that the risk 
of CVC infection is higher in children requiring HPN from early infancy than those 
started after the first year of life (196). The populations in the other studies contain data 
collected from much broader age ranges with lower risks of CVC complications. It is 
difficult to assess whether sepsis could be a result of poor training/aseptic technique or 
could be a consequence of underlying disease.   
 
In our series, only 2 children were exclusively fed by PN. The practice of complimentary 
enteral feeding can help gut adaptation, reduce the need for PN (4), decrease the 
occurrence of PN related complications (455) (for example the risk of cholelithiais and 
liver disease), and allow the acquisition of the social skills of eating (31).   
 
If paediatric HPN continues over 3 years – it is likely to be permanent (82) so according 
to this rationale 9 out of our 12 children will probably be permanently on HPN. Eleven 
out of 12 of the children had been receiving HPN for longer than 2 years (Child 11 had 
been on   HPN for 1 year 7 months), so it can be assumed that parents have typically 
transitioned from the acute phase of HPN management into the phase of long term care. 
This is of interest as parents of a child on HPN have reported that the initial 8 days to 1 
month are extremely trying, but they felt after this they feel much more secure (200). 
This is comparable to what was conveyed anecdotally by 4 parents when conducting the 
telephone questionnaires, they felt the first 3 – 6 months were the hardest in terms of 
adjustment to the HPN.    
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There was no opiate dependence reported in our series, reducing the use of narcotics has 
been shown to improve prognostic factors in adults (277). Only one child died during the 
study period and this was due to the underlying disease.   
 
5.4.4 Inclusion Criteria 
This was a case-control, cross-sectional, multi-centred study which was initially 
conceptualised in 2001. At this time the most relevant data on the epidemiology of 
paediatric HPN in the UK was the 1998 British Artificial Nutrition Survey (456) which 
estimated that there were approximately 63 children receiving HPN and the majority of 
these were under 5 years of age. There was a low incidence of children in all the older 
age groups (n=<10). By definition, children are evolving and undergoing major changes, 
including alteration in the level of their dependency and cognitive development, and there 
is poor agreement on the normal roles and functions of children at different ages (383). 
Therefore it is difficult to obtain information over a wide age range without using several 
measures or QoL tools, which means the data obtained will not be uniform in nature or 
comparable. For this reason we came to the decision to only recruit children who were 
under 5 years old as we felt there would not be enough children in each of the other age 
groups to derive meaningful data. Unfortunately by the time we had obtained ethical 
approval, many of the children were over 5 years old, so could not be included in this 
study.  
 
Parents had to be sufficiently fluent in spoken and written English to complete the postal 
and telephone questionnaires and we did not need to exclude any potential participants 
based on these criteria. 
 
5.4.5 Ethical Approval 
One of the major problems faced in the organisation of this study was acquiring ethical 
approval. Because we intended to recruit from more than 4 centres we were required to 
obtain COREC approval, which took 11 months from initial application to final approval. 
After this we were obliged to attain LREC (Local Research Ethics Committee) approval 
from each centre. The LRECs are supposed to vet the application for any logistical 
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difficulties that could cause a problem to the NHS trust. However we found that certain 
LRECs were pedantic about the study principles and design. This process took up to 1 
year in some cases. Finally after obtaining COREC and LREC approval we had to seek 
research and development approval from each trust which again, took up to a year in 
some cases. Part of the reason this process took far longer than anticipated is because we 
were undertaking research in children, a group that is considered vulnerable. 
 
We can reject the Null Hypothesis that there is no difference in WOCQ, GHQ28, HAD 
and EQ5D scores in parents who have a child on HPN compared with parents who do not 
have a child on HPN and that FSIIR scores are not different in children who do or do not 
receive HPN. However we must accept the null hypothesis that there is no difference in 
FAD scores in families who have a child on HPN compared with case controls. 
5.5 Limitations of the Study 
5.5.1 Study 1 Limitations  
This study was limited by time, resulting in the limited period available for both 
recruitment and follow up of subjects. The duration and overall outcome of HPN varies 
between countries. A UK study showed only 46% of patients were still on HPN at the 
end of nine years (321). This highlights a problem for survey follow up, indicating the 
need for a large sample size at the beginning of the study. The effect of age on HPN 
therapy needs to be evaluated over a reasonable time period, Howard and Malone found 
age had a significant effect on all indicators (457). A longer time allocated for obtaining 
QoL data would allow further analysis of longitudinal HPN QoL data. This study has 
identified an increase in QoL over 6 months, and it would be interesting to see where this 
trend goes.  
 
We hoped to recruit a larger sample; however recruitment was limited because of the 
inclusion criteria. This project was funded by Calea, an HPN care provider, and to be 
included in the trial the patient had to be discharged with Calea. However some of the 
centres involved in the trial held HPN contracts with other companies. 
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The manner in which opiate use was recorded failed to identify the specific opiates that 
were prescribed. Codeine phosphate is generally taken as an anti-motility agent – and not 
necessarily as an analgesic. This oversight in data collection meant that this could be a 
confounding factor that can not be interrogated further.  
 
There are both advantages and disadvantages of using generic questionnaires to measure 
QoL. This study employed generic questionnaires as we were trying to measure general 
changes in QoL. A gastrointestinal specific questionnaire would have given us more 
information about the disease state which may have resulted in more meaningful analysis 
if used in conjunction with generic questionnaire.  
 
We concentrated on measuring the QoL of the patient, and it may have been beneficial to 
identify the impact of HPN on the family and carers by encouraging relatives and carers 
to complete questionnaires. A common social problem to arise in long term HPN is the 
chronic dependence on a caregiver (250). 
 
Medical records were accessed from 7 different hospitals in the UK. The quality of 
record keeping varies greatly and although where possible, information was cross 
checked with the actual patient, the completeness of the data is uncertain.    
 
A treatment specific QoL questionnaire for adult patients on HPN has been developed. 
The use of this questionnaire should become part of the routine clinical management of  
all HPN patients (458) and in future HPN QoL studies.   
 
5.5.2 Study 2 Limitations 
Our method of recruitment involved sending out letters asking if people would like to 
participate. This proved to be a successful method; however we were relying on The 
Royal London hospital medical records which often did not provide accurate or up to date 
information regarding patient contact details. This means that we are not sure if all 
patients received the invitation to participate, which could have introduced some 
selection bias (437). 
 171     
When it came to stratifying our data, we found that in some cases there were not enough 
people in each group to yield to statistical analysis. This may be because certain criteria 
were too broad. For example instead of just recording the presence of abdominal pain, we 
should have measured the severity of abdominal pain. The use of a disease specific 
questionnaire would have perhaps endowed us with this information. 
 
The subjective presence or absence of diarrhoea was recorded in this study, but the 
results were not analysed in this study as patient’s perception of diarrhoea does not 
correlate well with objective measures (429-431). However obtaining a valid gauge of 
diarrhoea would not have been possible from case note analysis. 
 
Single case studies have merit as a means of generating new ideas or hypotheses or 
demonstrating areas for future research. But because of the cross sectional design, it is 
not known if poor QoL continues unabated over time. 
 
5.5.3 Study 3 Limitations 
Although this was a multi-centred study, we still only managed to recruit a small sample 
size of patients. Unfortunately the low incidence of paediatric HPN in the UK makes 
accrual of large samples difficult. Only 53% of the families invited chose to take part in 
this project. A much higher referral was seen from Birmingham Children’s Hospital and 
this was probably due to the increased involvement from the nutrition nurse specialists in 
this centre. 
 
Another shortcoming is that we report only the parent’s views of their children’s 
functional status. It would be of great interest to also report the child’s own views. This 
was believed to be impossible with regard to the children’s age, and this was certainly 
true in the younger children. However it may have been possible in the children who 
were in preschool. 
 
QoL was only assessed in the main carer of a child on HPN, in the majority of cases this 
being the mother. Caring for a child on HPN affects the whole family and comparing 
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responses on this impact on both mothers and fathers may have provided some 
enlightening results. 
 
More detailed information on parents occupation, employment / social and marital status, 
would have allowed more detailed comparisons with the QoL outcomes. However due to 
the insufficient statistical power of this study it is not known if this would have offered 
meaningful analysis. 
 
Since our results are cross-sectional, they do not allow for causal interpretation. It may be 
useful to examine caregivers QoL at different stages of time such as prior to diagnosis 
and at intervals while the child is home.  
 
Another potential limitation is that not all respondents returned the surveys in the same 
manner. The Birmingham caregivers completed the questionnaires in the presence of the 
nutrition nurse specialist whilst all the other caregivers completed the tools either at home 
(WOCQ & FAD) and returned them by mail, or over the telephone (GHQ28, HADS & 
FSIIR). Although mode of administration may have an impact on survey results, with 
face to face administration yielding higher results, several studies comparing supervised 
and postal administration  have demonstrated these differences to be small (459;460). 
There is also a possibility that the mothers and fathers completed FAD together while 
comparing and sharing responses. 
 
5.6 Areas for Further Investigation 
5.6.1 Study 1 HPN QoL and Telemedicine 
Measurement of QoL using the HPN-QOL (410) would be an exciting area to research in 
this population. Direct continuation of this study would increase the sample size, thus 
increasing and adding to the statistical power of the study.  
 
The use of telemedicine did not appear to have any impact on QoL or hospital contact. 
This may partly be due to both nurses and patients apprehensions about the new 
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technology and it may be beneficial to look at this and other aspects of clinical 
management. A study which examined various features and uses of telemedicine 
including its clinical advantages from both the patient and practitioners point of view 
would be constructive.  
 
One of the limitations of this study was that the impact of HPN on the whole family was 
overlooked. The results from study 3 highlight the effect having a child on HPN has on 
the whole family and it would be intriguing to see if this effect was similar in adults. 
 
HPN is provided by a number of hospitals located throughout the UK, which means 
obtaining national data can be challenging. The total UK HPN population is not 
unsubstantial but research in this field can be demanding. Development of an HPN 
national database may alleviate this situation. 
 
5.6.2 Study 2 QoL in Pseudo-obstruction 
Pseudo-obstruction is a condition which has received little attention in terms of QoL 
research. Our results indicate that further QoL research is warranted which may require 
multi centred trials. This should include QoL tools which aim to elicit presence and 
severity of symptoms. 
 
We undertook a one off cross sectional QoL measurement and longitudinal or repeated 
measurements would depict a more inclusive perspective of the impact pseudo-
obstruction has on QoL. 
 
5.6.3 Study 3 QoL of Children on HPN and their Carers 
There are very few children on HPN in the UK and thus our sample size was small. 
Direct continuation of this study would increase sample size and increase statistical 
power allowing more dissection of how the different types and syndromes of intestinal 
failure affect QoL. As with the adult HPN population, a national database would facilitate 
further research.   
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This study highlighted the problems faced by the carers of a child on HPN and it would 
be interesting to look at this in greater detail.  
 
This was a cross sectional study which looked at families with a child under 5 years old. 
Further research could follow these children as they grow older and identify different 
problems faced at different ages. Older children would also be able to self report their 
QoL instead of using proxy measurements.   
5.7 Conclusions 
These studies highlighted some very clear results from which several conclusions can be 
made.  
 
The adult HPN population have a much lower QoL than the rest of the UK population, 
which agrees with previous studies. Patients on HPN report increased levels of bodily 
pain, anxiety and depression, a reduction in physical functioning, social functioning, 
general health, vitality and satisfactory mental health and emotional functioning. Vitality, 
physical role, physical and social functioning significantly improve over the first 6 
months on HPN. This is new data which needs to be researched further. Anxiety and 
depression do not change over the first 6 months. Continued research in this field is 
essential if progress is to be made. 
 
Delaying death or improving QoL are the basic reasons to implement nutrition support, 
even if there is no hope for a cure. This patient group have to deal with a life changing 
therapy, and QoL indexes are in the process of being developed and refined which should 
be specific enough to identify areas that need to be examined. 
 
Pseudo-obstruction has a negative impact on all aspects of QoL indicated by significantly 
lower QoL scores than the normal population. Age and parenteral nutrition had no effect 
on QoL. There was a trend for those who did not require nutritional support to have better 
physical functioning scores, with enteral nutrition causing lower physical functioning 
scores. As with study one, opiate use had a significantly negative impact on the QoL and 
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opiate users also reported significantly more depression (but not anxiety). Diarrhoea and 
small bowel dilation did not yield any statistically significant results. A previous 
intestinal resection had a negative impact on physical role. 
 
Concern has been expressed that the psychological aspects of treatments are overlooked 
in the training of paediatric HPN, which concentrates only on technical and logistic 
competencies required to get children home, with families reporting that more emphasis 
is placed on medical rather than social problems (202) and it is suggested that we need to 
look beyond the care of the child to the needs of the mother (449). Our results 
demonstrate that carers of a child on HPN use different coping strategies from parents 
who do not care for a child on HPN, seeking more social support and using more positive 
reappraisal. The contribution of coping strategy also differs, parents caring for a child on 
HPN use more planful problem solving and less distancing than the control group. A 
higher level of psychiatric disorder characterised by anxiety is seen although depression 
does not seem to be clinically significant. Children on HPN have a poorer functional 
status than those not on HPN, and there is a correlation between level of child 
dysfunction and parental general health. Families caring for a child on HPN have normal 
healthy functioning.  
 
Members of the family are affected by a child’s medical condition and, in turn, the way in 
which the family adapts and copes will affect the course of some illnesses. Home 
management certainly reduces pressure on expensive hospital beds, but ultimately places 
more pressure on parents and the family. 
 
The medical treatment of intestinal failure gives the chronically ill reason to hope, even if 
it produces limitations with which these persons have to live by making adjustments to 
meet everyday requirements. Our studies indicate that the loss of intestinal function does 
have a negative impact on aspects of QoL but this generates the question; is it the loss of 
intestinal function of the institution or nutritional support which causes this reduction? 
Intravenous nutrition is certainly not normal, but yet in some way it is reminiscent how 
each of us were all fed during the first 9 months of our existence.  
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Appendix 1  
Short Form 36 (SF36) Questionnaire (telephone script) 
These first questions are about your health now and your current daily activities. 
Q1 (GH)        
In general would you say your health is…  
Excellent (5.0)  
Very Good (4.4)  
Good (3.4)  
Fair (2.0)  
Poor (1.0)  
 
Q2 (HT) 
Compared to 1 year ago, how would you rate your health in general now? Would you say it is… 
Much better than 1 year ago (1)  
Somewhat better now than 1 year ago (2)  
About the same as 1 year ago (3)  
Somewhat worse than 1 year ago (4)  
Much worse than 1 year ago (5)  
 
Now I’m going to read a list of activities that you might do during a typical day. As I read each item, please 
tell me if your health now limits you a lot, limits you a little, or does not limit you at all in these activities 
 
Q3 (PF) 
First vigorous activities, such as running, lifting heavy objects or participating in strenuous sports. Does 
your health now limit you a lot, limit you a little or not limit you at all? 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
 
Q4 (PF) 
Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling or playing golf. Does your 
health now limit you a lot, limit you a little, or not limit you at all. 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
 
Q5 (PF) 
Lifting or carrying groceries. Does your health now limit you a lot, limit you a little, or not limit you at all? 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
 
Q6 (PF) 
Climbing several flights of stairs. Does your health now limit you a lot, limit you a little, or not limit you at 
all? 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
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Q7 (PF) 
Climbing one flight of stairs. Does your health now limit you a lot, limit you a little, or not limit you at all? 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
 
Q8 (PF) 
Bending kneeling or stooping. Does your health now limit you a lot, limit you a little, or not limit you at 
all? 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
 
Q9 (PF) 
Walking more than one mile. Does your health now limit you a lot, limit you a little, or not limit you at all? 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
 
Q10 (PF) 
Walking half a mile. Does your health now limit you a lot, limit you a little, or not limit you at all? 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
 
Q11 (PF) 
Walking 100 yards. Does your health now limit you a lot, limit you a little, or not limit you at all? 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
 
Q12 (PF) 
Bathing or dressing yourself. Does your health now limit you a lot, limit you a little, or not limit you at all 
If respondent replies they don’t do that activity ask: Is that because of your health? 
Yes, limited a lot (1)  
Yes, limited a little (2)  
No, not limited at all (3)  
 
The following 4 questions ask you about your physical health and your daily activities: 
 
Q13 (RP) 
During the past 4 weeks, have you had to cut down on the amount of time you spent on work or any other 
regular activities as a result of your physical health? 
Yes (1)  
No  (2)  
 
Q14 (RP) 
During the past 4 weeks, have you accomplished less than you would like as a result of your physical 
health? 
Yes (1)  
No  (2)  
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Q15 (RP) 
During the past 4 weeks, were you limited in the kind of work or other regular daily activities as a result of 
your physical health, for example, it took extra effort?  
Yes (1)  
No  (2)  
 
Q16 (RP) 
During the last 4 weeks have you had difficulty performing work or other regular daily activities as a result 
of your physical health, for example it took extra effort? 
Yes (1)  
No  (2)  
 
The following 3 questions ask you about your emotions and your daily activities: 
 
Q17 (RE) 
During the past 4 weeks, have you cut down on the amount of time you spent on work or regular daily 
activities as a result of any emotional problems, such as feeling depressed or anxious? 
Yes (1)  
No  (2)  
 
Q18 (RE) 
During the past 4 weeks, have you accomplished less than you would like as a result of any emotional 
problems, such as feeling depressed or anxious? 
Yes (1)  
No  (2)  
 
Q19 (RE) 
During the past 4 weeks, did you not do work or other regular daily activities as carefully as usual as a 
result of any emotional problems, such as feeling depressed or anxious? 
Yes (1)  
No  (2)  
  
Q20 (SF) 
During the past 4 weeks how much of the time has your physical health or emotional problems interfered 
with your social activities like visiting friends or relatives? Has it interfered… 
Not at all (5)  
Slightly (4)  
Moderately (3)  
Quite a bit (2)  
Or Extremely (1)  
 
Q21 (BP) 
During the past 4 weeks, how much did pain interfere with your normal work, including both outside the 
home and housework? Did it interfere… 
Not at all (5)  
A little bit (4)  
Moderately (3)  
Quite a bit (2)  
Or Extremely (1)  
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Q22 (BP) 
How much bodily pain have you had during the past 4 weeks? Have you had… 
None (6.0)  
Very mild (5.4)  
Mild (4.2)  
Moderate (3.1)  
Severe (2.2)  
Or very severe (1.0)  
 
Q23 (SF) 
During the past 4 weeks, how much time has your physical health or emotional problems interfered with 
your physical activities like visiting with friends or relatives? Has it interfered… 
All of the time (1)  
Most of the time (2)  
Some of the time (3)  
A little of the time (4)  
Or none of the time (5)  
 
The next questions are about how you feel and how things have been with you during the past 4 weeks. 
As I read each statement, please give me the one answer that comes closest to the way you have been 
feeling; is it all of the time, most of the time, a good bit of the time, some of the time, a little of the time or 
none of the time?  
 
Q24 (VT) 
How much of the time during the past 4 weeks…..did you feel full of life? Read categories. 
All of the time (6)  
Most of the time (5)  
A good bit of the time (4)  
Some of the time (3)  
A little of the time (2)  
None of the time (1)  
  
Q25 (MH) 
How much of the time during the past 4 weeks…..have you been a very nervous person? Read categories. 
All of the time (1)  
Most of the time (2)  
A good bit of the time (3)  
Some of the time (4)  
A little of the time (5)  
None of the time (6)  
 
Q26 (MH) 
How much of the time during the past 4 weeks…..have you felt so down in the dumps that nothing could 
cheer you up? Read categories only if necessary. 
All of the time (1)  
Most of the time (2)  
A good bit of the time (3)  
Some of the time (4)  
A little of the time (5)  
None of the time (6)  
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Q27 (MH) 
How much of the time during the past 4 weeks…..have you felt calm and peaceful? Read categories only if 
necessary. 
All of the time (6)  
Most of the time (5)  
A good bit of the time (4)  
Some of the time (3)  
A little of the time (2)  
None of the time (1)  
 
Q28 (VT) 
How much of the time during the past 4 weeks…..did you have a lot of energy? Read categories only if 
necessary. 
All of the time (6)  
Most of the time (5)  
A good bit of the time (4)  
Some of the time (3)  
A little of the time (2)  
None of the time (1)  
 
Q29 (MH) 
How much of the time during the past 4 weeks…..have you felt downhearted and low?  Read categories 
only if necessary. 
All of the time (1)  
Most of the time (2)  
A good bit of the time (3)  
Some of the time (4)  
A little of the time (5)  
None of the time (6)  
 
Q30 (VT) 
How much of the time during the past 4 weeks…..did you feel worn out? Read categories only if necessary. 
All of the time (1)  
Most of the time (2)  
A good bit of the time (3)  
Some of the time (4)  
A little of the time (5)  
None of the time (6)  
 
Q31 (MH) 
How much of the time during the past 4 weeks…..have you been a happy person? Read categories only if 
necessary. 
All of the time (6)  
Most of the time (5)  
A good bit of the time (4)  
Some of the time (3)  
A little of the time (2)  
None of the time (1)  
 
Q32 (VT) 
How much of the time during the past 4 weeks…..did you feel tired? Read categories only if necessary. 
All of the time (1)  
Most of the time (2)  
A good bit of the time (3)  
Some of the time (4)  
A little of the time (5)  
None of the time (6)  
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Now I’m going to read a list of statements. After each one, please tell me if it is definitely true, mostly true, 
mostly false, or definitely false. If you don’t know, just tell me. 
 
Q33 (GH) 
I seem to get ill a little easier than other people. Would you say that’s….Read categories.  
Definitely True (1)  
Mostly true (2)  
Don’t Know (3) (don’t read)  
Mostly false (4)  
Definitely false (5)  
 
Q34 (GH) 
I am as healthy as anybody I know. Would you say that’s….Read categories. 
Definitely True (5)  
Mostly true (4)  
Don’t Know (3) (don’t read)  
Mostly false (2)  
Definitely false (1)  
 
Q35 (GH) 
I expect my health to get worse. Would you say that’s….Read categories. 
Definitely True (1)  
Mostly true (2)  
Don’t Know (3) (don’t read)  
Mostly false (4)  
Definitely false (5)  
 
Q36 (GH) 
My health is excellent. Would you say that’s….Read categories. 
Definitely True (5)  
Mostly true (4)  
Don’t Know (3) (don’t read)  
Mostly false (2)  
Definitely false (1)  
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Appendix 2  
Hospital Anxiety & Depression Scale (HADS) Questionnaire (telephone script) 
The next 14 questions are about how you feel. As I read each statement please give me the one answer 
which comes closest to the way you have been feeling in the last week. 
Don’t take too long over your replies, your immediate reaction to each item will probably be more accurate 
than a long thought out response. 
 
Q1(A) 
I feel tense or wound up; 
Most of the time (3)  
A lot of the time (2)  
From time to time occasionally (1)  
Not at all (0)  
 
Q2 (D) 
I still enjoy the things I used to enjoy; 
Definitely as much (0)  
Not quite so much (1)  
Only a little (2)  
Hardly at all (3)  
 
Q3 (A) 
I get a sort of frightened feeling as if something awful is about to happen; 
Very Definitely and quite badly (3)  
Yes but not too badly (2)  
A little, but it doesn’t worry me (1)  
Not at all (0)  
 
Q4 (D) 
I can laugh and see the funny side of things; 
As much as I always could (0)  
Not quite so much now (1)  
Definitely not so much now (2)  
Not at all (3)  
  
Q5 (A) 
Worrying thoughts go through my head; 
A great deal of the time (3)  
A lot of the time (2)  
From time to time but not too often (1)  
Only occasionally (0)  
 
Q6 (D) 
I feel cheerful; 
Not at all (3)  
Not often (2)  
Sometimes (1)  
Most of the time (0)  
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Q7 (A) 
I can sit at ease and feel relaxed; 
Definitely (0)  
Usually (1)  
Not often (2)  
Not at all (3)  
 
Q8 (D) 
I feel as if I am slowed down; 
Nearly all the time (3)  
Very often (2)  
Sometimes (1)  
Not at all (0)  
 
Q9 (A) 
I get a sort of frightened feeling like “butterflies” in the stomach; 
Not at all (0)  
Occasionally (1)  
Quite often (2)  
Very Often (3)  
 
Q10 (D) 
I have lost interest in my appearance; 
Definitely (3)  
I don’t take so much care as I should (2)  
I may not take quite as much care (1)  
I take just as much care as ever (0)  
 
Q11 (A) 
I feel restless as if I have to be on the move; 
Very much indeed (3)  
Quite a lot (2)  
Not very much (1)  
Not at all (0)  
 
Q12 (D) 
I look forward with enjoyment to things;  
As much as I ever did (0)  
Rather less than I used to (1)  
Definitely less than I used to (2)  
Hardly at all (3)  
 
Q13 (A) 
I get sudden feeling of panic; 
Very often indeed (3)  
Quite often (2)  
Not very often (1)  
Not at all (0)  
 
Q14 (D) 
I can enjoy a good book or radio or TV programme; 
Often (0)  
Sometimes (1)  
Not often (2)  
Very seldom (3)  
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Appendix 3  
EuroQoL 5 Dimensions (EQ5D) Questionnaire (telephone script) 
 
These questions are about your health state 
Please indicate which statement best describes your own health state today 
 
Q51 
Mobility; 
I have no problems walking about (1)  
I have some problems walking about (2)  
I am confined to bed (3)  
  
Q52  
Self-care; 
I have no problems with self care (1)  
I have some problems washing and dressing myself (2)  
I am unable to wash and dress myself (3)  
 
Q53  
Usual activities (e.g. work, housework, family or leisure activities); 
I have no problems with performing my usual activities (1)  
I have some problem performing my usual activities (2)  
I am unable to perform my usual activities (3)  
 
Q54  
Pain or discomfort; 
I have no pain or discomfort (1)  
I have moderate pain or discomfort(2)  
I have extreme pain or discomfort (3)   
  
 
Q55 
Anxiety or depression; 
I am not anxious or depressed (1)  
I am moderately anxious or depressed(2)   
I am extremely anxious or depressed (3)  
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Appendix 4  
Ways of Coping Questionnaire (WOCQ) 
 
 
 
Ways of Coping 
Test booklet 
 
 
 
By 
Susan Folkman Ph.D. and 
Richard S Lazarus Ph.D. 
 
 
 
 
 
 
 
 
Distributed by MIIND GARDEN 
1690 Woodside \road Suite 202, Redwood City California 94061 (650) 261-3500 
 
Copyright © 1988 Consulting Psychologists Press, Inc. All rights reserved. 
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Please provide the following information: 
 
Name__________________________________       Date_________________________ 
 
Gender (circle)  M        F           Age__________ 
 
 
Marital Status (tick): Single      Married     Widowed  Separated/divorced  
 
TO THE COUNSELOR 
 
Fill out institutional address below: 
 
 
Name / Institution: 
 
 
Address: 
 
 
 
 
 
Instructions 
 
To respond to the statements in this questionnaire, you must have a specific stressful 
situation in mind. Take few moments and think about the most stressful situation that you 
have experienced in the past week. 
 
By “stressful” we mean a situation that was difficult to or troubling to you, either because 
you felt distressed about what happened, or because you had to use considerable effort to 
deal with the situation. The situation may have involved your family, your job, your 
friends or something else important to you. Before responding to the statements, think 
about the details of this stressful situation, such as where it happened, who was involved, 
how you acted, and why it was important to you. While you may still be involved in the 
situation, or it could have already happened, it should be the most stressful situation that 
you experienced during the week.  
 
As you respond to each of the statements, please keep this stressful situation in mind. 
Read each statement carefully and indicate, by circling 0, 1, 2 or 3, to what extent 
you used it in the situation 
 
Key: 0 = Does not apply or not used 1 = Used somewhat 
 2 = Used quite a bit   3 = Used a great deal 
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PLEASE TRY TO RESPOND TO EVERY QUESTION 
0 = Does not apply 1 = Used somewhat 2 = used quite a bit 3 = Used a great deal 
1 I just concentrated on what I had to do next – the next step 0 1 2 3 
2 I tried to analyse the problem in order to understand it better 0 1 2 3 
3 I turned to work or another activity to take my mind off things 0 1 2 3 
4 I felt that time would have made a difference – the only thing was to wait 0 1 2 3 
5 I bargained or compromised to get something positive from the situation 0 1 2 3 
6 I did something I didn’t think would work, but at least I was doing something 0 1 2 3 
7 I tried to get the person responsible to change his or her mind 0 1 2 3 
8 I talked to someone to find out more about the situation 0 1 2 3 
9 I criticised or lectured myself 0 1 2 3 
10 I tried not to burn my bridges, but leave things open somewhat 0 1 2 3 
11 I hoped for a miracle 0 1 2 3 
12 I went along with fate: Sometimes I just have bad luck 0 1 2 3 
13 I went on as if nothing happened 0 1 2 3 
14 I tried to keep my feelings to myself 0 1 2 3 
15 I looked for the silver lining, so to speak: I tried to look on the bright side of things 0 1 2 3 
16 I slept more than usual 0 1 2 3 
17 I expressed anger to the person(s) who caused the problem 0 1 2 3 
18 I accepted sympathy and understanding from someone 0 1 2 3 
19 I told myself things that helped me feel better 0 1 2 3 
20 I was inspired to do something creative about the problem 0 1 2 3 
21 I tried to forget the whole thing 0 1 2 3 
22 I got professional help 0 1 2 3 
GO ON TO NEXT PAGE 
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0 = Does not apply 1 = Used somewhat 2 = used quite a bit 3 = Used a great deal 
23 I changed or grew as a person 0 1 2 3 
24 I waited to see what would happen before doing anything  0 1 2 3 
25 I apologised or did something to make up 0 1 2 3 
26 I made a plan of action and followed it 0 1 2 3 
27 I accepted the next best thing to what I wanted 0 1 2 3 
28 I let my feelings out somehow 0 1 2 3 
29 I realized that I had bought the problem on myself 0 1 2 3 
30 I came out of the experience better than  when I went in 0 1 2 3 
31 I talked to someone who could do something concrete about the problem 0 1 2 3 
32 I tried to get away from it a while by taking a rest or vacation 0 1 2 3 
33 I tried to make myself feel better by eating, drinking, smoking, using drugs or medications etc. 0 1 2 3 
34 I took a big chance or did something very risky to solve the problem 0 1 2 3 
35 I tried not to act too hastily or follow my first hunch 0 1 2 3 
36 I found new faith 0 1 2 3 
37 I maintained my pride and kept a stiff upper lip 0 1 2 3 
38 I rediscovered what is important in life 0 1 2 3 
39 I changed something so things would turn out alright 0 1 2 3 
40 I generally avoided being with people 0 1 2 3 
41 I didn’t let it get to me: I refused to think too much about it 0 1 2 3 
42 I asked advice from a relative or friend I respected 0 1 2 3 
43 I kept others from knowing how bad things were 0 1 2 3 
44 I made light of the situation: I refused to get too serious about it 0 1 2 3 
GO ON TO NEXT PAGE 
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0 = Does not apply 1 = Used somewhat 2 = used quite a bit 3 = Used a great deal 
45 I talked to someone about how I was feeling 0 1 2 3 
46 I stood my ground and fought for what I wanted 0 1 2 3 
47 I took it out on other people 0 1 2 3 
48 I drew on my past experiences: I was in a similar situation before 0 1 2 3 
49 I knew what had to be done, so I doubled my efforts to make things work 0 1 2 3 
50 I refused to believe that it has happened 0 1 2 3 
51 I promised myself that things would be different next time 0 1 2 3 
52 I came up with a couple of different solutions to the problem 0 1 2 3 
53 I accepted the situation since nothing could be done 0 1 2 3 
54 I tried to keep my feeling about the problem from interfering with other things 0 1 2 3 
55 I wished that I could change what happened or how I felt 0 1 2 3 
56 I changed something about myself 0 1 2 3 
57 I daydreamed or imagined a better time or place than the one I was in 0 1 2 3 
58 I wished that the situation would go away  or somehow be over with 0 1 2 3 
59 I had fantasies or wishes about how things might turn out 0 1 2 3 
60 I prayed 0 1 2 3 
61 I prepared myself for the worst 0 1 2 3 
62 I went over in my mind what I would say or do 0 1 2 3 
63 I thought about how a person I admire would handle this situation and used that as a model 0 1 2 3 
64 I tried to see things from the other person’s point of view 0 1 2 3 
65 I reminded myself how much worse things could be 0 1 2 3 
66 I jogged or exercised 0 1 2 3 
STOP HERE 
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Appendix 5  
General Health Questionnaire (GHQ) – Telephone Script  
GENERAL HEALTH QUESTIONNAIRE 
 
Please read this carefully 
 
We should like to know if you have had any medical complaints, and how your health 
has been in general, over the past few weeks. Please answer ALL the questions on the 
following pages simply by underlining the answer which you think most nearly applies to 
you. Remember that we want to know about present and recent complaints, not those that 
you had in the past. It is important that you try to answer all the questions. 
Thank you very much for your cooperation.  
HAVE YOU RECENTLY: 
 
 
A1  Been feeling perfectly well and in good health? Better than usual Same as usual Worse than usual Much worse than usual 
A2 Been feeling in need of a good tonic? Not at all No more than usual Rather more than usual Much more than usual 
A3  Been feeling run down and out of sorts? Not at all No more than usual Rather more than usual Much more than usual 
A4 Felt that you are ill Not at all No more than usual Rather more than usual Much more than usual 
A5 Been getting any pains in your head? Not at all No more than usual Rather more than usual Much more than usual 
A6 Been getting a feeling of tightness or pressure in your 
head? 
Not at all No more than usual Rather more than usual Much more than usual 
A7 Been having hot or cold spells? Not at all No more than usual Rather more than usual Much more than usual 
      
B1 Lost much sleep over worry? Not at all No more than usual Rather more than usual Much more than usual 
B2 Had difficulty in staying asleep once you are off? Not at all No more than usual Rather more than usual Much more than usual 
B3 Felt constantly under strain Not at all No more than usual Rather more than usual Much more than usual 
B4 Been getting edgy and bad tempered? Not at all No more than usual Rather more than usual Much more than usual 
B5 Been getting scared or panicky for no reason Not at all No more than usual Rather more than usual Much more than usual 
B6 Found everything getting on top of you? Not at all No more than usual Rather more than usual Much more than usual 
B7 Been feeling nervous and strung up the whole time Not at all No more than usual Rather more than usual Much more than usual 
      
C1 Been managing to keep yourself busy & occupied? More so than usual Same as usual Rather less than usual Much less than usual 
C2 Been taking longer over the things you do? Quicker than usual Same as usual Longer than usual Much longer than usual 
C3 Felt on the whole you were doing things well? Better than usual About the same Less well than usual Much less wee 
C4 Been satisfied with the way you’ve carried out your 
task? 
More satisfied About the same as 
usual 
Less satisfied than usual Much less satisfied 
C5 Felt that you are playing a useful part in things? More so than usual Same as usual Less useful than  usual Much less useful 
C6 Felt capable of making decisions about things? More so than usual Same as usual Less so than usual Much less capable 
C7 Been able to enjoy your normal day to day activities? More so than usual Same as usual Less so than usual Much less than usual 
      
D1 Been thinking of yourself as a worthless person? Not at all No more than usual Rather more than usual Much more than usual 
D2 Felt that life is entirely hopeless? Not at all No more than usual Rather more than usual Much more than usual 
D3 Felt that life isn’t worth living Not at all No more than usual Rather more than usual Much more than usual 
D4 Thought about the possibility that you might make away 
with yourself? 
Definitely not I don’t think so Has crossed my mind Definitely have 
D5 Found at times you couldn’t do anything because your 
nerves were too bad? 
Not at all No more than usual Rather more than usual Much more than usual 
D6 Found yourself wishing you were dead and away from it 
all? 
Not at all No more than usual Rather more than usual Much more than usual 
D7 Found that the idea of taking your own life kept coming 
into your mind? 
Definitely not I don’t think so Has crossed my mind Definitely has 
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Appendix 6  
Functional Status II – R (FSIIR)  
Ask part 1 of all age relevant questions for the complete instrument. Then return and 
probe each item for which the response category in part 1 is marked with an asterisk (*) 
 
It is important that part 1 of all the questions that are applicable to a child of a given age 
be asked first as one sequence without probing whether the response was due to illness 
(part 2). After asking all part 1 items, the interviewer returns to the beginning of the 
instrument to probe with part 2 those items receiving a starred response in part 1. The 
purpose of this procedure is to minimise a response set.   
 
TELEPHONE ADMINISTRATION 
Here are some statements that mothers have made to describe their children. Thinking 
about_____ during the last 2 weeks did he/she…. 
  
  Part 1 Part 2  
  Never or 
Rarely 
Some of 
the time 
Almost 
always 
Fully  Partly Not at all  
A Eat well 0*    1*    2      2    1    0    FS1 
B Sleep well  0*    1*    2      2    1    0    FS2 
C Seem contented and cheerful 0*    1*    2      2    1    0    FS3 
D Act moody 0      1*    2*    2    1    0    FS4 
E Communicate what (he/she) 
wanted 
0*    1*    2      2    1    0    FS5 
F Seem to feel sick and tired 0      1*    2*    2    1    0    FS6 
G Occupy him/herself 0*    1*    2      2    1    0    FS7 
H Seem lively and energetic 0*    1*    2      2    1    0    FS8 
I Seem unusually irritable or cross 0      1*    2*    2    1    0    FS9 
J Sleep through the night 0*    1*    2      2    1    0    FS10 
K Respond to your attention 0*    1*    2      2    1    0    FS11 
L Seem unusually difficult 0      1*    2*    2    1    0    FS12 
M Seem interested in what was 
going on around him/her 
0*    1*    2      2    1    0    FS13 
N React to little things by crying 0      1*    2*    2    1    0    FS14 
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Appendix 7  
Family Assessment device (FAD) 
 
Family Assessment Device 
 
 
 
Nathan B. Epstein M.D. 
Lawrence M. Baldwin Ph.D. 
Duane S. Bishop, M.D. 
 
 
The Brown University / Rhode Island Hospital Family Research Program 
 
Rhode Island Hospital 
593 Eddy Street 
Providence, RI 02903 
Email: Family Research@lifespan.org 
 
Date of Administration ____________________________________________________ 
 
Family Role _____________________________________________________________ 
 
Identification Number or Family Name ________________________________________ 
 
 
 
 
 
 
Epstein NB, Baldwin LM, Bishop DS. The McMaster family assessment device. J 
Marital Family Therapy 1983; 9:171-180  
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INSTRUCTIONS 
 
This booklet contains a number of statements about families. Please read each statement 
carefully, and decide how well it describes your own family. You should answer 
according to how you see your family. 
 
For each statement there are four (4) possible responses. 
 
Strongly Agree (SA) Tick SA if you feel the statement describes your family 
very accurately. 
 
Agree (A) Tick A if you feel the statement describes your family for 
the most part. 
 
 
Disagree (D) Tick D if you feel the statement does not describe your 
family for the most part. 
 
 
Strongly Disagree (SD) Tick SD if you feel the statement does not describes your 
family at all. 
 
 
These four responses will appear below each statement like this: 
 
 
41. We are not satisfied with anything short of perfection 
 
__________ SA __________ A __________D __________ DS  __________ 
 
 
 
The answer spaces for statement 41 would look like this. For each statement in the 
booklet there is an answer space below. Do not pay attention to the blanks at the far right-
hand side of each answer space. They are for office use only. 
 
Try not to spend too much time thinking about each statement, but respond as honestly as 
you can. If you have trouble with one, answer with your first reaction. Please be sure to 
answer every statement and mark all your answers in the space below each statement.  
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1. Planning family activities is difficult because we misunderstand each other. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
2. We resolve most everyday problems around the house. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
3. When someone is upset the others know why. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
4. When you ask someone to do something, you have to check that they did it. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
5. If someone is in trouble, the others become too involved. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
6. In times of crisis we can turn to each other for support. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
7. We don’t know what to do when an emergency comes up. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
8. We sometimes run out of things we need. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
9. We are reluctant to show our affection for each other. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
10. We make sure members meet their family responsibilities. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
11. We cannot talk to each other about the sadness we feel. 
 
__________ SA __________ A __________D __________ DS          __________ 
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12. We usually act on our decisions. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
13. You only get the interest of others when something is important to them. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
14. You can’t tell how a person is feeling from what they are saying. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
15. Family tasks don’t get spread around enough. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
16. Individuals are accepted for what they are. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
17. You can easily get away with breaking the rules. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
18. People come right out and say things instead of hinting at them. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
19. Some of us just don’t respond emotionally. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
20. We know what to do in an emergency. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
21. We avoid discussing fears and concerns. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
22. It is difficult to talk to each other about tender feelings. 
 
__________ SA __________ A __________D __________ DS          __________ 
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23. We have trouble meeting our bills 
 
__________ SA __________ A __________D __________ DS          __________ 
 
24. After our family tries to solve a problem, we usually discuss whether it worked or 
not. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
25. We are too self-centred. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
26. We can express feelings to each other. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
27. We have no clear expectations about toilet habits. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
28. We do not show our love for each other. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
29. We talk to people directly rather than through go-betweens. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
30. Each of us has particular duties and responsibilities. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
31. There are a lot of bad feelings in the family. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
32. We have rules about hitting people. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
33. We get involved with each other only when something interests us. 
 
__________ SA __________ A __________D __________ DS          __________ 
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34. There’s little time to explore personal interests. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
35. We often don’t say what we mean. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
36. We feel accepted for what we are. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
37. We show interest in each other when we can get something out of it personally. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
38. We resolve most emotional upsets that come up. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
39. Tenderness takes second place to other things in our family. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
40. We discuss who is to do household jobs. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
41. Making decisions is a big problem for our family. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
42. Our family shows interest in each other only when they can get something out of 
it. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
43. We are frank with each other. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
44. We don’t hold to any rules or standards. 
 
__________ SA __________ A __________D __________ DS          __________ 
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45. If people are asked to do something, they need reminding. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
46. We are able to make decisions about how to solve problems. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
47. f the rules are broken, we don’t know what to expect. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
48. Anything goes in or family. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
49. We express tenderness. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
50. we confront problems involving feelings. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
51. We don’t get along well together. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
52. We don’t talk to each other when we are angry. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
53. We are generally dissatisfied with the family duties assigned to us.  
 
__________ SA __________ A __________D __________ DS          __________ 
 
54. Even though we mean well, we intrude too much on others lives. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
55. There are rules about dangerous situations. 
 
__________ SA __________ A __________D __________ DS          __________ 
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56. We confide in each other. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
57. We cry openly. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
58. We don’t have reasonable transport. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
59. When we don’t like what someone has done, we tell them. 
 
__________ SA __________ A __________D __________ DS          __________ 
 
60. We try to think of different ways to solve problems.  
 
__________ SA __________ A __________D __________ DS          __________ 
 
 
 
 
 
 
Thank you for taking the time to complete this survey. 
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Appendix 8 
Quality of Life of Children on Home Parenteral Nutrition 
Protocol Organisation Chart 
 
 
Trial Coordinator (Alison Chambers) contacts participating hospitals 
↓ 
The NNS in each centre provides contact details for all eligible families with a child on 
HPN 
↓ 
Trial coordinator sends these families an information pack 
↓ 
If the family wishes to participate they return: 
 Family information sheet 
 Consent form 
 Assent form 
↓ 
Within 1 week the trial coordinator (Alison Chambers) contacts the family by telephone 
to arrange a time for the telephone questionnaires 
↓ 
Telephone questionnaires are administered at the agreed time. After the telephone 
questionnaires the family is sent 2 further postal questionnaires to complete. The main 
carer is asked if they can nominate a control family - if they can they are sent a written 
invitation to pass to said control family 
↓ 
The case family return the postal questionnaires 
↓ 
If the control family wishes to participate participate they return: 
 Family information sheet 
 Consent form 
 Assent form 
 
↓ 
Within 1 week the trial coordinator (Alison Chambers) contacts the control family by 
telephone to arrange a time for the telephone questionnaires 
↓ 
Telephone questionnaires are administered at the agreed time. After the telephone 
questionnaires the family is sent 2 further postal questionnaires to complete.  
 
 
